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ABSTRACT OF DISSERTATION 
 
 
EFFECT OF ESTRADIOL SUPPLEMENTATION ON BLOOD ESTRADIOL AND 
METABOLITE LEVELS, AND HEPATIC PROTEIN EXPRESSION, IN GROWING, 
MATURE, AND SENESCENT BEEF CATTLE 
Estradiol (Compudose®, COM) implants are extensively used in beef cattle 
production systems to alter body composition and feed efficiency. Little information 
exists about the physiological mechanisms affected by COM treatment in growing, 
mature, and senescent female cattle. Moreover, no reports describe the level of blood 
estradiol resulting from COM treatment. The effect of COM on levels of plasma estradiol 
and blood metabolites and proteins, and relative content of glutamine synthetase (GS) 
and other amino acid nitrogen-metabolizing enzymes in liver tissue, was studied using 
three experimental models relevant to cow-calf production regimens: senescent cows 
(Trial 1), young mature (young) versus senescent (old) cows (Trial 2), and growing 
heifers (Trial 3). In Trial 1, plasma estradiol concentrations were 222 % more after 14 
and 28 d in COM-implanted than sham implanted (Control) cows. COM treatment did 
not affect measured blood metabolites and enzymes, but increased hepatic GS protein 
expression by 350% after 14 d and 200% after 28 d of implantation. In contrast, protein 
expression of alanine transaminase, aspartate transaminase, glutamate dehydrogenase, 
and two glutamate transporters was not affected by COM. In Trial 2, plasma estradiol 
concentrations of COM implanted young and old cows were 48% higher than Control 
groups, whereas blood metabolites were not affected. COM implantation did not affect 
GS protein expression in young cows, but tended to increase GS expression in the old 
cows by 283% after 14 d and 41% after 28 d. GS mRNA content was increased about 
38% in both young and old COM-treated cows. Hepatic content of beta-catenin and G 
protein-coupled receptor 30 (GPR30) content was not affected by COM treatment, 
indicating that estradiol-mediated GS expression was not regulated by beta-catenin- or 
GPR30-controlled pathways. In Trial 3, plasma estradiol levels in COM-treated heifers 
were 70% higher in COM heifers, concomitant with increased levels of total bilirubin and 
creatine kinase, and decreased creatinine. Correlation analysis of plasma estradiol levels 
and blood constituents only identified  a positive correlation between plasma estradiol 
and potassium. Collectively, these data describe positive estradiol-mediated effects on 
hepatic metabolism and blood parameters in female cattle. 
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The age of a beef cow has a major impact on many economically important 
production traits of beef cattle, including milk yield and calf weaning weight (BIF, 1996). 
The physiological and molecular mechanisms responsible for these age-related effects are 
not well understood. It is known that aging can have detrimental effects on the function 
of many organs including the small intestine, muscle, and liver. The liver is an important 
central organ because it is responsible for coordinating whole-body energy and nitrogen 
metabolism. Two metabolically important enzymes involved with these processes are 
glutamine synthetase (GS) and alanine transaminase (ALT). Initial studies from this 
laboratory have found that hepatic glutamine synthetase and alanine transaminase protein 
expression is decreased in aged cows (Matthews and Sipe, 2006).  
Given the current international, and growing national, resistance to consumable 
beef products from cattle raised using exogenous agents, there is a need in the beef cattle 
industry to understand the underlying cellular mechanisms and processes by which the 
administration of exogenous estradiol and other anabolic steroids promote the efficient 
growth of developing cattle (Chung and Johnson, 2008). Much research has been 
performed regarding the effects of anabolic implants on growth rate and carcass traits of 
growing steers and heifers (Heitzman, 1976). However, given the length of time that 
estradiol supplements have been used in cattle, little is known regarding the relationship 
between time of estradiol implantation, blood estradiol levels, and their correlation to 
clinical blood parameters. Moreover, little is known about the effect of estradiol 
supplementation on hepatic cellular mechanisms. Recently, research from this laboratory 
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found that administration of exogenous estradiol plus progesterone (Synovex-S® ear 
implants) to growing steers increased hepatic glutamine synthetase protein expression 
(Sipe, 2004).  
The purpose of this dissertational research was to determine if estradiol 
administration positively affects the expression of two important nitrogen-metabolizing 
enzymes, in old cows (greater than 10 years of age), young cows, and growing heifers. 
The specific objectives of this dissertational research were:  
1. To determine the effects of supplemental exogenous estradiol to old beef cows 
on (1) plasma estradiol and progesterone concentrations, (2) hepatic 
expression of GS and ALT, and other proteins involved in the hepatic 
glutamate/glutamine/alanine metabolism, and (3) blood biochemical and 
clinical indicators of whole body metabolism. (Chapter 3). 
2. To test the hypotheses that (1) glutamine synthetase expression will be up-
regulated by estrogen in old and young mature cows and (2) that this 
regulation is affected by the β-catenin/Wnt pathway and/or GPR30. (Chapter 
4) 
3. To evaluate the effects of estrogen on the clinical blood metabolites of 
growing heifers (Chapter 5). 




Amino Acid Metabolism 
In ruminants versus non-ruminants, glutamate has a heightened role in nitrogen 
and carbon metabolism given the importance of glutamate for amino acid-derived 
gluconeogenesis (Heitmann and Bergman, 1981).  
From a whole-body view, glutamate is important for neurotransmission, protein 
synthesis, nitrogen turnover, and energy metabolism, but its use by specific tissues in the 
body differ. In the mammalian CNS, glutamate is considered to be the major excitatory 
neurotransmitter and an important component of many processes by the brain (Fonnum, 
1984; Collingridge and Lester, 1989).  
In peripheral tissues, glutamate serves as a source of oxidizable fuel and plays an 
antecedent role in the synthesis of new amino acids. Also, glutamate can be utilized to 
support whole-animal energy and nitrogen metabolism (Figure 2.1) as well as tissue- and 
cellular specific functions within the peripheral tissues (Heitmann and Bergman, 1981; 
Wu, 1998; Matthews, 2005). In renal tissue, reabsorbed glutamate acts as an 
ammoniagenesis regulator and acts as a precursor for glutathione and extracellular matrix 
protein (Welbourne and Matthews, 1999). In the placenta, primarily fetal-derived 
glutamate pools serve as sources of oxidizable fuel, with a limited addition of maternal-
derived glutamate into the pool (Moores et al., 1994; Vaughn et al., 1995). Also, adipose 
subcutaneous fat is another peripheral tissue thought to be involved in ammonia 
detoxification (Kowalski and Watford, 1994). In the gastrointestinal tract, glutamate 
metabolized from glutamine (a major fuel for intestinal tissue) by phosphate-dependent 
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glutaminase, undergoes transamination with pyruvate (by alanine transaminase or 
aspartate transaminase) generating L-alanine and α-ketoglutarate (Heidger and 
Welbourne, 1999). 
In ruminants, glutamate is an important precursor of metabolic energy in certain 
peripheral tissues. In sheep, the small intestinal mucosa extensively oxidized glutamate as 
indicated by the recovery of only 4% of gut-infused [14C]glutamate appears in the form of 
[14C]-labeled glutamate and/or glutamine in the portal blood (Tagari and Bergman, 1978). 
Furthermore, the kidney provides reserved glutamate-derived gluconeogenic capacity, 
accounting for 33 to 50% of glutamate-derived glucose in fasted and starved sheep, 
respectively (Heitmann and Bergman, 1981).  
Muscle Glutamate and Alanine Metabolism.  Glutamate taken from the blood as 
a main anaplerotic precursor for the tricarboxylic acid cycle (Bowtell and Bruce, 2002) is 
utilized by the muscle to synthesize glutamine and alanine (Holecek, 2002).  Delivered 
from the blood, branched-chain amino acids (valine, isoleucine, and leucine) can be also 
utilized by the muscle to make new proteins or to produce glutamine and alanine 
(Holecek, 2002). Muscle-derived glutamine and alanine are released in large amounts in 
the postabsorptive state and during the absorption of a protein-containing meal in humans 
(Wagenmakers, 1998).  
Muscle Glutamate Metabolism. The skeletal muscular uptake of plasma glutamate, 
its conversion into glutamine, and the ensuing release of glutamine into the blood allows 
the skeletal muscle to play an important role in ammonia recovery and detoxification of 
the body (Biolo et al., 1995; Rennie et al., 1996; Vesli et al., 2002). Glutamate levels in 
skeletal muscle can decrease quickly during vigorous exercising, even though plasma 
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glutamate levels are constant (Rennie et al., 1996). For example, human muscle and the 
canine gastrocnemius exhibit an efflux of ammonia and glutamine during extended and 
intense exercises, whereas intramuscular glutamate level quickly decrease by more than 
50% and remain steady during the exercising period (Graham and MacLean, 1998). 
Glutamate seems to be an important substrate for the rapid increase in muscle 
tricarboxylic acid cycle intermediates that arises at the beginning of moderate to intense 
exercise because alanine transaminase is converting glutamate and pyruvate to alanine 
and α-ketoglutarate  (Gibala, 2001). 
After ingestion of a protein-inclusive meal, branched chain amino acid and 
glutamate are taken up by the muscle, in which their carbon atoms are used for the 
synthesis of glutamine (Wagenmaker, 1998). As a net exporter of glutamine, skeletal 
muscle branched-chain transaminase transfers α-amino groups from branched-chain 
amino acids to α-ketoglutarate to produce glutamate, which is then aminated with 
ammonia by glutamine synthetase activity (Rennie et al., 1996).   
Muscle Alanine Metabolism. Muscle-type alanine transaminase converts 
glutamate into pyruvate, alanine and  α-ketoglutarate (Palmer et al., 1985; Wagenmakers, 
1998; Gibala, 2001; Holecek, 2002). In the skeletal muscle of humans, alanine 
transaminase helps to build and maintain high levels of tricarboxylic acid cycle 
intermediates during the first ten minutes of exercise (Wagenmakers, 1998). The carbon 
skeleton of the exported alanine is derived predominantly from breakdown of blood 
glucose and from muscle glycogen (Wagenmakers, 1998).  The released alanine is 
transported into the blood and is utilized by the liver to synthesized glucose via 
gluconeogenesis  (Palmer et al., 1985; Holecek, 2002). For instance, human muscle and 
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the canine gastrocnemius have been reported to produce alanine during intense and 
extended exercises, concurrently with the export of muscle-derived glutamine and 
ammonia (Graham and MacLean, 1998). 
Hepatic Glutamate and Alanine Metabolism. In the liver, hepatic transport and 
intermediary metabolism of glutamate and alanine are necessary for nitrogen metabolism 
and whole-body energy regulation (Figure 2.2).    
Hepatic Glutamate Metabolism. Glutamate plays an important role in the 
intercellular glutamate/glutamine cycle in the liver, specifically acting as the main 
substrate for hepatic ureagenesis, gluconeogenesis, de novo protein synthesis, and 
nitrogen shuttling via glutamine (Matthews, 2005). Hepatic entry of glutamine from the 
portal vein is thoroughly uptaken by the periportal heptacytes and deaminated by liver-
specific glutaminase to release ammonia and glutamate (Kilberg et al., 1980). The 
liberated ammonia is incorporated into carbamoyl phosphate by carbamoyl phosphate 
synthetase for ureagenesis, whereas glutamate is available for conversion to α-
ketoglutarate to be used for gluconeogenesis, protein synthesis, or transported back into 
hepatic sinusoids. When α-ketoglutarate is oxidized in the tricarboxylic acid cycle, it 
generates malate, which, by the action of NADP+-dependent malic enzyme, generates 
pyruvate. The NADH and FADH2 generated via this pathway are used for electron 
donation to the electron transporting chain in the mitochondria and thus promote ATP 
synthesis.  
Once glutamate is released into the sinusoidal blood, it is available for absorption 
by the pericentral hepatocytes and is incorporated with free sinusoidal ammonia having 
escaped conversion into urea by the periportal hepacytes for the synthesis of glutamine. 
7 
In the pericentral hepatocytes, glutamine synthetase catalyzes the ATP-dependent 
conversion of glutamate and ammonia into glutamine (Cadoret et al., 2002; Gebhardt 
andn Mecke, 1983).  
Hepatic Alanine Metabolism. In the periportal hepatocytes, alanine transaminase 
converts alanine into pyrvate, which is utilized in hepatic gluconeogenesis to produce 
glucose for whole-body energy metabolism (Schutz, 2011). Sakagishi (1995) has 
suggested that cytosol alanine transaminase is connected to the utilization of pyruvate in 
glycolysis, whereas mitochondrial alanine transaminase is involved in the production of 
alanine-derived pyruvate for gluconeogenesis in humans.  
Molecular Components of Alanine Transaminase and Glutamine Synthetase. 
Alanine Transaminase (ALT). Alanine transaminase is found in the blood, muscle, 
liver, and kidney (Baudhuin et al., 1984; DeRosa and Swick, 1975; Philippson, 1979). 
Two genes account for ALT activities (Sookoian and Pirola, 2012). GPT1 (glutamate-
pyruvate transaminase 1) encodes for the protein that accounts for cytosolic ALT activity 
(ALT1) whereas GPT2 encodes for mitochondrial ALT activity (ALT2). GPT1 has been 
reported to be located to chromosomes 8 and 16 in humans whereas GPT2 is located on 
chromosome 16 (Yang et al., 2002). Also, GPT1 and GPT2 differ in mRNA expression in 
that GPT1 is mainly expressed in kidney, liver, and heart whereas GPT2 is expressed 
highly in muscle, fat, and kidney (Yang et al., 2002). 
In rats and pigs, glycolytic tissues (ex. skeletal muscle), cytosolic alanine 
transaminase is the predominant form and is responsible for the conversion of pyruvate 
into alanine (DeRosa and Swick, 1975).  In gluconeogenic tissues (ex. liver and kidney), 
mitochondrial alanine transaminase has been found in cattle, pig, and rat; where it 
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catalyzes alanine into pyruvate (DeRosa and Swick, 1975; Sipe et al., 2004). In rats, there 
is increased expression of ALT mRNA in periportal hepatocytes versus the ALT mRNA 
expression in pericentral hepatocytes (Boon et al., 1999). Also, rat ALT mRNA 
expression is affected by the presence of protein in the diet in which mRNA content was 
lowest at 0% protein diet and highest at 60% protein diet in the periportal hepatocyte, 
whereas there was no change in ALT mRNA content of pericentral hepatocytes in the 
presence of 0-60% protein diet (Boon et al., 1999). The specific activity of ALT1 is 
found to be 15 fold higher than ALT2 during purification from crude hepatic lysate (Liu 
et al., 2008). In terms of serum ALT activity, ALT1 is mainly responsible for basal ALT 
activity (Lindblom et al., 2007). 
Glutamine synthetase (GS). Whereas prokaryotes express glutamine synthetase I, 
eukaryotes express glutamine synthetase II (GS; Eisenberg et al., 2000). In a report by 
Eisenberg et al. (2000), the structure of glutamine synthetase was characterized by X-ray 
crystallography, using S. typhimurium bacteria as a source sample, which has a molecular 
mass of 620 kDa. It was determined that Mycobacterium tuberculosis GS has a molecular 
weight of 640 kDa. In bacteria, GS form dodecamers, containing 12 active sites (Almassy, 
et al., 1986, Valentine et al., 1968). The GS dodecamer is held together mainly by 
hydrophobic and hydrogen bonding between two hexameric rings (Almassy et al., 1986). 
Both the N- and C-terminus of each subunit form a helical structure. The N-terminal 
helix is exposed to solvent whereas the C-terminal helix is covered by a hydrophobic 
subunit on the opposite hexameric ring. At each active site, bidirectional binding in 
which glutamate and ATP bind at opposite ends. Also, the main channel of the 
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dodecamer contained six four-stranded beta-sheets. In this study, non-bacteria GS was 
not examined for structural analysis via X-ray crystallography.  
The gene GLUL (glutamate-ammonia ligase) encodes mammalian glutamine 
synthetase (GS; Kung et al., 2011). GLUL is expressed by pericentral hepatocytes 
(hepatocytes surrounding the central lobular vein) (Brosnan and Brosnan, 2009). It is 
known that part of the 5’-upstream enhancer region of the GLUL gene is responsible for 
GS localization around the pericentral vein (Lie-Venema et al., 1995). The enhancer 
region contains a single T-cell factor/lymphoid enhancer that is required for 
responsiveness to β-catenin (Clinkenbeard et al., 2012). It is not known if estrogen 
receptors directly activate the promoter region for glutamine synthetase. Proximal to the 
transcription-start site, TATA, CCAAT, and GC elements are present in the first 117 base 
pairs of rat GS gene. These elements constitute the functional promoter region of GLUL 
(Fahrner et al., 2005).  The addition of an upstream sequence of AP2-binding site triggers 
a four-fold increase of the GS gene promoter activity (Fahrner et al., 1993).  The cloning 
and characterization of the GS gene has led to the identification of several cis-acting 
elements that enhanced reporter gene expression in transient transfections (Fahrner et al., 
1993). The rat GS gene consists of 7 exons separated by 6 introns, which spans 10 kb and 
containing two consensus sequences for the binding site of the transcriptional regulatory 
protein SP1 in the first exon, playing a part in the regulation of GS expression (Mill et al., 
1991). 
Eukaryotic glutamine synthetase has been reported to form an eight-subunit 
oligomer (Eisenberg et al., 2000). All identified active residues of GS II structure are 
invariant among all species and are similar to the active sites of bacterial GS I, indicating 
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that the mechanism of action can be predicted to be similar (Meister, 1974). For 
activation, eukaryotic GS II can be highly regulated by nitrogen starvation in E. coli 
strains (Eisenberg et al., 2000). It has been reported that insulin and hydrocortisone can 
trigger changes in the rate of eukaryotic GS II biosynthesis (Meister, 1984; Berl and 
Clark, 1983; Cooper et al., 1983). Also, GS II can be regulated in vitro by assosication 
and dissociation of subunits in the presence of manganese and magnesium, presence of 
substrates, and enzyme concentrations (Denman and Wedler, 1984). 
Eukaryotic GS acts in the presence of L- and D-glutamate and its analog (e.g. 
beta-glutamate, cis-cycloglutamate, and alpha-methly-L-glutamate) but is inhibited by 
MetSox and carbamoyl phosphate in the presence of manganese ion only (Tate et al., 
1972). Furthermore, there are tissue-specific differences in the regulation of eukaryotic 
GS. Specifically, liver GS isoform reacts differently than brain GS isoform to feedback 
inhibition by L-glutamate-derived metabolites (ex. glycine, L-alanine, L-serine, L-
glutamine, L-histidine, and carbamoyl phosphate in the presence of manganese ion only) 
and is activated by alpha-ketoglutarate and citrate (Meister, 1974; Meister; 1984). Non-
brain GS type II responds to end-product feedback inhibition in which low concentrations 
of glutamate-dependent metabolites stimulate GS activity and high concentrations of the 
end products will inhibit it, whereas brain GS type II is not affected by end-product 
feedback inhibition (Tate et al., 1972). Rat GS mRNA expression is affected by the 
presence of protein in the diet in which mRNA content was lowest at 0% protein diet and 
1.5 to 2.0-fold higher at 20% and 60% protein diets in the periportal hepatocytes (Boon et 
al., 1999).   
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Amino Acid Transport Systems 
In mammals, System X
-
AG is a high affinity glutamate transport system (Km = 4-
40 µM), predominantly transport glutamate and L/D-aspartate with an obligatory counter-
exchange of K+, and plays a major role in the central nervous system (Danbolt, 2001). 
System ASC is another high affinity Na+-dependent amino acid transport system which 
mainly transports L-alanine, L-serine, and L-cysteine (Matthews, 2005). Systems ASC 
and Bo also transport L-glutamate and L-aspartate, but only in acidic (pH < 5.5) 
environments (Utsunomiya-Tate et al., 1996). 
System X-AG Transport Proteins. Five mammalian proteins have been cloned that 
are capable of System X-AG transport activity. They are known as EAAC1 (SLC1A1), 
GLT-1 (SLC1A2), GLAST1 (SLC1A3), EAAT4 (SLC1A6), and EAAT5 (SLC1A7) 
(Kanai and Hediger, 2004). Functionally, the transport process by all SLC1A proteins 
involves the extracellular binding and translocation of three Na+ ions and one amino acid 
(L-glutamate, D-aspartate, or L-aspartate); with reorientation of the transporter to the 
extracellular face of the membrane being driven by the intracellular-to-extracellular 
counter-transport of one K+ ion. Although System X-AG transporters usually transport 
anionic amino acids from the extracellular fluid into the cytosol, they are capable of 
reverse transport when the intracellular K+ levels are too low (Zerangue and Kavanaugh, 
1996; Levy et al., 1998).  
The System X-AG proteins have been reported to be expressed in many tissue 
types. For instance, EAAC1 mRNA and/or protein have been detected in the heart 
(Nakayama et al., 1996), small intestine (Kanai and Hediger, 1992; Howell et al., 2001), 
kidney (Kanai and Hediger, 1992; Gissendanner, 2003; Sipe, 2004), skeletal muscle 
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(Velaz-Faircloth et al., 1996) and liver (McGivan and Nicholson, 1999; Howell et al., 
2001, 2003; Gissendanner, 2004; Sipe, 2004).  
Using isolated membrane vesicles, system X
-
AG activity has been demonstrated in
canalicular-enriched fractions and a Na+-independent activity in the sinusoidal membrane 
domain of the liver (Ballatori et al., 1986; Cariappa and Kilberg, 1992). In contrast, 
others have measured both system X
-
AG activity and Na
+-independent (exchanger)
glutamate transport activity, in sinusoidal membranes of rat hepatocytes (Low et al., 
1992). System X
-
AG is known to be extremely high in cells that also express high
activities of glutamine synthetase (Hertz, 1976), as is the case for pericentral hepatocytes. 
Glutmate transporters EAAC1, EAAC2, and GLT-1 are reported to be expressed in the 
liver of rodents (Fremeaux et al., 2002). By Northern blot analysis, EAAT5 appears to be 
expressed at low levels in liver. In cattle, both of the protein and mRNA expressions of 
EAAC1 and GLT-1 were found in the liver, whereas other transporters from system X
-
AG
were not detected (Howell et al., 2001).  
Moreover, EAAC1 protein has been observed on the apical membrane of rat renal 
proximal tubule brush borders (Shayakul et al., 1997), nephrons isolated from rats 
(Verrey et al., 2005), and neonatal porcine epithelial cells (Fan et al., 2004). GLT-1 
mRNA has been detected in the kidney (Welbourne and Matthews, 1999) and liver 
(Howell et al., 2001, 2003; Kim et al., 2003). In sheep and cattle, our group found that 
both proteins and mRNA of EAAC1 and GLT-1 were expressed in small intestinal 
epithelia isolated from the rumen, omasum, duodenum, jejunum, ileum, cecum, and colon 
(Howell et al., 2001). Also, GLAST1 mRNA has been detected in the heart (Nakayama et 
al., 1996). In placental tissue, EAAC1, GLAST1, and GLT-1 mRNA and protein are 
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expressed (Matthews et al., 1998a; 1998b; Danbolt et al., 2001). In the brain, only 
GLAST1 and GLT-1 proteins (Torp et al., 1994; Schmitt et al., 1996; Torp et al., 1997; 
Berger and Hediger, 1998) are expressed in astrocytes, whereas EAAC1 and EAAT4 are 
the predominant transporters in neurons (Rothstein et al., 1994; Kanai et al., 1995; Berger 
and Hediger, 1998). High concentration of GLT-1 and GLAST1 proteins has been 
identified in astroglial membranes facing the nerve terminals (synaptic cleft), axons 
and/or dendrites, whereas GLT-1 and GLAST-1 levels were lower in astroglial 
membranes facing other astrocytes, cell bodies, or the basement membrane of the 
endothelium (Chaudhry et al., 1995). Furthermore, EAAT4 and EAAT5 are 
predominantly expressed in the cerebellum (Fairman et al., 1995; Nagao et al., 1997) and 
in the retina (Arriza et al., 1997), respectively.  
Glutamate absorption by mammalian skeletal muscle initially was thought to 
occur by a Na+-independent process, based on conclusions drawn from a rat hindlimb 
perfusion study (Hundal et al, 1989). Subsequently, and in accordance with that observed 
in the muscle of barnacles (Revest and Baker, 1988), the expression of both Na+-
dependent and –independent glutamate uptake activities was identified in skeletal muscle 
using primary cultures of rat myotubules (Low et al, 1994). The Na+-dependent uptake of 
glutamate activity was inhibited by both L- and D-aspartate and displayed an affinity 
constant for glutamate of 0.7 mM. Therefore, the affinity is too low, although the profile 
of substrates that inhibit Na+-dependent uptake of glutamate by myotubules is consistent 
with system X
-
AG transporters. Though specific information about the molecular identity
of potential glutamate transporters expressed by muscle tissue is very limited, EAACl 
mRNA has been identified in skeletal muscle (Kanai and Hediger, 1992), which 
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confirmed the possibility that EAACl could account for the system X
-
AG activity found in
skeletal (Revest and Barker, 1988; Low et al., 1994; Frank et al, 2002) myocytes. In 
cattle, both mRNA and protein for two system X
-
AG transporters (EAACl and GLT-1) are
expressed in the longissimus dorsi muscle (Gissendanner et al, 2003).  
Also, the activities of some SLC1A transporters can be regulated by protein-
protein interaction. For example, EAAC1 function is regulated by glutamate transport 
associated protein 3-18 (GTRAP3-18). GTRAP3-18 is a protein that reduces the affinity 
of EAAC1 for glutamate by interacting with the carboxy-terminal end of EAAC1, as 
shown with yeast two-hybrid analysis (Lin et al., 2001). 
System X-c Transport Proteins. System Xc
-
 is the most widely expressed Na+-
independent transport activity for anionic amino acids, mediating the influx of L-cystine 
into the cell coupled to the efflux of glutamate (predominant anionic amino acid) or 
aspartate at a 1:1 ratio (Bannai and Kitamura, 1980). 
Administration of Exogenous Sex Steroids and its Application in the Beef Cattle 
Industry 
In the United States feedlot industry, the administration of exogenous sex steroids 
(e.g.-androgens, estrogens, and progestogens) and their derivatives are given to improve 
production efficiency of the cattle while reducing the production cost. Specifically, these 
steroidal implants influence growth rates and body composition of growing and mature 
cattle (Kahl, 1978). In the United States feedlots, the common estrogenic hormones 
utilized are estradiol 17β, zeranol and estradiol benzoate, whereas trenbolone acetate and 
testosterone are common androgenic compounds given to cattle through ear implants 
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(Reinhardt, 2007).   
After implantation, exogenous estrogen and other steroidal compounds are 
transferred from the ear implant into the blood when it dissociates from the delivery 
capsule. The length of time in which the implant can trigger growth depends on the 
release rate of the sex steroids from the implant which usually occurs in a biphasic 
pattern in which there is a higher rate of release earlier in the growth-promoting period 
than later in the time period (Reinhardt, 2007). Compudose® (25.7 mg estradiol 17beta) 
has been indicated to be effective for 200 days, whereas Synovex-S (200 mg 
progesterone plus 20 mg estradiol benzoate) is effective for 70 days (per manufacturers’ 
directions). During the release of these hormones, a concentration threshold needs to be 
reached before these compounds can improve growth rates (Preston, 1999). After 60 days 
of Synovex-S implantation and then its removal, 24% of the initial estradiol  and 27% of 
the initial progesterone dosage remained in the implant, with a linear reduction of 0.16 
and 0.15% of the initial dosage per day for estrogen and progesterone, respectively 
(Rumsey et al., 1992). However, surprisingly, there are no published reports describing 
the concentration of estradiol in blood in response to Compudose® implantation. 
Reproductive Physiology of Endogenous Estrogen and Progesterone in Cattle 
The estrous cycle in cattle lasts for 18 to 24 days, with an average of 21 days, 
consisting of a luteal phase (14-18 days) and a follicular phase (4-6 days) (Hadley and 
Levine, 2007; Forde et al., 2011). During the beginning stage of estrus, the hypothalamic 
emergence of gonadotropin-releasing hormone (GnRH) causes the anterior pituitary 
release of the follicle stimulating hormone (FSH), which initiates follicle maturation, and 
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thus increasing secretion of estradiol to induce estrous behavior in cattle (Allrich, 1994). 
After ovulation, in the luteal stage, estrogen-induced circulation of  the luteinizing 
hormone (LH) causes the formation of the corpus luteum, and thus the production of 
progesterone, an inhibitor of the gonadotropins (LH and FSH) to prevent ovulation 
(Hadley and Levine, 2007).  
Whole-Animal Parameters Affected by Steroidal Implantation 
Exogenous estrogen and its combination with progesterone or with androgenic 
derivatives have been well characterized to affect certain steer carcass parameters 
including improved muscle composition and fat beds (Heitzman, 1976; Duckett et al., 
1996; 1999). In feedlot heifers, the implant combination of estrogen and trenbolone 
acetate at various concentrations positively affected carcass traits including increased 
longissimus muscle area (Heitzman, 1976; Schneider et al., 2007; Boles et al., 2009). 
Increased weight gain of steer and heifer calves occurs when these animals are treated 
with either estradiol 17 beta or zeranol, a non-steroidal estrogen agonist (Sawyer, 1987). 
However, there are conflicting reports about the effectiveness of implants containing both 
estrogen and testosterone in improving growth rates and carcass parameters. For instance, 
the carcass composition of mature cows has been shown to be affected by 200 mg 
testosterone proprionate plus 20 mg estradiol benzoate (Cranwell et al., 1996; Neill et al., 
2009). In contrast, carcass traits of culled cows were not affected by a combination of 
200 mg testosterone and 20 mg estradiol benozoate (Jones, 1982; Matulis et al., 1987). In 
pigs, nitrogen retention was improved by the treatment of 20 mg 17beta-estradiol + 140 
mg trenbolone acetate (van Weerden and Grandadam, 1976). 
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Mechanistic Regulation of Steroidal Implants 
 The effect of steroidal implants on whole-animal parameters has been well 
elucidated. However, little information is known regarding how sex steroid 
administration affects specific mechanisms (genes, proteins, biochemical pathways) 
responsible for alteration of muscle and adipose tissue composition. It has been reported 
that estrogenic implants affect muscle protein accumulation by increasing the 
concentration of hepatic somatotropin and insulin-like growth factor 1 (Reinhardt, 2007).  
Even less is known about whether/how sex steroid administration alters specific 
mechanisms of the liver, the tissue responsible for coordinating alteration of whole-body 
nutrient fluxes.  For example, in the liver, glutamate serves as precursor for glutamine 
(which is exported to the plasma as a nitrogen carrier), gluconeogenic carbons, and 
incorporation into de novo protein synthesis (Haussinger and Gerok, 1983). Prior 
findings from our lab demonstrated that liver glutamine synthetase is up-regulated by 
Synovex-S® (20 mg 17β-estradiol benzoate + 200 mg progesterone) in finishing steers 
(Sipe et al., 2004). Also, glutamine synthetase activity and protein expression in rat C6-
glioma cells is increased by estrogen (Haghighat, 2005). In the hypothalamus and 
hippocampus of humans, estradiol up-regulates glutamine synthetase mRNA and protein 
content (Blutstein et al., 2006). In addition, the activity of ALT and aspartate 
transaminase (AST) can be down-regulated by estradiol, and by the combination of 
estradiol, and by the progesterone, in aged cyclical rats (Moorthy et al., 2005).  
Recently, the detection of mRNA for estrogen receptors α and β in cattle liver 
(Pfaffl et al., 2001) suggests that sex steroid administration to cattle has a direct effect on 
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hepatic mechanisms through specific sex steroid receptor-activated mechanisms, and not 
only through IGF-mediated effects.  
Estrogen and Progesterone Receptor Cell Signaling 
Estrogen and progesterone receptors belong to the nuclear receptor superfamily 
and have also been expressed on the cell surface membranes. To date, the expression of 
progesterone receptors has not been reported in the liver of cattle.  It has been reported 
that estrogen α and β receptors are expressed in the liver of cattle and that the mRNA 
content of these receptors is not affected by administration of zeranol, a strong estrogenic 
and anabolic compound (Pfaffl et al., 2001). In contrast, mRNA expression of estrogen 
receptor α appeared to increase with increasing concentrations of melengestrol acetate, a 
potent synthetic progestagen (Pfaffl et al., 2002). Furthermore, estrogen receptor β has 
been shown to inhibit estrogen α receptor-dependent transcription of target genes when 
co-expressed together in murine and breast cancer cells (Matthews and Gustafssoni, 
2006).  It has been suggested that estrogen receptor β can inhibit estrogen receptor α by 
altering binding of co-transcriptional factors to estrogen receptor α and by causing 
enhanced the degradation of estrogen receptor α in T47D cell lines (Heldring et al., 2007). 
Even though estrogen receptor isoforms result from the transcription of different 
genes, these estrogen receptors can mediate the activation of target proteins through 
multiple cell signaling pathways when they form homeodimers (Matthews and 
Gustafsson, 2003). The classical pathway involves the transport of the ligand-bound 
estrogen receptors from the plasma membrane into the cell to promote transcription 
and/or mediate cell signaling cascades (Figure 2.3). In the genomic pathway, estrogen-
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bound estrogen receptors can  directly bind to the estrogen response element located on 
the promoter region of target genes or interact with other transcription factors (e.g. β-
catenin) to initiate the transcription of target genes with no estrogen response elements 
present on the promoter region (Heldring et al., 2007).   
In the non-genomic pathway, estrogen has been reported to be able to trigger 
rapid events that occur within seconds or minutes after exposure to estrogen through 
certain cell signaling cascades. Specifically, these prompt effects involve the activation of 
protein kinases and phosphatases and increased movement of ions across the plasma 
membrane and other membranes possibly mediated by GPR30, a newly discovered 
membrane bound plasma receptor (Heldring et al., 2007).  
Moreover, ligand-independent estrogen receptor activation can occur when 
growth factor cell signaling cascade activates certain protein kinases to 
phosphorylate/activate estrogen receptors (Kato et al., 1995). In humans, this type of 
estrogen signaling has been indicated to be a factor in the growth of certain breast cancers 
in the absence of estrogen (Coutts and Murphy, 1998; Shim et al., 2000).  
The cell signaling pathway(s) involved in estrogen up-regulation of glutamine 
synthetase expression in the liver has not been elucidated. However, two pathways that 
are good candidates  for the regulation of hepatic glutamine synthetase expression by 
estrogen are those mediated by  GPR30 and  β-catenin.   In the non-classical pathway, 
GPR30 is thought to be a prime target in the activation of non-genomic regulation of 
target genes by estrogen. Currently, the non-genomic estrogen pathway is not fully 
understood. However, in the human brain, estrogen can activate certain cell signaling 
pathways through GPR30, a plasma membrane-bound receptor. In the human liver, 
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estrogen has been indicated to enhance liver function after a trauma-induced hepatic 
hemorrhage via GPR30-mediated protein kinase A activation (Hsieh et al., 2007).  
In the canonical Wnt pathway, Wnt signals by activating β-catenin for 
translocation into the nucleus (Figure 2.4). As lipoglycoproteins, Wnts are secreted from 
neigboring cells to interact with two plasma-membrane bound receptors, frizzled and 
low-denisity-lipoprotein-related protein (LRP) receptors (Daugherty and Gottardi, 2007). 
Wnt triggers the activation of β-catenin by inhibiting the β-catenin degradation complex 
through the transducer protein, disheveled (Dvl). This complex contains two scaffolding 
proteins, axin and adenomatous polyposis coli (APC), and two serine/threonine protein 
kinases, glycogen synthase kinase 3β (GSK3β) and casein kinase I. The regulatory 
actions of Wnt allows for the non-phosphorylated form of β-catenin to dissociate from 
the degradation complex and bind to T cell factor (TCF) and other transcription factors 
for translocation into the nucleus to activate target genes. In the absence of Wnt 
activation, β-catenin is phosphorylated by GSK3β or casein kinase I and is targeted for 
ubiquitin-mediated degradation by the APC and axin proteins.  Estrogen is thought to be 
a major modulator in the Wnt pathway. In the uterine epithelium, estradiol can up-
regulate the expression of two Wnt proteins (Wnt4 and Wnt5a) to trigger nuclear 
translocation of β-catenin in an estrogen receptor-independent manner (Hou et al., 2004). 
In past studies, it has been demonstrated that estrogen receptor alpha can interact with 
beta catenin in osteoblasts (Foo et al., 2007), Drosophila and certain human cancer cell 
lines (Kouzmenko et al., 2004). Furthermore, in the rat hippocampus, estradiol can inhibit 
GSK3β and bind to β-catenin for translocation into the nucleus (Cardonna-Gomez et al., 
2004).  
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Certain proteins involved in glutamate metabolism have been shown to be 
regulated by β-catenin. Ornithine aminotransferase is up-regulated in transgenic mice 
overexpressing hepatic β-catenin, but is not regulated by β-catenin in human 
hepatocellular carcinomas, whereas GLT-1 and glutamine synthetase mRNA expression 
is up-regulated by the overexpression of β-catenin (Cadoret et al., 2002; Zucman et al., 
2007).  However, the interaction of β-catenin and estrogen on glutamine synthetase 
expression is unknown.  
Age-associated Reduction of Amino Acid N Metabolism 
Aging (senescence) can be defined as the “progressive, time dependent 
deterioration in the ability of an organism to respond adaptively to environmental 
changes” (Balin and Allen, 1986). Aging influences numerous metabolic and physical 
mechanisms. Age of a cow has a vital relationship to various cost-effective parameters of 
beef cattle production including fecundity, milk yield, and weaning weight. For instance, 
the increase of milk yields and weaning weights has been positively correlated for Angus 
cows from three to six years of age (Baker and Boyd, 2003). Additionally, increased birth 
and weaning weights have been shown to be positively associated to multiparous British 
crossbred beef cows with ages ranging from three to eight years of age (Renquist et al., 
2006). However, in senescent cows (beyond 8 yrs of age), age has been negatively 
correlated with reproductive capacity and weaning weights of numerous beef cattle 
breeds (BIF, 1996; Renquist et al., 2006). 
At the biochemical level, the physiological mechanisms responsible for age-
associated changes are poorly understood in cattle and other ruminants. However, age-
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related changes in hematologic and metabolic profiles, and amino acid concentrations for 
non-ruminants, have been reported (Lowseth et al., 1990; Militante and Lombardini, 
2004). Consistently, decrease in protein synthesis and putative loss of muscle protein in 
which amino acid availability is known to be a limiting factor in protein synthesis in 
older animals has been observed (Volpi et al., 1998; Pitkanen et al., 2003). Nonetheless, 
it is evident that the degree to which age affects amino acid metabolism is highly 
dependent upon the species and the sex of the animal (Militante and Lombardini, 2004). 
In addition to changes in blood amino acid levels, the hematologic and metabolic profiles, 
including enzymes associated with organ function and blood mineral content also are 
affected by age, and are differentially altered across species. For example, as dogs age, 
serum aspartate transferase levels decrease whereas ALT increase (Lowseth et al., 1990; 
Swanson et al., 2000). Furthermore, ornithine aminotransferase and glutamate 
dehydrogenase are increased, whereas alanine transaminase is decreased in the liver of 
senescence accelerated mice via 2-DE proteomic analysis (Cho et al., 2003). Moreover, 
metabolic syndrome- and sex-independent serum alanine transaminase levels decrease 
with age in both men and women, after adjustments for alcohol use, sex, metabolic 
syndrome constituents, and adiposity biomarkers were made (Dong et al., 2010). 
The process of senescence is known to be associated by a reported decrease in 
whole-body protein synthesis (Karakelides and Nair, 2005). In different tissues, the 
protein synthetic rates may decrease, not change, or increase, depending on the organism 
(Ward, 2000). In the muscle, aging has been known to affect the nitrogen-metabolizing 
enzymes involved with ammonia detoxification (Dhahbi, et al., 1999). Also, in humans, 
there is a reduced capacity for nitrogen retention, which can be up-regulated by growth 
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hormone therapy (Corpas et al., 1993). Also, in senescent humans, there is a decrease in 
urinary nitrogen excretion and muscle mass, affecting nitrogen metabolism (Evans, 2004). 
In the liver, aging has been associated with decreased metabolic functions and decreased 
gene expression of proteins responsible for intermediary metabolism in the liver (Sersté 
and Bourgeois, 2006). Moreover, the mRNA content and activity of murine hepatic 
glutamine synthetase has been reported to decrease (Dhahbi et al., 1999). 
In cattle, little information is known about the relationship between hepatic 
function and aging. However, previous research in our lab has shown that old beef cows 
vs. young mature beef cows have reduced hepatic expression of glutamine synthetase and 
alanine transaminase, two enzymes critical for N recycling. Specifically, glutamine 
synthetase protein content decreased by 46 to 71% in old, mature cows compared to the 
young mature cows (Matthews et al., 2006). This finding suggests that glutamine 
synthetase catalyzed conversion of L-glutamate to L-glutamine in pericentral hepatocytes 
may be reduced in old cows. Old cows also had a 61 to 73% reduction in ALT content, 
indicating that ALT-mediated conversion of α-ketoglutarate and alanine into glutamate 
and pyruvate is impaired in periportal hepatocytes (Matthews and Sipe., 2006). GTRAP3-
18 content, an inhibitory regulator of EAAC1 glutamate transporter, was increased 132 to 
192% in old cows suggesting that the decrease in glutamine synthetase content was 
related to an inhibition glutamate uptake capacity from plasma (Matthews and Sipe, 2006) 
Dissertation Objectives 
Because we were interested in understanding the physiological mechanisms involved 
with steroidal regulation, three animal models (old cows; young mature versus old cows; 
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developing heifers). The overall goal of the dissertation was to answer the following 
questions: 
1) Can estrogenic implants increase the expression of glutamine synthetase and other
critical liver proteins in old, mature cows? (Trial 1; Chapter 3)
2) Will exogenous estrogen increase the expression of glutamine synthetase and
other proteins in the liver of young, mature cows versus old mature cows (Trial 2;
Chapter 4)?
3) What are the potential hepatic mechanisms (i.e., estrogen receptors, transcription
factors) affected by exogenous estrogen in the liver (Trial 2; Chapter 4)? 
4) What are the potential effects of exogenous estrogen on blood parameters of
developing heifers (Trial 3; Chapter 5)?
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1SN1 (SLC38A3), Na+ and H+-coupled glutamine transporter;  EAAC1, high-affinity glutamate transporter; GTRAP3-18, regulator of EAAC1 function that binds to EAAC1 on cytosolic side of 
membrane; GLT-1, high-affinity glutamate transporter;  ASC, system ASC, originally named for three of its preferred substrates alanine, serine, cysteine; ATA2, SLC38A2; ATA3, SLC38A4; GA, 
glutaminase;  
GDH, glutamate dehydrogenase; ALT, alanine transaminase; AST, aspartate transaminase; GS, glutamine synthetase; PEPCK, Phosphoenolpyruvate carboxykinase, cytosolic; CPS, 
carbamoylphosphate synthethase; CP, carbamoyl phosphate; Cit, citrulline;  
Orn, ornithine; AS, arginiosuccinate; 
2 l
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Figure 2.2: Liver glutamine/glutamate metabolism 
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Glutamine synthetase is up-regulated in the liver of old beef cows by 17β-
estradiol implants 
INTRODUCTION 
The age of a beef cow has a major impact on many economically important 
production traits of beef cattle, including milk yield and calf weaning weight (BIF, 1996). 
For instance, increased milk yield and weaning weights have been shown to be positively 
correlated to the productive age of three to six years for Angus cows (Baker and Boyd, 
2003). Conversely, after 8 years of age, these aging cows produce calves with lower birth 
and weaning weights (BIF, 1996). Moreover, old cows (> 8 y) have daughters with 
reduced milk yield and productive lifespans (Fuerst-Waltl et al., 2004).  
The physiological mechanisms responsible for these senescence-related effects 
are not well understood. It is known that aging can have detrimental effects on the 
function of many organs including the small intestine, muscle, and liver. In the small 
intestine, aging can cause a decline in the ability to absorb glucose (Drozdowski et al., 
2003). For the muscle, aging can trigger sarcopenia, a loss of muscle mass and strength 
(Attaix et al., 2005). Furthermore, aging is associated with decreased metabolic functions 
and decreased gene expression of proteins responsible for intermediary metabolism in the 
liver (Serstè and Bourgeois, 2006).  
The liver is an important central organ because it is responsible for coordinating 
whole-body energy and nitrogen metabolism. For example, glutamate serves as precursor 
for glutamine (which is exported to the plasma as a nitrogen carrier), gluconeogenic 
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carbons, and incorporation into de novo protein synthesis (Haussinger and Gerok, 1983). 
In cattle, little information is known about the relationship between hepatic function and 
aging. However, previous research in our lab has shown that old beef cows vs young 
mature beef cows have reduced hepatic expression of glutamine synthetase (GS) and 
alanine transaminase (ALT), two enzymes in the liver that are critical for optimal N 
recycling. Specifically, the content of GS protein in the liver of old (≥ 10 years old), 
mature cows is decreased by 46 to 71% compared that of young (3-5 years old) adult 
cows (Matthews et al., 2006). This reduction is important because GS catalyzes the 
conversion of L-glutamate to L-glutamine in pericentral hepatocytes. The livers of old 
cows also express 61 to 73% less ALT than young cows (Matthews and Sipe, 2006). In 
the periportal hepatocytes, ALT is responsible for the conversion of α-ketoglutarate (α-
KG) and alanine into glutamate and pyruvate. Furthermore, it was observed that the 
content of GTRAP3-18, an inhibitory protein regulator of pericentral hepatocyte-
localized glutamate transporter (EAAC1) activity, is increased 132 to 192% in old cows 
(Matthews and Sipe, 2006). Thus, the capacity for plasma glutamate uptake, intracellular 
glutamate production, and glutamine synthesis all are reduced in liver tissue of old cows.  
Prior findings from our lab demonstrated that liver GS mRNA and protein content 
is up-regulated in finishing steers by implantation of Synovex-S® (20 mg 17β-estradiol 
benzoate + 200 mg progesterone) into the ear (Sipe et al., 2004). In rat C6-glioma cells, 
GS activity and protein content is increased by 17β-estradiol (Haghighat, 2005). In the 
hypothalamus and hippocampus of humans, estradiol up-regulates GS mRNA and protein 
content (Blutstein et al., 2006). In addition, the activity of ALT and aspartate 
transaminase (AST) in the brain, heart, liver, kidney and uterus can be down-regulated by 
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estradiol and by the combination of estradiol and progesterone, in aged, acyclic rats 
(Moorthy et al., 2005).  
The primary goal of this experimentation was to determine if administration of 
exogenous 17β-estradiol (estradiol), in the form of Compudose ear implants (25.7 mg 
estradiol), affects the expression of GS, ALT, AST, and other proteins involved in the 
hepatic glutamate/glutamine/alanine metabolism by old beef cows. The hypothesis tested 
in this experiment is that hepatic GS mRNA and protein expression would be up-
regulated by exogenous estradiol, whereas ALT mRNA and protein, and AST protein, 
expression would be down-regulated. The specific experimental objectives were to 
determine the effects of supplemental exogenous estradiol to old beef cows on (1) plasma 
estradiol and progesterone concentrations, (2) hepatic expression of GS, ALT, AST, and 
other proteins involved in the hepatic glutamate/glutamine/alanine metabolism, and (3) 
blood biochemical and clinical indicators of whole-body metabolism.  
MATERIALS AND METHODS 
Animals 
All experimental procedures were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. Fourteen old (> 10 y) non-pregnant beef 
cows were obtained from a stockyard and housed in a dry lot at the University of 
Kentucky Agricultural Research Center, located in Woodford County, KY. Cows had ad 
libitum access to alfalfa hay and water for 28 d. Representative sampling of the alfalfa 
hay was conducted for proximate and mineral analyses (Figure 3.1) by a commercial 
laboratory (Dairy One Forage Lab, Ithaca, NY).  
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COMPUDOSE and Sham Implant Treatments 
Cows were judged to be at least 10 years of age based on the amount of wear of 
their teeth (Johnson, 1959).  At the beginning of this trial, cows were weighed and 
subdivided into 2 groups based on BW and then randomly allotted (n = 7) to either 
receive a sham (control; 0.5 mg oxytetracycline; 585 kg) using 1 mL sterile corn oil as a 
vehicle for oxytetracycline (0.5 mg) or estradiol (Compudose Implant; 25.7 mg estradiol; 
Vetlife, Des Moines, IA; 621 kg) implant treatment. The back of the ear was clipped, 
cleansed with 70% ethyl alcohol solution, and dried. Seven cows received the controlled-
release estrogen implant subcutaneously in the dorsal-medial area of the left ear using the 
manufacturer’s implantation device (Compudose® Implanter; Vetlife, Des Moines, IA) 
and instructions. In addition, seven cows received a sham implant.  
Blood Collection and Fractionation 
Jugular venous blood samples were collected by venipuncture on d 14 and d 28. 
For preparation of plasma, 16 mL of blood was collected in EDTA-containing (0.9375 
mg/mL) blood collection tubes (Becton Dickinson, Franklin Lakes, NJ). For serum, 16 
mL of blood was collected in serum blood collection tubes without an anticoagulant. For 
whole blood, 2 mL of blood was collected in EDTA containing (2.7 mg/mL) blood 
collection tubes(Becton Dickinson). Plasma and serum were recovered by refrigerated 
centrifugation at 3,000 × g for 10 min at 4°C and stored at −80°C.  
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Analysis of Blood Analytes 
Plasma estradiol levels were evaluated using the Ultra-Sensitive Estradiol 
Radioimmunoassay kit (Diagnostic Systems Labs, Webster, TX). Briefly, 125 µL of 
MgCl2 and 125 µL Dextran were added to microcentrifuge tubes containing 750 µL of 
the samples to delipidate the plasma. Samples were incubated for 1 hr at room 
temperature. Tubes were centrifuged for 15 minutes at 10,000 rpm and the supernatant 
removed for analysis.  
Using the RIA kit, all samples, standards, and controls were assayed in duplicate. 
Tubes provided from the kit were labeled for total counts (TC), non-specific binding 
(NSB), standards, controls, and the blood samples. The standards used were 0.5, 0.62, 1, 
2.5, 5, 7.5, 10, 15, 20, 35, 50, and 250 pg/ml. The volume for the standards and controls 
was 200 µL per tube. On the other hand, 266.7 µL of plasma samples were added to the 
proper tubes. To the NSB tubes, 300 µL of the 0 pg/mL estradiol standard was added. 
Estradiol antiserum (1st antibody; 100 µL) was added to all tubes except for the NSB and 
TC tubes. All tubes were vortexed and allowed to incubate overnight at 4°C. After the 
incubation, 125iodine-labeled estradiol (100 µL) was added to each tube. Then, tubes were 
vortex, covered, and allowed to incubate at 4°C overnight. On the third day, precipitating 
reagent (secondary antibody; 1 mL) was added to all tubes except for TC. Tubes were 
incubated at room temperature for 1 hr. Next, tubes were centrifuged for 30 minutes at 
4°C with a speed of 3000 rpm. The tubes were decanted except for the TC tube to remove 
any excess liquid moisture. Afterwards, tubes were counted in the gamma counter for 1 
minute. The intraassay CV was 7.1%, whereas the interassay CV was 11.9%. The 
detection limit of this assay is 0.67 pg/mL.  
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Plasma progesterone levels were measured using the Coat-A-Count Progesterone 
125I Radioimmunoassay kit per manufacturer’s instructions (Siemens Medical Solutions 
Diagnostics, Los Angeles, CA). The sensitivity of this assay was determined to be 0.038 
ng/mL, and an interassay CV of 5% was observed. Also, the intrassay CV was 11%. All 
other serum analytes, minerals, and blood cell types were analyzed by the University of 
Kentucky Livestock Disease Diagnostic Center as described by Brown et al. (2009).  
Plasma samples were analyzed for ammonia-N by modifications of the L-Glu 
dehydrogenase assay (Da Fonesca-Wollheim, 1973) using the Konelab 20XTi analyzer 
(Thermo Electron Corp., Vantaa, Finland). The sensitivity of this assay is 0.010 mM, and 
an interassay CV of 11.0% is typically realized. For this experiment, plasma ammonia 
concentrations were determined in a single assay event. The intraassay CV was 7.4%.  
All other serum analytes, minerals, and blood cell types were analyzed by the 
University of Kentucky Livestock Disease Diagnostic Center as described by Brown et 
al. (2009). For serum enzymes, the following specific activities were assayed: ALP, E.C. 
3.1.3.1; ALT, E.C. 2.6.1.2; AST, E.C. 2.6.1.1; γ-glutamyltransferase, E.C. 2.3.22; 
creatine kinase, E.C. 2.7.3.2; LDH, E.C. 1.1.1.27. 
Liver Tissue Biopsy 
On d 14 and 28, hepatic tissue was collected by a modification of the aspiration 
technique in cattle (Brown et al., 2009). Briefly, the area from the 10th to the 12th 
intercostal spaces and 10 to 30 cm from the dorsal median plane on the right side of each 
animal was clipped free of hair and cleansed with povidine-iodine and two subsequent 
70% ethyl alcohol solution washes. The remaining 70% ethyl alcohol solution was dried 
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with gauze. Lidocaine (Lidocaine 2% Injectible; The Butler Company, Dublin, OH; 1.6 
mL per biopsy site) was subcutaneously injected between the 12th and 13th ribs 
approximately 10 cm from the dorsal medial plane. A topical anesthetic spray 
(Cetacaine® 300 mg; Cetylite Industries, Pennsauken, NJ) was administered to the skin 20 
cm from the dorsal median plane at the 12th intercostal space for 2 seconds and an 
incision made with a scalpel. A trocar (7 mm diameter) was used to obtain tissue from the 
liver. The collected tissue was weighed and separated for RNA (400 mg wet tissue) and 
protein extraction (200 mg wet tissue). Samples were placed in foil packs and snap frozen 
in liquid nitrogen and stored at -80°C. After completion of biopsy, the incision site was 
treated with a topical broad spectrum antibacterial spray (Furazolidone® 4%; Veterinary 
Products Laboratories, Phoenix, AZ). 
Immunoblot Analysis 
Approximately 200 mg of liver, kidney, and LM were homogenized on ice for 30 
s (setting 11, Polytron Model PT10/35, Kinematic Inc., Lucerne, Switzerland) in 7.5 mL 
of 4°C sample extraction buffer solution [0.25 mM sucrose, 10 mM HEPES-KOH pH 
7.5, 1 mM EDTA, and 50 μL of protease inhibitor (Sigma, St. Louis, MO)]. Protein was 
quantified by a modified Lowry assay, using bovine serum albumin as a standard 
(Kilberg, 1989). Proteins (60 µg/lane) were separated using 12% SDS-PAGE and 
electrotransferred to a 0.45-μm nitrocellulose membrane (BioRad, Hercules, CA) as 
described previously (Howell et al., 2001, 2003), except that proteins were separated 
using a 12% acrylamide gel instead of 7.5%. Blots were stained with fast-green and the 
relative amount of stained protein per lane/sample determined by densitometric analysis. 
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The relative tissue content of specific proteins in liver was evaluated using a 
standard immunoblot protocol as described previously (Howell et al., 2001, 2003; Brown 
et al., 2009). Relative contents of GS, ALT, AST, G-protein-coupled receptor 30 
(GPR30), glutamate dehydrogenase (GDH), glutamate transporter-1 (GLT-1), excitatory 
AA carrier 1 (EAAC1), and glutamate transporter-associated protein 3–18 (GTRAP3–18) 
were evaluated. For the detection of GLT-1, EAAC1, GTRAP3–18, and GDH, blots were 
hybridized with 5 to 10 μg of IgG anti-rat GLT-1 polyclonal antibody (Affinity 
BioReagents, Golden, CO), 1 μg of IgG anti-human EAAC1 polyclonal antibody (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA), 4 μg of IgG anti-human GTRAP3–18 (Abcam 
Inc., Cambridge, MA), and 85 μg of IgG anti-bovine GDH (United States Biological, 
Swampscott, MA), respectively, per mL of blocking solution [1% nonfat dry milk 
(wt/vol; Carnation, Nestle, Solon, OH) in 30 mM Tris-Cl (pH 7.5), 200 mM NaCl, 0.1% 
Tween 20 (vol/vol)] for 1.5 h at room temperature with gentle rocking. For AST and 
ALT detection, blots were hybridized with 20 μg of IgG anti-mouse AST (Fitzgerald 
Industries International Inc., Concord, MA) or 40 μg of IgG anti-porcine ALT (United 
States Biological), respectively, per mL of blocking solution [1.5% nonfat dry milk 
(wt/vol) in 30 mM Tris-Cl (pH 7.5), 200 mM NaCl, 0.1% Tween-20] for 1.5 h at room 
temperature with gentle rocking. GPR30 was probed using 0.4 µg of IgG anti-human 
GPR30 polyclonal antibody (Abcam Inc., Cambridge, MA) per mL of blocking solution 
[1% nonfat dry milk (wt/vol), 30 mM Tris-Cl (pH 7.5), 150 mM NaCl, 0.1% Tween 20 
(vol/vol)] overnight at 4°C with gentle rocking.  Lastly, GS was probed using 1.25 μg of 
IgG anti-sheep polyclonal antibody (BD Biosciences, San Jose, CA) per mL of blocking 
37
solution [5% nonfat dry milk (wt/vol), 10 mM Tris-Cl (pH 7.5), 100 mM NaCl, 0.1% 
Tween 20 (vol/vol)] for 1 h at 37°C with gentle rocking. 
All protein-primary antibody binding reactions were visualized with a 
chemiluminescence kit (Pierce, Rockford, IL) after hybridization of primary antibodies 
with horseradish peroxidase-conjugated donkey antirabbit IgG (Amersham, Arlington 
Heights, IL; GLT-1 and EAAC1, 1:5,000; and GDH, 1:7,500); horseradish peroxidase-
conjugated goat antimouse IgG (BD Biosciences; GS, 1:5,000); horseradish peroxidase-
conjugated rabbit anti-sheep IgG (Santa Cruz Biotechnology; ALT and AST, 1:5,000); 
horseradish peroxidase-conjugated goat anti-rabbit IgG (Abcam Inc.; GPR30, 1:5,000); 
or horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology; 
GTRAP3–18, 1:5,000). 
Densitometric analysis of immunoreactive products was performed as described 
previously (Howell et al., 2003; Fan et al., 2004). Briefly, after exposure of 
autoradiographic film (Amersham), digital images of all observed immunoreactive 
species were recorded and quantified using the BioRad Versadoc imaging system and the 
Quantity One Program (version 2.3, BioRad). A single immunoreaction product was 
assessed for treatment effect by densitometric analysis as follows: 
AST, 41kDa; ALT, 23 kDa; GDH, 55 kDa; GS, 43 kDa; GLT-1, 74 kDa; EAAC1, 69 
kDa; and GTRAP3–18, 41 kDa. The linearity of antibody-ligand immunoreactions and 
densitometry were validated using immunoblots containing protein gradients (data not 
shown). Data were collected as arbitrary densitometric units and then were corrected for 
unequal loading, transfer of proteins, or both by normalization to densitometric values of 
Fast-Green-stained (Fisher Scientific, Pittsburgh, PA) proteins common to all 
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immunoblot lanes/samples. For all results, densitometric values were normalized to the 
average d16 control value for each protein by dividing the actual value for the animal by 
the average control value. Digital images were prepared with Power-Point (Microsoft 
PowerPoint 2003, Bellevue, MA). 
Extraction of Total RNA and Relative Real-Time Reverse-Transcriptase-
Polymerase Chain Reaction Assay 
RNA Extraction and Purification. Approximately 200 mg of liver were 
homogenized on ice for 30 s (setting 11, Polytron Model PT10/35, Kinematic, Inc., 
Switzerland) in 2 mL of 4°C TRIzol Reagent (Invitrogen, Carlsbad, CA).  
Total RNA was obtained by an acidic phenol-chloroform extraction as per 
instruction of the manufacturer (Invitrogen). Briefly, chloroform (3 mL or volume to 
volume) was added to each TRIzol® homogenate sample in sterile 7-mL polypropylene 
tubes (Fisher Scientific) and samples were shaken vigorously. After 3 min incubation in 
ice, samples were spun at 12,000 x g for 10 min at 4°C. The aqueous phase containing 
RNA was transferred to a fresh, sterile 7-mL polypropylene tube. After the addition of an 
equal volume of ice-cold isopropanol, samples were precipitated at -80°C for 10 min, and 
then at -20°C overnight. Samples were then thawed and spun at 12,000 x g for 10 min at 
4°C and the supernatant was removed. Each RNA-containing pellet then was washed 
gently with 75% ethanol (0.5 mL) and spun at 7,500 x g for 5 min at 4°C. After the 
supernatant was removed, each tube was allowed to dry for 10 min. Pellets were 
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resuspended in 100 µL of DNAse/RNAse-free water, transferred to 1.5 mL 
microcentrifuge tubes, and stored at -80°C.  
After the crude RNA was recovered, a purification procedure was performed 
using RNeasy Mini Kit (Qiagen, Valencia, CA) to minimize genomic DNA 
contamination (Applied Biosystems, 2004) and enrich all the mRNA longer than 200 
nucleotides in molecular size. Purified RNA was then eluted with 60 µL of RNase-free 
distilled H2O and stored at –80°C.  
Purified RNA was then eluted with 60 µL of RNase-free distilled H2O and stored 
at –80°C. The integrity of the purified RNA was examined by gel electrophoresis using 
Agilent 2100 Bioanalyzer System (Agilent Technologies, Santa Clara, CA) at the 
University of Kentucky Microarray Core Facility. Visualization of the gel images and 
electropherograms showed that all RNA samples had high quality with RNA integrity 
number greater than 8.0 and 28S/18S rRNA ratio greater than 1.8. The purity and 
concentration of the purified RNA samples was analyzed by a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE), which revealed that all 
the samples were of high purity with 260/280 absorbance ratios greater than 2.0 and 
260/230 absorbance ratios greater than 1.75. 
Reverse Transcription (RT). Approximately 3 µg of crude RNA was first 
treated with DNase I enzyme (amplification grade) in accordance with the manufacturer’s 
instructions (Invitrogen) to ensure that no DNA was present. Briefly, one RNA sample 
was combined with 1 µL of 10x reaction buffer, 1 µL of DNase I (1 U/µL), and DEPC-
treated H2O up to 10 µL, incubated at room temperature for 15 min, and then 1 µL of 25 
mM EDTA was added to stop the reaction by incubating at 65°C for 10 min. Then the 
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DNase-treated RNA samples were reverse transcribed to cDNA by using SuperScript III 
First-Strand Synthesis System in accordance with the manufacturer’s instructions 
(Invitrogen). Briefly, a solution of hexamers (50 ng/µL) and oligo (dT)20 primer (50 µM) 
mix (1 µL each) was added to one DNase-treated sample (7 µL in volume), incubated at 
70°C for 10 min, and then chilled on ice for 1 min. A solution containing 2 µL of RT 
buffer (10x), 2µL of dithiothreitol (0.1 M), 4 µL of MgCl2 (25 mM), 1 µL of dNTP (10 
mM each), and 1 µL of RNAse Out was then added to the reaction. After incubation at 
37°C for 2 min, the reaction was incubated with 1 µL reverse transcriptase at room 
temperature for 10 min, and then incubated at 50°C for 50 min. To stop the reaction, the 
reaction mixture was incubated at 70°C for 10 min and then chilled on ice. The resulting 
reaction products, cDNA, were stored at –20°C until used in real-time PCR. 
Real-Time RT-PCR. The relative mRNA quantification methodology for the 
selected DEG identified from the microarray analysis were developed using 2-step real-
time RT-PCR technique following the standard procedure routinely used in our 
laboratory (Liao et al., 2008, 2010).  Before conducting real-time RT-PCR with ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA), primer
and probe sets for GS, ALT, and 18S cDNA were designed and manufactured using ABI 
Assays-by-Design Service (Applied Biosystems). Bovine-specific nucleotide sequences 
were obtained from previously published Genbank (http://www. 
ncbi.nlm.nih.gov/Genbank/GenbankSearch.html) sequences or from the bovine-specific 
database (Cattle Gene Index database) of The Institute for Genomic Research (TIGR) 
(http://www.tigr.org/tdb/tgi/) by using the Basic Local Alignment Search Tool (BLAST) 
function and the appropriate human ortholog nucleotide sequence (Genbank).  These 
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specific parameters including the sequences of the forward and reverse primers and 
probes for relative real-time polymerase chain reaction are provided (Table 3.2). Each 
Assays-by-Design primer and probe set consists of 2 unlabeled PCR primers and one 
TaqMan Minor Groove Binding probe with FAM, a reporter dye labeled at 5' end. 
Components of a 25-µL real-time PCR reaction were an Assays-by-Design Primer and 
Probe set (1.25 µL), TaqMan Universal PCR Master Mix-No AmpErase UNG (12.5 µL), 
cDNA template (1.0 to 2.0 µL), and DNase/RNase free H2O (9.25 to 10.25 µL).
 The PCR 
conditions used for the amplification and quantification were an initial denaturing stage 
(95°C for 10 min), followed by 40 cycles of 2 amplification stages for denaturing (95°C 
for 15 s) and annealing/extension (60°C for 1 min), with a melting curve program (60 to 
95°C), a heating rate of 0.15°C/s, and continuous fluorescence measurements. To 
establish mRNA relative quantification methodology, the real-time PCR products were 
validated by DNA sequence verification, as per Liao et al. (2008). 
Relative mRNA Quantification Methods.  For the relative quantification of GS 
and ALT mRNA expression levels, real-time quantitative RT-PCR methodology that 
used 2-step regimen was developed in accordance with ABI guidelines (Applied 
Biosystems, 2004). In the first step, all the RNA samples were reverse-transcribed to 
cDNA as described above for RT reaction. In the second, real-time PCR step, relative 
standard curve methods were established for both GS and ALT cDNA. For each mRNA 
quantified, ribosmal 18S RNA was selected as an endogenous control to normalize the 
variations in sample preparation, mRNA inputs, and RT efficiencies (Liao et al., 2008). 
Bovine liver total RNA was reverse transcribed, the cDNA sample was serially diluted 
2.5×, 5×, 25×, 125×, 625×, 3,125×, 15,625×, 78,125×, and 390,625×, and the linear range 
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for target mRNA quantification was established to ascertain an appropriate amount of 
cDNA to be used for a standard curve method. For each cDNA sample the real-time PCR 
reactions (as described above) were conducted in triplicate to average out the potential 
pipetting, mixing, or plate preparation errors. The minimal threshold (CT) values detected 
using these dilutions were 35 and 21 for the target and 18S cDNA, respectively. As a 
result, the optimal detection of GS, ALT and 18S cDNA were achieved by using 1:5, 1:5 
and 1:15,625 dilutions of the RT product stocks, respectively. The estrogen treatment 
effect on the expression of 18S rRNA by the liver was evaluated by comparing the CT 
values obtained from the real-time PCR reactions (Applied Biosystems, 2004). The 
relative quantities of GS and ALT mRNA expression were normalized to the relative 18S 
quantities by calculating the target gene:18S relative quantity ratios, and these 18S-
normalized quantity ratios were used for estrogen treatment effect on GS and ALT 
mRNA expression, the 18S-normalized ratio from the control animals (i.e., sham-
implanted) was designated as a calibrator. Then the 18S-normalized ratios for the 
estrogen-implanted cows, as well as the control animals, were divided by the ratio of the 
calibrator, respectively. The CT values for 18S rRNA quantities and the calibrated values 
for estradiol treatment effect were all subjected to statistical analysis. 
Statistical Analysis 
Data are presented as least square means (± SEM). Experimental parameters were 
evaluated for treatment differences by ANOVA (version 8.01, SAS Inst. Inc., Cary, NC). 
For all parameters, the MIXED procedure of SAS with the REPEATED statement was 
used. Cow was the experimental unit and the effects of estrogen treatment (TRT), time 
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after implant (DAY), and their interaction (TRT x DAY) were assessed. The statistical 
model used estrogen treatment as the fixed effect. Class variables were estrogen 
treatment (TRT) and cow, with cow included in the random statement. Kenward-Roger 
adjustment was used to calculate the denominator df (Kenward and Roger, 1997).  
RESULTS AND DISCUSSION 
Plasma Estradiol Concentrations, but not Progesterone, Were Increased in 
Compudose-implanted Cows 
The primary goal of this project was to determine if exogenous estradiol affects 
the expression of GS, ALT, AST, and other proteins associated with hepatic metabolism 
of alanine and glutamine in old beef cows. To elaborate these findings, the potential 
effects of estradiol supplementation on various blood analytes also were determined. 
However, first, to validate that estradiol implantation actually increased plasma estradiol 
levels, plasma estrogen levels were compared between control and implanted cows 
(Table 3.3). Estradiol levels of control cows were typical (personal communication, Keith 
Schillo, University of Kentucky). The overall experimental mean plasma estradiol 
concentration of implanted cows (5.07 pg/mL) was 221% more (P = 0.007) than for 
control cows (1.58 pg/mL). In contrast, neither DAY nor TRT × DAY interactions were 
detected. These results reflect similarly increased levels of estrogen in estradiol-
implanted cows at d 14 and 28 d after implantation, vs non-implanted control cows. 
Normally in reproductively mature cows, the ovary is the main source of 
progesterone, estrogen, and androgens (Allen and Doisy, 1923) and the relative amounts 
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of these steroids vary during the estrous cycle and throughout pregnancy. During the 
follicular stage of the estrous cycle, estradiol is the predominant steroid hormone secreted 
by the ovarian follicles. Specifically, in the follicle, thecal cells produce androstenedione 
that is then delivered to the granulosa cells to be aromatized into estradiol and other 
estrogens (Hillier et al., 1994). As the follicle matures, estrogen production continually 
increases until an abrupt release of two anterior pituitary hormones, luteinizing hormone 
(LH) and follicle stimulating hormone (FSH), induce ovulation.  Generally, after 
ovulation, progesterone becomes the predominant hormone secreted by the ovary. 
Specifically, the corpus luteum (CL), formed from the ruptured follicle, is responsible for 
the production of progesterone during the luteal phase of the estrous cycle and, if 
applicable, throughout pregnancy.   
In our old cow model, plasma progesterone levels were not affected by estradiol 
TRT (P = 0.229), DAY (P = 0.226), or TRT x DAY (P = 0.337) (Table 3.3). These results 
indicate that the administration of exogenous estradiol did not affect plasma progesterone 
concentrations after 14 or 28 d of implantation. Thus, exogenous estradiol did not appear 
to affect the estrus cycle of implanted cows even though, quantitatively, the mean 
progesterone concentration of implanted cows was about 50% that of implanted cows on 
d 14 and non-implanted cows on both d 14 and 28. Comparison of d 14 and d 28 estradiol 
and progesterone levels within each cow (data not shown) revealed that all cows 
experienced estrous during the experimental period.  
Cow BW were measured at d 0, 14, and 28. By design, initial BW did not differ 
(P = 0.392) between control (585 kg) and implant (621 kg) cows. By d 14, both groups 
had lost 13 ± 2 kg (P = 0.019), with no difference in BW (P = 0.407) between control 
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(573 kg) and implant (607 kg) groups. From d 14 to d 28, control group cows gained 4 ± 
3 kg and implanted cows gained 6 ± 4 kg. However, these apparent differences in BW 
gain were not statistically significant (P ≥ 0.407). Consistently, there was no differences 
(P = 0.407) in the BW between control and implant animals over the whole 28 d 
experiment. These results indicate that despite an elevated blood estradiol, BW was not 
affected after 28 d of cows consuming the alfalfa hay-based diet ad libitum.   
Estradiol Implantation Increases Hepatic GS mRNA and Protein Content, But has 
Little Effect on Other Glutamate/Glutamine/Alanine Metabolizing Proteins 
The activities of GS, ALT, and other anionic amino acid-metabolizing enzymes 
are essential to facilitate the metabolism of glutamine and aspartate (Heidger and 
Welbourne, 1999; Welbourne and Nissim, 2001). In the liver, glutamine arriving from the 
portal vein is absorbed by the periportal hepatocytes by the hepatic system N activity 
(Kilberg et al., 1980) and converted to L-glutamate and ammonia by mitochondrial 
glutaminase. Mitochondrial ALT also can produce glutamate by converting skeletal 
muscle-derived alanine to glutamate and pyruvate in the periportal hepatocytes. 
Glutaminase- and ALT-derived glutamate can be metabolized by periportal hepatoycte-
localized GDH to ammonia and α-ketoglutarate, or glutamate can be exported into the 
sinusoid and then absorbed by pericentral hepatocyte-localized EAAC1 or GLT-1 
glutamate transporter. Recently, GTRAP3-18 has been shown to be an inhibitory 
regulator of at least neuronal EAAC1 activity and GTRAP3-18 abundance is reversely 
proportional to EAAC1 activity (Ruggiero et al., 2008; Watabe et al., 2008). Once 
absorbed by the periportal hepatocytes, sinusoidal glutamate and ammonia can be 
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conjugated by GS to glutamine. In cultured rat glial cells (Hagheighat, 2005) and mouse 
brain tissue (Blutstein et al., 2006), estradiol is known to upregulate GS content and 
function. In contrast, estrogen did not affect GS activity in cultured primary rat 
hepatocytes (Sirma et al., 1996).  
To determine the effect(s) of implant-administered exogenous estrogen (Table 
3.3-3.4) on certain proteins responsible for aspartate, alanine, and glutamine metabolism 
in the liver, immunoblot analysis was performed to quantify the relative liver content of 
GS, ALT, AST, GDH, GLT-1, EAAC1, and GTRAP3-18 in estradiol implanted vs non-
implanted old cows (Table 3.4). For GS, estradiol TRT (P = 0.008), DAY (P = 0.024), 
and TRT x DAY (P = 0.024) effects were observed. More specifically, GS content was 
increased 350% by d 14 and 200% by d 28. However, in contrast to GS, estradiol 
supplementation did not affect (P ≥ 0.159) the relative content of any other evaluated 
protein. Although a DAY effect was observed for ALT (P = 0.033), AST (P = 0.083), 
GLT-1 (P = 0.005), EAAC1 (P = 0.083), and GTRAP3-18 (P = 0.014), no TRT x DAY 
interactions were found for these proteins.  Collectively, these findings indicate that 
hepatic expression of GS in old beef cows is sensitive to stimulation by supplemental 
estradiol, whereas expression of other proteins that support hepatic glutamate metabolism 
are not. 
To determine if estradiol implantation affected the transcription of ALT and GS, 
the relative mRNA content of ALT and GS was compared in control vs estradiol-
implanted cows (Table 3.5). GS mRNA expression was increased (P = 0.024) 34 and 
99% at d 14 and 28, respectively, in implanted vs non-implanted cows. These results are 
consistent with the observed increase in GS protein content in estradiol-implanted cows 
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and indicate that estradiol-mediated upregulation of GS expression occurs at least at the 
transcriptional level. For ALT mRNA content, a tendency (P = 0.087) for a TRT x DAY 
interaction was observed, apparently reflecting a 39% increase in ALT mRNA content at 
d 28 by old cows receiving the estradiol implants, and suggesting that that any effect of 
estradiol on ALT mRNA expression is over-ridden by post-transcriptional events.   
Estradiol Supplementation Increases Blood Content of Total Protein, Globulin, γ-
glutamyltransferase, and Potassium 
To gain a greater understanding of the potential effects of increased estradiol 
blood levels and hepatic GS content on whole-body metabolism of old cows, the profiles 
of serum enzymes and other blood constituents were compared between control and 
estradiol-implanted cows (Table 3.6). Plasma ammonia and serum urea N levels were not 
affected by estradiol (P ≥ 0.348) or day (P ≥ 0.724), suggesting that the urea cycle 
function was not influenced by estrogen supplementation. Similarly, no estradiol TRT (P 
≥ 0.635) or DAY (P ≥ 0.255) effects were found on the amount of serum alkaline 
phosphatase (ALP), ALT, or AST activities.  
As an indicator of whole-body protein synthetic status, the concentration of total, 
albumin, and globulin serum proteins was determined. Total serum protein was increased 
by estradiol TRT (P = 0.021) and DAY (P = 0.001), and no TRT x DAY interaction (P = 
0.279) was observed, reflecting 6.5 and 8.6% more total serum protein at d 14 and d 28, 
respectively, in estradiol- vs non-implanted cows. Two principal proteins measured in the 
total serum protein levels are albumin and globulin. Albumin is produced predominantly 
by the liver, whereas globulin is synthesized by the immune system and by the liver, 
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depending on the globulin type. Serum albumin concentration was not affected (P = 
0.827) by estradiol TRT. An observed DAY effect (P = 0.011) without a TRT x DAY 
interaction (P = 0.240) appears to reflect the 3% greater amount of albumin in both 
groups of cows by d 28 vs d 14. In contrast, serum globulin levels in estradiol-treated 
cows were greater (P = 0.035) than for control cows, even though globulin levels for both 
groups were higher on d 28 than 14. Globulins have various functions, including 
triggering immune responses to infections and transporting metals and other molecules. 
Even though the albumin/globulin ratio values were numerically lower for estradiol-
treated cows, no estradiol TRT (P = 0.122) or DAY (P = 0.796) effects were observed. 
However, a tendency for a TRT x DAY interaction was observed, which likely reflects 
the higher globulin, thus lower albumin/globulin ratio, of the estradiol-treated cows by d 
28. The observation that serum albumin concentrations were within reference values for
both groups, indicates that the cows were not suffering from dehydration. In contrast, 
serum globulin levels for both groups were higher than the reference value.  
Although not affected by TRT alone (P = 0.271), there was a DAY effect (P = 
0.011) and DAY x TRT interaction (P = 0.020) on γ-glutamyltransferase activity, 
apparently reflecting a 36% increase in on γ-glutamyltransferase from 14 d to 28 d. γ-
glutamyltransferase is involved in glutathione metabolism by catalyzing the conversion 
of glutathione + an amino acid to cystinylglycine + 5-L-glutamyl amino acid (Kaneko et 
al., 1997).  GGT is localized to cell membranes that have high secretory and absorptive 
capacity such as those in the liver, kidney, pancreas, and most other cells, except skeletal 
muscle which lacks GGT activity. In the liver, γ-glutamyltransferase is produced by the 
hepatic microsomes which is ubiquitously distributed in cells involved in bile absorption 
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and secretion, and is an important indicator of liver cell damage and cholestasis (Cabrera-
Abreu and Green, 2002). Hepatic γ-glutamyltransferase activity is primarily utilized to 
identify hepatobillary insults because it is more sensitive to minimal liver damage than 
ALP (Nemesanszky and Lott, 1985; Bartholomew et al., 1987) and typically increases 
with liver damage.  
The breakdown of hemoglobin by the reticuloendothelial system results in 
formation of bilirubin (Giannini et al., 2005), and the hemoglobin for the production of 
bilirubin comes from the senescent erythrocytes (Dufour et al., 2000). An increase in 
serum bilirubin suggests liver damage, however, total bilirubin activity was not affected 
by TRT (P = 0.904). Similar to bilirubin levels, changes in blood creatinine levels can be 
indicative of altered levels of protein catabolism in cattle (Roubicek et al., 1970), or be 
indicative of altered glomerular filtration rates and, thus, renal dysfunction (Perrone et al., 
1992). However, creatinine levels in plasma were not affected by estradiol TRT, DAY or 
their interaction (P > 0.128).  
In terms of indicators of energy metabolism, no TRT (P ≥ 0.494), DAY (P ≥ 
0.099), or TRT x DAY interactions (P ≥ 0.556), were found for concentrations of creatine 
kinase, glucose, and cholesterol, or for LDH activity. However, a TRT x DAY interaction 
on triglyceride concentration appears to reflect a % higher (P = 0.035) level of 
triglycerides on d 14 in estradiol-implanted vs control cows.  
To determine if estrogen treatment affect mineral metabolism, serum minerals 
were measured in control and estradiol implanted cows (Table 3.7). There was no TRT 
effect (P > 0.197) on serum levels of calcium, chloride, magnesium, phosphorus, or 
sodium. However, there was a DAY effect (P ≤ 0.046) on calcium, chloride, and 
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magnesium concentrations. Over time, both calcium and chloride increased by 9% and 
2%, respectively, whereas, magnesium decreased by 10% from 14 d to 28 d. However, a 
DAY effect was not detected (P = 0.598) on serum phosphorus concentration. In contrast 
to the other minerals, there was an estrogen TRT (P = 0.031) and DAY (P = 0.001) effect 
on potassium concentrations, but no TRT x DAY interaction (P = 0.367).  Overall, the 
potassium serum concentration of implanted cows was 8% higher than for control cows 
and potassium levels of both control and implanted cows increased 14.5% from 14 d to 
28 d.  
Because estrogen is known to affect immunological responses after injury 
(Kovacs et al., 2002; Bird et al., 2008), the effect of estrogen on the presence of blood 
cell types was evaluated (Table 3.8). Between treatments, no TRT or TRT x DAY 
interaction effects were detected for hemoglobin (P > 0.599) or packed cell volume (P ≥ 
0.390), nor for RBC, WBC, neutrophil, lymphocyte, or eosinophil counts (P ≥ 0.227). In 
both control and implanted cows, there was a DAY effect (P ≤ 0.006) on both 
hemoglobin concentration and monocyte cell counts. From d 14 to 28, hemoglobin levels 
increased 3%, whereas monocyte levels decreased 60%. Overall, all values from the 
complete blood count fall within the normal reference ranges, thus indicating a normal 
health status for both groups.  
Estrogen Receptor-mediated Cell Signaling 
In representations of the classical (intracellular) estrogen signaling pathway (Behl, 
2002; Kelly et al., 2005), estrogen can transverse across the plasma membrane to bind to 
the estrogen receptor (ER) α (ERα) or β (ERβ). After binding with an ER, the 
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estrogen/ER complex migrates into the nucleus and initiates transcription by either 
directly interacting with the estrogen response element (ERE) on the promoter region of 
target genes or indirectly by interacting with other transcriptional factors (e.g., . β-
catenin, Ras). These effects are considered long-term “genomic” effects.  
Besides activating the classical estrogen pathway through binding of ERα and 
ERβ, estrogen also can bind to described membrane-bound plasma receptors, such as 
GPR30 (Thomas et al., 2005; Heldring et al., 2007). Although this “non-genomic” 
estrogen pathway is not fully understood, or even described in cattle, in the human brain, 
estrogen binding of GRP30 activates the adenylyl cyclase, phosphoinositol 3 kinase 
(PI3K), and the phospholipase C pathways (Thomas et al., 2005; Heldring et al., 2007, 
Albanito et al., 2007). Also, in the human liver, estrogen has been indicated to enhance 
liver function after a trauma-induced hepatic hemorrhage via GPR30-mediated protein 
kinase A activation (Hsieh et al., 2007). Moreover, evidence for cross-talk between ER 
and GPR30 has been accumulating (Sheng and Zhu, 2011). 
In cattle, ERα and ERβ mRNA have been observed in the liver, uterus, mammary 
gland, lung, heart, kidney, gastrointestinal tract, and skeletal muscle (Pfaffl et al., 2001). 
We attempted to measure the relative content of ERα but were unable to because of the 
failure of commercially-available antibodies to recognize ERα in cow liver homogenates. 
However, the specificity of the human anti-GPR30 antibody against the putative bovine 
GPR30 was validated using antibody:antigen peptide prehybridization methods (Xue et 
al., 2011) and homogenates of liver from control animals (Figure 3.1). Two (40 and 58 
kDa) GPR30 immuno-reactive products were observed to be sensitive to increasing 
amounts of the GPR30 antigen. To determine if the expression of GPR30 played a role in 
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the estrogen-mediated effect of glutamine synthetase up-regulation, the protein content of 
GPR30 was evaluated in the liver of old cows given exogenous estrogen (Table 3.4). 
Although a DAY effect was observed (P = 0.010), neither a TRT (P = 0.968) nor TRT x 
DAY interaction (P = 0.732) were found. This result indicates that GPR30 protein 
expression was not affected by increased levels of estradiol supplementation achieved 
through the use of Compudose.   
Overall, there are three salient observations from this study. First, the levels of 
plasma estradiol resulting from 28 days of Compudose implantation in old cycling beef 
cows have been characterized. To our knowledge, this is the first report of actual plasma 
estradiol concentrations resulting from estradiol implantation in cows. Second, the 
hypothesis that hepatic GS mRNA and protein expression would be up-regulated by 
exogenous estradiol is accepted as the defined (1- to 2-fold) increase in plasma estradiol 
of Compudose-implanted old cows was concomitant with an increase in GS protein (3-
fold) and mRNA (0.3- to 0.6-fold). Conversely, the hypothesis that ALT and AST 
expression would be decreased is rejected. Future experimentation that characterizes 
amino acid concentrations in liver and blood of estradiol-implanted cattle will be required 
to understand the significance of these finding on whole-body N metabolism. Third, the 
identification that cattle liver expresses GRP30 protein is a novel observation, and 
enables subsequent research into GRP30-mediated cellular metabolism. Fourth, elevated 
plasma estradiol for 28 d had little affect on blood biochemical and clinical indicators of 
whole-body metabolism.  
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Table 3.1: Proximate and mineral analysis of alfalfa hay fed to old cows throughout the 
trial (dry matter basis)1  
Item 
Proximate analysis 
  DM, % 91.4 
  CP, % 13.4 
  Available Protein, % 12.0 
  ADICP, % 1.4 
  Adjusted CP, % 13.3 
  Soluble Protein % CP 27.5 
  Degradable Protein %CP 60.0 
  NDICP, % 4.9 
  ADF, % 41.2 
  NDF, % 62.6 
  Lignin, % 7.9 
  NFC, % 18.8 
  NSC, % 7.0 
  Starch, % 2.0 
  Sugar, % 5.1 
  Crude Fat, % 2.0 
  TDN, % 54 
  NEL, Mcal/lb 0.47 
  NEM, Mcal/lb 0.45 
  NEG, Mcal/lb 0.20 
Mineral analysis 
  Ash, % 8.18 
  Calcium, % 0.92 
  Phosphorus, % 0.29 
  Magnesium, % 0.24 
  Potassium, % 2.09 
  Sulfur, % 0.19 
  Chloride Ion, % 0.50 
1Proximate and mineral values are an average of 15 samples collected throughout the trial 
and presented on a DM basis. 
Table 3.2:  Primer and probe sets used for the real-time quantitative PCR analyses of metabolic enzyme mRNA and 18S rRNA 
Primer and Probea Location on template (bp) Sequence
b Amplicon size (bp) 
GS (TIGR  
TC274284) 
  Forward 702-720 5'-CACGAATGCCGAGGTCATG-3' 
  Probe (fwd.) 726-739 5'-FAM-ACAGTGGGAATTCC-3' 62 
  Reverse 740-763 5'-CGATTCCTTCACAGGGTCCTATCT-3'
ALT (TIGR  
TC310617) 
  Forward 975-996 5'-CCTCCTTCCACTCGATCTCCAA-3' 
  Probe (rev.) 1002-1017 5'-FAM-CCGCACTCGCCCATGT-3' 79 
  Reverse 1031-1053 5'-TCCATATTCACCACCTCCACGTA-3'
18S (GenBank  
DQ222453) 
  Forward 548-572 5'-CCCTGTAATTGGAATGAGTCCACTT-3' 
  Probe (rev.) 593-611 5'-FAM-CCAGACTTGCCCTCCAATG-3' 100 
  Reverse 625-647 5'-ACGCTATTGGAGCTGGAATTACC-3'
aGS = glutamine synthetase; ALT = alanine transaminase; 18S = 18S ribosomal RNA.  The contents in the parentheses associated with 
each protein are the accession numbers for the reported sequences retrieved from the public databases (TIGR or GenBank) and used as 
templates for designing primers and probes. The custom TaqMan probes were supplied in either the forward (fwd.) or the reverse (rev.) 
orientation as indicated in the parentheses for each probe. 
b“FAM” labeled at the 5’ end of the TaqMan probe is six-carboxy-fluorescein which is used as a reporter dye in the real-time PCR 
procedure. 
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Table 3.3: Plasma estradiol and progesterone concentrations of old cows receiving Control or Estradiol treatment1 
Treatment
Control  Estradiol   Overall P-value
Item 14 d 28 d Overall 14 d 28 d Overall SEM2  TRT DAY TRT × DAY 
Estradiol, pg/mL 1.65 1.50 1.58  4.14 5.99 5.07 1.04  0.007 0.415 0.339 
Progesterone, 
ng/mL 
4.56 4.29 4.43 4.45 2.22 3.34 0.92  0.229 0.226 0.337 
1Data are presented as least square means (n = 7) ± SEM for hormone concentrations of Control and Estradiol (25.7 mg estradiol) 
treatment cows collected at 14 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials and 
Methods. 
2Most conservative error of the mean. 
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Table 3.4: Densitometric analysis of content of AA enzymes and transporters in liver homogenates of old cows receiving Control or 
Estradiol treatment1 
Treatment
Control Estradiol Overall P-value
Item2 14 d 28 d Overall 14 d 28 d Overall SEM3 TRT DAY TRT× DAY 
GS4 1.00a 0.97a 0.99 4.50b 2.90c 3.70 0.65 0.008 0.024 0.028 
ALT 1.00 0.34 0.67 0.61 0.34 0.48 0.21 0.402 0.033 0.332 
AST 1.00 1.48 1.24 0.90 1.39 1.15 0.26 0.713 0.083 0.978 
GDH 1.00 0.82 0.91 1.00 1.05 1.03 0.14 0.514 0.514 0.251 
GLT-1 1.00 1.95 1.48 0.90 1.56 1.23 0.24 0.329 0.005 0.534 
EAAC1 1.00 0.63 0.82 1.19 0.84 1.02 0.16 0.159 0.083 0.980 
GTRAP3-
18 
1.00 0.64 0.82 0.86 0.53 0.70 0.13 0.409 0.014 0.874 
GPR30 1.00 2.06 1.53 1.13 1.97 1.55 0.44 0.968 0.010 0.732 
1Values (normalized arbitrary units) are arithmetic means (n = 7) ± SEM of relative protein content from liver biopsy samples 
of Control and Implant (25.7 mg estradiol) treatment cows collected at 14 and 28 d after implanting. Densitometric evaluation 
of all immunoreactive species was performed. Data were analyzed as a repeated measure as described in Materials and 
Methods. 
2Values were normalized to the average control value at 16 d for each protein by dividing the actual value for the animal by the 
average control value. The following is a list of those average control values (in arbitrary units) ± SE used for normalization: 
ALT, 892 ± 259; AST, 1,542 ± 397; EAAC1, 1,614 ± 155; GDH 2,605 ± 270; GPR30, 1,108 ± 425; GS, 569 ± 245; GLT-1, 
830 ± 164; GTRAP3-18, 2,590 ± 448. 
3Most conservative error of the mean. 
4Means in a column that lacks a common letter differ (P ≤ 0.056). 
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Table 3.5: Relative content of ALT and GS mRNA in liver homogenates of old cows receiving Control or Estradiol treatment1 
Treatment
Control Estradiol  Overall P-value
Item2 14 d 28 d Overall 14 d 28 d Overall SEM3 TRT DAY TRT × DAY 
GS 1.00 0.79 0.90 1.34 1.57 1.46 0.23 0.024 0.961 0.313 
ALT 1.00 1.04 1.02 0.90 1.43 1.17 0.16 0.410 0.054 0.087 
1Data are the least square means (n = 6-7) ± SEM of the relative mRNA quantities from liver biopsy samples of Control and 
Implant (25.7 mg estradiol) treatment cows collected at 16 and 28 d after implanting. 
2The normalized quantities of the control and estrogen treatment groups on 14 and 28 d calibrated to the control group on 14 d. 
Data were analyzed as a repeated measure as described in Materials and Methods. 
3Most conservative error of the mean. 
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Table 3.6: Serum and plasma analytes of old cows receiving Control or Estradiol treatment1 
Treatment
Control  Estradiol Overall P-value
Item2 14 d 28 d Overall 14 d 28 d Overall SEM3 TRT DAY TRT ×DAY 
Reference 
Range4
Ammonia, mM6 0.028 0.028 0.028 0.030 0.032 0.031 0.004 0.567 0.724 0.724  - 
Urea nitrogen, 
mg/100 mL 
11 12 12 11 11 11 1 0.348 1.000 0.341  5.0-27.0 
ALP, U/L 50 46 48 54 45 50 7 0.856 0.255 0.674  100-500 
ALT, U/L 22 23 23 23 23 23 2 0.889 0.570 0.400  11-405
AST, U/L 79 69 74 70 71 70.5 5 0.635 0.289 0.223  0-160 
Total protein, g/100 
mL 
7.7 8.1 7.9 8.2 8.8 8.5 0.18 0.021 0.001 0.279  6.50-7.50 
Albumin, g/100 mL 3.3 3.4 3.4 3.3 3.4 3.4 0.1 0.827 0.011 0.240  2.3-3.7 
Globulin, g/100 mL 4.5 4.7 4.6 4.9 5.4 5.2 0.2 0.035 0.014 0.178  3.0-3.5 
Albumin/Globulin 
ratio 




14 14 14 14 19 17 1 0.271 0.011 0.020  2-20 
Total bilirubin, 
mg/100 mL 
0.40 0.43 0.42 0.41 0.43 0.42 0.05 0.904 0.577 0.852  0.0-0.5 
Creatinine, mg/100 
mL 
1.4 1.3 1.4 1.5 1.4 1.5 0.1 0.342 0.128 0.381  1.00-2.00 
1Data are presented as least square means (n = 6-7) ± SEM for serum enzymes of Control and Implant (25.7 mg estradiol) treatment 
cows collected at 14 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase. 
3Most conservative error of the mean. 
4Taken from the University of Kentucky Livestock Disease Diagnostic Lab unless noted otherwise. 
5Taken from Kaneko et al., 1997. 
6Plasma. 
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Table 3.6: Serum and plasma analytes of old cows receiving Control or Estradiol treatment1  (con’t) 
Treatment
Control  Estradiol Overall P-value
Item2 14 d 28 d Overall 14 d 28 d Overall SEM3 TRT DAY TRT ×DAY 
Reference 
Range4
Creatine kinase, U/L 114 143 129 124 161 143 19 0.494 0.099 0.834 100-650 
Glucose, g/100 mL 105 101 103 105 101 103 13 0.983 0.627 0.977  40-100 
LDH, U/L 997 1037 1017 1008 1020 1014 55 0.960 0.510 0.715  629-1445 
Triglycerides, g/100 
mL 
25 29 27 32 30 31 2 0.153 0.351 0.035  - 
Cholesterol, mg/100 
mL 98 107 103 99 102 101 5 0.757 0.179 0.556  62-193 
1Data are presented as least square means (n = 6-7) ± SEM for serum enzymes of Control and Implant (25.7 mg estradiol) treatment 
cows collected at 14 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase. 
3Most conservative error of the mean. 
4Taken from the University of Kentucky Livestock Disease Diagnostic Lab unless noted otherwise. 
5Taken from Kaneko et al., 1997. 
6Plasma. 
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Table 3.7: Serum minerals of old cows receiving Control or Estradiol treatment1 
Treatment
Control Estradiol Overall P-value





8.4 9.2 8.8 8.5 9.2 8.9 0.2 0.874 0.001 0.653  9-12 
Chloride, 
mg/dL 
107 109 108 107 108 108 1 0.928 0.046 0.664  97-111 
Magnesium,  1.6 1.5 1.6 1.7 1.4 1.6 0.1 0.673 0.011 0.261 1.5-2.4 
Phosphorus, 
mg/dL 
5.6 5.5 5.6 5.9 5.4 5.7 0.6 0.874 0.598 0.719  4-7 
Potassium, 
mmol/L 
3.1 3.7 3.4 3.5 3.9 3.7 0.1 0.031 0.001 0.367  3.9-5.8 
Sodium, 
mmol/L 
142 143 143 145 143 144 1 0.197 0.438 0.186  132-152 
1Data are presented as least square means(n = 6-7) ± SEM for serum minerals of Control and Implant (25.7 mg estradiol) treatment 
cows collected at 14 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Most conservative error of the mean. 
3Taken from the University of Kentucky Livestock Disease Diagnostic Lab. 
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Table 3.8: Blood cell types of old cows receiving Control or Estradiol treatment1 
Treatment
Control Estradiol  Overall P-value





7.22 7.30 7.26 6.86 7.01 6.94 0.25 0.369 0.367 0.771  5-10 
Hemoglobin, 
g/dL 
12.6 13.0 12.8 12.3 12.7 12.5 0.45 0.599 0.006 0.961  8-15 
Packed cell 
volume, % 
38.8 39.3 39.1 36.9 37.7 37.3 1.42  0.390 0.312 0.745  24-46 
WBC, 1 × 
103/µL 
7.19 7.18 7.19 7.72 7.40 7.56 1.10 0.801 0.801 0.806  4-12 
Neutrophils, 
1 × 103/µL 
2.236 2.586 3.529 2.226 2.429 2.328 0.556 0.905 0.556 0.874  0.06-4.004 
Lymphocytes, 
1 × 103/µL 
3.724 3.888 3.806 4.360 4.058 4.209 0.843 0.739 0.763 0.320  2.5-7.54 
Monocytes, 1 
× 103/µL 
0.694 0.280 0.487 0.555 0.215 0.385 0.091 0.227 0.001 0.650  0.0-0.94 
Eosinophils, 
1 × 103/µL 
0.508 0.430 0.469 0.573 0.692 0.633 0.196 0.387  0.900 0.551  0.0-2.44 
1Data are presented as least square means (n = 6-7) ± SEM for serum minerals of Control and Implant (25.7 mg estradiol) 
treatment cows collected at 14 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials 
and Methods. 
2Most conservative error of the mean. 
3Taken from the University of Kentucky Livestock Disease Diagnostic Lab unless noted otherwise. 
4Taken from Duncan et al., 1994. 
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Figure 3.1: Detection of GPR30 protein in bovine liver, using human anti-GPR30 
polyclonal antibody. 
 
The specificity of human anti-GPR30 polyclonal antibody (Ab) to detect bovine GPR30 
was tested in homogenates (60 µg) of bovine liver from three cows (lanes 1, 2, 3) by 
preabsorption of Ab with 0 (Ab only), 0.052 (Ab + 0.0524 µM Ag), or 0.520 (Ab + 0.524 
µM Ag) µM of the Ab antigenic polypeptide (Ag) before immunoblotting. The apparent 
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Chapter 4 
17β-estradiol stimulation of glutamine synthetase expression in the liver of old (but 
not of young) beef cows maybe refractory and independent of β-catenin or GRP30 
expression 
INTRODUCTION 
Aging is associated with decreased metabolic functions and decreased gene 
expression of proteins responsible for intermediary metabolism in the liver (Serstè and 
Bourgeois, 2006). In cattle, little information is known about the relationship between 
hepatic function and aging. However, previous research in our lab has shown that the 
content of GS protein in the liver of old (≥ 10 years old), mature cows is decreased by 46 
to 71% compared that of young (3-5 years old) adult cows, whereas ALT content was 61 
to 73% less in old cows (Matthews and Sipe, 2006). In the previous trial (Chapter 3), it 
was determined that 17β-estradiol (estradiol) supplementation in the form of 
COMPUDOSE implants for 28 days increased the basal content of GS mRNA and 
protein, but not ALT, in the liver tissue of old beef cows with unknown and mixed 
genetic (breed) backgrounds, and having had ad libitum access to alfalfa hay-based diet.  
However, the role of putative mediators of estradiol stimulation of GS expression were 
not evaluated.  
Estrogen regulated cellular events can be divided into “classical” and “non-
classical” pathways.  The classical pathway of estrogen regulation of cellular events 
involves the transport of the ligand-bound α- or β-estrogen receptors (ER) from the 
plasma membrane into the cell to promote in nuclear transcription and/or mediate non-
nuclear cell signaling cascades (Figure 4.1). In the genomic pathway, estradiol-bound 
estrogen receptors bind to the estrogen response element located on the promoter region 
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of target genes or interact with other transcription factors (e.g. β-catenin) to initiate the 
transcription of target genes with no estrogen response elements present on the promoter 
region (Heldring et al., 2007).  Estrogen α and β receptor mRNA are expressed by liver 
tissue of cattle but not affected by zeranol, a strong estrogenic and anabolic compound 
(Pfaffl et al., 2001).  Our attempts to validate commercially-available ERα and ERβ 
antibodies to detect bovine orthologs failed.  
Non-classical estrogen pathways include estrogen activation of the G protein-
coupled receptor 30 (GPR30)-dependent and the β-catenin/Wnt pathways (Figure 4.2).  G 
protein-coupled receptor 30, a recently discovered membrane-bound plasma receptor, is 
thought to be a prime target in the activation of non-genomic regulation of target genes 
by estrogen (Figures 4.1, 4.2).  Although the GPR30 pathway is poorly understood, in the 
human liver estrogen has been indicated to enhance liver function after a trauma-induced 
hepatic hemorrhage via GPR30-mediated protein kinase A activation (Hsieh et al., 2007). 
In the canonical Wnt pathway, Wnt signals by activating β-catenin for 
translocation into the nucleus (Figure 4.2). As a lipoglycoprotein, Wnts are secreted from 
neigboring cells to interact with two plasma-membrane bound receptors, frizzled and 
low-denisity-lipoprotein-related protein (LRP) receptors (Daugherty and Gottardi, 2007; 
Sonderegger et al., 2010). Ligand binding (e.g., estradiol) of Wnt and LPR5/6 triggers the 
activation of β-catenin by inhibiting the β-catenin degradation complex through the 
transducer protein, disheveled (Dvl).  This complex contains two scaffolding proteins, 
axin and adenomatous polyposis coli (APC), and two serine/threonine protein kinases, 
glycogen synthase kinase 3β (GSK3β) and casein kinase I.  The regulatory actions of Wnt 
allows for the non-phosphorylated form of β-catenin to dissociate from the degradation 
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complex and bind to T cell factor (TCF) and other transcription factors for translocation 
into the nucleus to activate target genes.  In the absence of Wnt activation, β-catenin is 
phosphorylated by GSK3β or casein kinase I and is targeted for ubiquitin-mediated 
degradation by the APC and axin proteins. 
Estrogen is thought to be a major modulator in the Wnt pathway.  In the uterine 
epithelium, estradiol can up-regulate the expression of two Wnt proteins (Wnt4 and 
Wnt5a) and to trigger nuclear translocation of β-catenin in an estrogen receptor-
independent manner (Hou et al., 2004). However, it also has been demonstrated that ERα 
is known to interact with β-catenin in osteoblasts (Foo et al., 2007), Drosophila, and 
certain human cancer cell lines (Kouzmenko et al., 2004).  Furthermore, in the rat 
hippocampus, estradiol can bind to β-catenin for translocation into the nucleus 
(Cardonna-Gomez et al., 2004).  
β-catenin may be a modulator of estradiol stimulation of GS expression because 
of its additional reputed role in maintaining GS expression in pericentral hepatocytes 
(Burke and Tosh, 2006).  In addition, other proteins involved in glutamate metabolism 
are regulated by β-catenin.  For example, pericentral hepatocyte-expressed ornithine 
aminotransferease is up-regulated in transgenic mice overexpressing hepatic β-catenin, as 
is mRNA for pericentral hepatocyte-expressed high-affinity glutamate transporter GLT-1 
and glutamine synthetase is up-regulated by overexpression of β-catenin (Cadoret et al., 
2002; Zucman et al., 2007).  Although less studied, and not apparently sensitive to 
estradiol supplementation in old beef cows (Chapter 3), estrogen binding of GPR30 
results in activation of the adenylyl cyclase, phosphoinositol 3 kinase (PI3K), and the 
phospholipase C pathways in several cell types (Thomas et al., 2005; Heldring et al., 
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2007, Albanito et al., 2007) and human liver tissue (Hsieh et al., 2007).  Moreover, 
evidence for cross-talk between ER and GPR30 has been accumulating (Sheng and Zhu, 
2011). 
A direct relationship between estrogen, β-catenin, and GS expression in liver 
tissue has not been reported.  However, mRNA for ERα and ERβ are expressed in the 
cattle liver (Pfaffl et al., 2001), suggesting that estradiol administration to cattle likely has 
a direct effect on hepatic mechanisms, and not only through IGF-mediated effects.  
Moreover, GS activity and protein expression in rat C6-glioma cells is increased by 
estrogen (Haghighat, 2005), and estradiol up-regulates GS mRNA and protein content in 
the hypothalamus and hippocampus of humans (Blutstein et al., 2006).   
Aging is associated with decreased metabolic functions and decreased gene 
expression of proteins responsible for intermediary metabolism in the liver (Serstè and 
Bourgeois, 2006). In cattle, little information is known about the relationship between 
hepatic function and aging. However, previous research in our lab has shown that the 
content of GS protein in the liver of old (≥ 10 years old), mature cows is decreased by 46 
to 71% compared that of young (3-5 years old) adult cows, whereas ALT content was 61 
to 73% less in old cows (Matthews and Sipe, 2006). In the previous trial (Chapter 3), it 
was determined that 17β-estradiol (estradiol) supplementation (COMPUDOSE implants; 
Vetlife, Des Moines, IA) for 28 days increased the basal content of GS mRNA and 
protein, but not ALT, in the liver tissue of old beef cows with unknown and mixed 
genetic (breed) backgrounds, and having had ad libitum access to an alfalfa hay-based 
diet. 
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Our previous finding (Chapter 3) that estradiol supplementation ( implants) could 
increase GS content in the liver of old adult beef cows was exciting because it 
demonstrated the potential applicability of estradiol supplementation in a typical, 
commercial beef cattle production regimen.  However, not knowing the actual age, feed 
intake, and breed type, may have confounded or masked treatment effects. In addition, 
given its potential commercial applicability, it is important to know if estradiol 
supplementation results in increased GS expression by liver tissue of young adult beef 
cows. Therefore, to test the effect of estradiol supplementation using more defined cattle 
phenotypes, the first goal of the present trial was to determine if the same estradiol 
supplementation regimen equally affected GS expression in old and young adult Angus 
cows with known ages and pedigrees, receiving a known amount of a corn silage-based 
diet. The second goal was to gain insight into potential mechanisms affecting these 
putative changes. The first primary hypothesis tested in this experiment was that 
COMPUDOSE supplementation of estradiol to young and old adult cows would increase 
hepatic content of GS. The second primary hypothesis tested was that estradiol 
supplementation would increase hepatic expression of β-catenin, GRP30, or both, in 
supplemented young and old adult cows. The third hypothesis tested was that estradiol 
supplementation would alter blood biochemical and clinical indicators of whole-body 
physiological status.  
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MATERIALS AND METHODS 
Animals 
All experimental procedures were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. Twelve young, mature and twelve old, 
mature predominately Angus beef cows were housed in individual feeding pens (2.4 × 
14.6 m) at the University of Kentucky Agricultural Research Center, located in Woodford 
County, KY. Beginning 7 d before study initiation, cows were collectively acclimated to 
a diet consisting of 93.3% corn silage, 5.5% soybean meal, and 1.2% minerals (DM 
basis). All cows then were fed at 3.37% of BW thereafter. The diet was formulated to 
contain 10% CP on a DM basis and calculated to provide 1.3 x maintenance NEm 
requirements (NRC, 1996).  Representative sampling of the experimental diet was 
conducted for proximate and mineral analyses performed (Table 4.1) by a commercial 
laboratory (Dairy One Forage Lab, Ithaca, NY). Cows had ad libitum access to water for 
the duration of the trial.  Full BW were determined at days 0, 16, and 28 and average 
daily gain (ADG) calculated from BW difference between d 28 and d 0.  
Compudose and Sham Implant Treatments 
Before the beginning of this trial, cows were randomly allotted (n = 6) by age and 
weight into treatment groups to either receive a sham (Control; 0.5 mg oxytetracycline) 
or COMPUDOSE (estradiol; 25.7 mg estradiol; Vetlife) implant. The back of the ear was 
clipped, cleansed with 70% ethyl alcohol solution, and dried. Six young and 6 old cows 
received the controlled-release estradiol implant subcutaneously in the dorsal-medial area 
of the left ear using the manufacturer’s implantation device (COMPUDOSE Implanter; 
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Vetlife) according to manufacturer’s instructions. Furthermore, 6 young and 6 old cows 
received a sham implant using sterile corn oil as a vehicle for oxytetracycline (0.5 mg).  
Blood Collection and Fractionation 
Jugular venous blood samples were collected by venipuncture on d 16 and d 28. 
For preparation of plasma, 16 mL of blood was collected in EDTA-containing (0.9375 
mg/mL) vacutainers (Becton Dickinson, Franklin Lakes, NJ). For serum, 16 mL of blood 
was collected in serum vacutainers without an anticoagulant. For whole blood, 2 mL of 
blood was collected in EDTA-containing (2.7 mg/mL) blood collection tubes, Becton 
Dickinson). Plasma and sera were recovered by refrigerated centrifugation at 3,000 × g 
for 10 min at 4°C and stored at −80°C.  
Analysis of Blood Analytes 
Plasma samples were analyzed for ammonia-N by modifications of the L-Glu 
dehydrogenase assay (Da Fonesca-Wollheim, 1973) using the Konelab 20XTi analyzer 
(Thermo Electron Corp., Vantaa, Finland).  The sensitivity of this assay is 0.010 mM, and 
an interassay CV of 11.0% is typically realized. For this experiment, plasma ammonia 
concentrations were determined in a single assay event.  The intraassay CV was 7.4%.  
Plasma estradiol levels were evaluated using the Ultra-Sensitive Estradiol 
Radioimmunoassay kit (Diagnostic Systems Labs, Webster, TX) by Dr. Brian McBride 
(University of Guelph in Ontario, Canada). Briefly, 125 µL of MgCl2 and 125 µL 
Dextran were added to microcentrifuge tubes containing 750 µL of the samples to 
duplicate the plasma. Samples were incubated for 1 hr at room temperature. Tubes were 
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centrifuged for 15 minutes at 10,000 rpm. The resulting spin produced a small pellet and 
the supernatant removed for further analysis.  
Using the RIA kit, all samples, standards, and controls were assayed in duplicate. 
Tubes provided from the kit were labeled for Total counts (TC), Non-specific binding 
(NSB), standards, controls, and samples. The estradiol standards used were 0.5, 0.62, 1, 
2.5, 5, 7.5, 10, 15, 20, 35, 50, and 250 pg/ml. The volume for the standards and controls 
was 200 µL per tube. On the other hand, 266.7 µL of plasma samples were added to the 
proper tubes. To the NSB tubes, 300 µL of the 0 pg/mL estradiol standard was added. 
Estradiol antiserum (1st antibody; 100 µL) was added to all tubes except for the NSB and 
TC tubes. All tubes were vortexed and allowed to incubate overnight at 4°C. After the 
incubation, 125iodine-labeled estradiol (100 µL) was added to each tube. Then, tubes were 
vortexed, covered, and allowed to incubate at 4°C overnight. On the third day, 
precipitating reagent (secondary antibody; 1 mL) was added to all tubes except for TC. 
Tubes were incubated at room temperature for 1 hr. Next, tubes were centrifuged for 30 
minutes at 4°C at a speed of 3000 rpm. The tubes were decanted except for the TC tube 
to remove any excess moisture. Afterwards, tubes were counted in the gamma counter for 
1 minute. The intraassay CV was 7.1%, whereas the interassay CV was 11.9%. The 
detection limit of this assay is 0.67 pg estradiol/mL.  
Plasma progesterone levels were measured using the Coat-A-Count Progesterone 
125I Radioimmunoassay kit per manufacturer’s instructions (Siemens Medical Solutions 
Diagnostics, Los Angeles, CA). The sensitivity of this assay was determined to be 0.038 
ng/mL, the interassay CV was 5% , and the intrassay CV was 11%.  
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All other serum analytes, minerals, and blood cell types were analyzed by the 
University of Kentucky Livestock Disease Diagnostic Center. For serum enzymes, the 
following specific activities were assayed: ALP, E.C. 3.1.3.1; ALT, E.C. 2.6.1.2; AST, 
E.C. 2.6.1.1; γ-glutamyltransferase, E.C. 2.3.22; creatine kinase, E.C. 2.7.3.2; LDH, E.C. 
1.1.1.27. 
Liver Tissue Biopsy 
On d 16 and 28, hepatic tissue was collected by a modification of the aspiration 
technique in cattle (Brown et al., 2009). Briefly, the area from the 10th to 12th intercostal 
spaces and 10 to 30 cm from the dorsal median plane on the right side of each animal was 
clipped free of hair and cleansed with povidine-iodine and two subsequent 70% ethyl 
alcohol solution washes. The remaining 70% ethyl alcohol solution was dried with gauze. 
Lidocaine (Lidocaine 2% Injectible; The Butler Company, Dublin, OH; 1.6 mL per 
biopsy site) was subcutaneously injected between the 12th and 13th ribs approximately 10 
cm from the dorsal medial plane.  A topical anesthetic spray (CETACAINE 300 mg; 
Cetylite Industries, Pennsauken, NJ) was administered to the skin 20 cm from the dorsal 
median plane at the 12th intercostal space for 2 seconds and an incision made with a 
scalpel.  A trocar (7 mm diameter) was used to obtain the tissue from the liver.  The 
collected tissue was weighed and separated for RNA (400 mg wet tissue) and protein 
extraction (200 mg wet tissue).  Samples were placed in foil packs, snap frozen in liquid 
nitrogen and stored at -80°C. After completion of biopsy, the incision side was treated 
with a topical broad spectrum antibacterial spray (FURAZOLIDINE 4%; Veterinary 
Products Laboratories, Phoenix, AZ). 
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Immunoblot Analysis 
Liver was (approximately 200 mg) was homogenized on ice for 30 s (setting 11, 
POLYTRON Model PT10/35, Kinematic, Inc., Switzerland) in 1.5 mL of 4°C sample 
extraction buffer solution (0.25 mM sucrose, 10 mM HEPES-KOH pH 7.5, 1 mM 
EDTA) that contained protease inhibitor cocktail (4-(2-Aminoethyl)benzenesulfonyl 
fluoride hydrochloride, 434 ng/ml; aprotinin, 0.0123 ng/ml; bestatin, 11.6 ng/ml; L-trans-
3-carboxyoxiran-2-carbonyl-L-leucylagmatine, 3.92 ng/ml; leupeptin, 4.21 ng/ml; 
pepstatin A, 2.19 ng/ml; Sigma, St. Louis, MO) to prevent proteolysis. Protein was 
quantified by a modified Lowry assay, using bovine serum albumin as a standard 
(Kilberg, 1989). After protein quantification, 60 µg/lane of protein homogenates were 
separated by 12% SDS-PAGE under reducing conditions, followed by electrotransfer of 
the proteins to a 0.45-µm nitrocellulose membrane (BioRad, Hercules, CA) using SDS-
PAGE standard protocols (Howell et al., 2001, 2003).  
The relative liver protein expression was evaluated using a general immunoblot 
regimen, described previously (Howell et al., 2001; 2003). Relative content of GS, ALT, 
AST, and GPR30, and β-catenin was evaluated in 60, 60, 60, and 90 µg/lane, 
respectively. For the detection of ALT and β-catenin, blots were hybridized with 40 µg of 
IgG anti-porcine ALT (Brown et al., 2009; United States Biological, Swampscott, MA) 
and 14.5 µg of IgG anti-chicken β-catenin (Abcam Inc., Cambridge, MA) respectively, 
per mL of blocking solution (1.5% nonfat dry milk (wt/vol) in 30 mM Tris-Cl [pH 7.5], 
200 mM NaCl, 0.1% Tween-20) for 1.5 h at room temperature with gentle rocking.  G 
protein coupled receptor 30 was probed (Chapter 3) using 0.4 µg of IgG anti-human 
73
GPR30 polyclonal antibody (Abcam Inc.) per mL of blocking solution [1% nonfat dry 
milk (wt/vol), 30 mM Tris-Cl (pH 7.5), 150 mM NaCl, 0.1% Tween 20 (vol/vol)] 
overnight at 4°C with gentle rocking.  Glutamine synthetase was probed (Brown et al., 
2009) using 1.25 µg of IgG anti-sheep polyclonal antibody (BD Biosciences, San Jose, 
CA) per mL of blocking solution (5% nonfat dry milk (wt/vol), 10 mM Tris-Cl [pH 7.5], 
100 mM NaCl, 0.1% Tween 20 (vol/vol)) for 1 h at 37°C with gentle rocking.  
All protein-primary antibody binding reactions were visualized with a 
chemiluminescence kit (Pierce, Rockford, IL) after hybridization of primary antibodies 
with horseradish peroxidase-conjugated goat anti-mouse IgG (BD Biosciences, San Jose, 
CA; GS, 1:5,000, and β-catenin, 1:10,000); horseradish peroxidase-conjugated goat anti-
rabbit IgG (Abcam Inc.; GPR30, 1:5,000) or horseradish peroxidase-conjugated rabbit 
anti-sheep IgG (Santa Cruz Biotechnology, Santa Cruz, CA; ALT, 1:5,000). 
The use of GS and ALT for cattle tissue previously was described by our 
laboratory (Brown et al., 2009), and use of anti-GRP30 was validated as discussed in 
Chapter 3. Use of the mouse monoclonal anti-chicken β-catenin against bovine β-catenin 
was justified given that Madin-Darby Bovine Kidney cell lysate is the positive control for 
this antibody (Abcam), whereas the use of relative β-catenin content to describe 
activation of the β-catenin/Wnt pathway by sex steroid receptor has recently been 
described for cattle skeletal muscle cells (Zhao et al., 2011). When probed with the 
mouse monoclonal anti-chicken β-catenin and horseradish peroxidase-conjugated goat 
anti-mouse IgG pair (Figure 4.3) a proportional increase in a single immunoreaction 
product (~ 94 kDa) was observed in response to increasing amounts of bovine liver tissue 
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homogenates. Conversely, no immunoreaction products were found when homogenates 
were probed with only the horseradish peroxidase-conjugated goat anti-mouse IgG.  
Densitometric analysis of immunoreactive products was performed as described 
previously (Howell et al., 2003; Fan et al., 2004).  Briefly, after exposure of 
autoradiographic film (Amersham), digital images of all observed immunoreactive 
species were recorded and quantified (Yamin et al., 1996; Dehnes et al., 1998; Ding et 
al., 1998) using the BioRad Versadoc imaging system and the Quantity One Program 
(Version 4.2.3, BioRad).  Data were collected as arbitrary densitometric units and then 
were corrected for unequal loading and/or transfer of proteins by normalization to 
densitometric values of Fast-Green-stained (Fisher Scientific, Pittsburg, PA) proteins 
common to all immunoblot lanes/samples.  For all results, densitometric values were 
normalized to young control animals by obtaining an average young control 
densitometric value on 16 d and dividing all results by this value.  Digital images were 
prepared with PowerPoint (Microsoft PowerPoint 2003, Bellvue, MA).  
Extraction of Total RNA and Relative Real-Time Reverse-Transcriptase-
Polymerase Chain Reaction Assay 
RNA Extraction and Purification. Liver (approximately 200 mg) was 
homogenized on ice for 30 s (setting 11, Polytron® Model PT10/35, Kinematic, Inc., 
Switzerland) in 2 mL of 4°C TRIzol® Reagent (Invitrogen, Carlsbad, CA). Total RNA 
was obtained by an acidic phenol-chloroform extraction as per instruction of the 
manufacturer (Invitrogen). Briefly, chloroform (3 mL or volume to volume) was added to 
each Trizol® homogenate sample in sterile 7-mL polypropylene tubes (Fisher Scientific) 
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and samples were shaken vigorously. After 3 min incubation in ice, samples were spun at 
12,000 x g for 10 min at 4°C. The aqueous phase containing RNA was transferred to a 
fresh, sterile 7-mL polypropylene tube. After the addition of an equal volume of ice-cold 
isopropanol, samples were precipitated at -80°C for 10 min, and then at -20°C overnight. 
Samples were then thawed and spun at 12,000 x g for 10 min at 4°C and the supernatant 
was removed. Each RNA-containing pellet then was washed gently with 75% ethanol 
(0.5 mL) and spun at 7,500 x g for 5 min at 4°C. After removing the supernatant, each 
tube was allowed to dry for 10 min. Pellets were resuspended in 100 µL of 
DNAse/RNAse-free water, transferred to 1.5 mL microcentrifuge tubes, and stored at -
80°C.  
After the crude RNA was recovered, a purification procedure was performed 
using RNeasy Mini Kit (Qiagen, Valencia, CA) to minimize genomic DNA 
contamination (Applied Biosystems, 2004) and enrich all the mRNA longer than 200 
nucleotides in molecular size. Purified RNA was then eluted with 60 µL of RNase-free 
distilled H2O and stored at –80°C.  
Purified RNA was then eluted with 60 µL of RNase-free distilled H2O and stored 
at –80°C. The integrity of the purified RNA was examined by gel electrophoresis using 
Agilent 2100 Bioanalyzer System (Agilent Technologies, Santa Clara, CA) at the 
University of Kentucky Microarray Core Facility. Visualization of the gel images and 
electropherograms showed that all RNA samples had high quality with RNA integrity 
number greater than 8.0 and 28S/18S rRNA ratio greater than 1.8. The purity and 
concentration of purified RNA samples were analyzed by a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE), which revealed that all 
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the samples were of high purity with 260/280 absorbance ratios greater than 2.0 and 
260/230 absorbance ratios greater than 1.75. 
Reverse Transcription (RT). Approximately 3 µg of crude RNA was first 
treated with DNase I enzyme (amplification grade) in accordance with the manufacturer’s 
instructions (Invitrogen) to ensure that no DNA was present. Briefly, one RNA sample 
was combined with 1 µL of 10x reaction buffer, 1 µL of DNase I (1 U/µL), and DEPC-
treated H2O up to 10 µL, incubated at room temperature for 15 min, and then 1 µL of 25 
mM EDTA was added to stop the reaction by incubating at 65°C for 10 min. Then the 
DNase-treated RNA samples were reverse transcribed to cDNA by using SuperScript III 
First-Strand Synthesis System in accordance with the manufacturer’s instructions 
(Invitrogen). Briefly, a solution of hexamers (50 ng/µL) and oligo (dT)20 primer (50 µM) 
mix (1 µL each) was added to one DNase-treated sample (7 µL in volume), incubated at 
70°C for 10 min, and then chilled on ice for 1 min. A solution containing 2 µL of RT 
buffer (10x), 2µL of dithiothreitol (0.1 M), 4 µL of MgCl2 (25 mM), 1 µL of dNTP (10 
mM each), and 1 µL of RNAse Out was then added to the reaction. After incubation at 
37°C for 2 min, the reaction was incubated with 1 µL reverse transcriptase at room 
temperature for 10 min, and then incubated at 50°C for 50 min. To stop the reaction, the 
reaction mixture was incubated at 70°C for 10 min and then chilled on ice. The resulting 
reaction products, cDNA, were stored at –20°C until used in real-time RT-PCR. 
Real-Time RT-PCR. Before conducting real-time RT-PCR with ABI PRISM 
7000 Sequence Detection System (Applied Biosystems, Foster City, CA), primer and 
probe sets for GS, ALT, and 18S cDNA were designed and manufactured using ABI 
Assays-by-Design Service (Applied Biosystems). Bovine-specific nucleotide sequences 
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were obtained from previously published Genbank (http://www. 
ncbi.nlm.nih.gov/Genbank/GenbankSearch.html) sequences or from the bovine-specific 
database (Cattle Gene Index database) of The Institute for Genomic Research (TIGR) 
(http://www.tigr.org/tdb/tgi/) by using the Basic Local Alignment Search Tool (BLAST) 
function and the appropriate human ortholog nucleotide sequence (Genbank).  These 
specific parameters including the sequences of the forward and reverse primers and 
probes for relative real-time polymerase chain reaction are provided (Table 4.2). Each 
Assays-by-Design primer and probe set consists of 2 unlabeled PCR primers and one 
TaqMan Minor Groove Binding probe with FAM, a reporter dye labeled at 5' end. 
Components of a 25-µL real-time PCR reaction were an Assays-by-Design Primer and 
Probe set (1.25 µL), TaqMan Universal PCR Master Mix-No AmpErase UNG (12.5 µL), 
cDNA template (1.0 to 2.0 µL), and DNase/RNase free H2O (9.25 to 10.25 µL).
 The PCR 
conditions used for the amplification and quantification were an initial denaturing stage 
(95°C for 10 min), followed by 40 cycles of 2 amplification stages for denaturing (95°C 
for 15 s) and annealing/extension (60°C for 1 min), with a melting curve program (60 to 
95°C), a heating rate of 0.15°C/s, and continuous fluorescence measurements. To 
establish mRNA relative quantification methodology, the real-time PCR products were 
validated by DNA sequence verification, using the general protocol (Liao et al., 2008). 
Relative mRNA Quantification Methods.  For the relative quantification of GS 
and ALT mRNA expression levels, real-time quantitative RT-PCR methodology that 
used 2-step regimen was developed in accordance with ABI guidelines (Applied 
Biosystems, 2004; Liao et al., 2008). In the first step, all the RNA samples were reverse-
transcribed to cDNA as described above for RT reaction. In the second, real-time RT-
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PCR step, relative standard curve methods were established for both GS and ALT cDNA. 
For each mRNA quantified, ribosomal 18S RNA was selected as an endogenous control 
to normalize the variations in sample preparation, mRNA inputs, and RT efficiencies 
(Liao et al., 2008). Briefly, bovine liver total RNA was reverse-transcribed, the cDNA 
sample was serially diluted 2.5×, 5×, 25×, 125×, 625×, 3,125×, 15,625×, 78,125×, and 
390,625×, and the linear range for target mRNA quantification was established to 
ascertain an appropriate amount of cDNA to be used for a standard curve method. For 
each cDNA sample the real-time RT-PCR reactions (as described above) were conducted 
in triplicate to average out the potential pipeting, mixing, or plate setting-up errors. The 
minimal threshold (CT) values detected using these dilutions were approximately 35 and 
21 for the target and 18S cDNA, respectively. As a result, the optimal detection of GS, 
ALT and 18S cDNA were achieved by using 1:5, 1:5 and 1:15,625 dilutions of the RT 
product stocks, respectively.  
The estradiol treatment effect on expression of 18S rRNA by the liver was 
evaluated by comparing the CT values obtained from the real-time PCR reactions 
(Applied Biosystems, 2004). The relative quantities of GS and ALT mRNA expression 
were normalized to the relative 18S quantities by calculating the target gene:18S relative 
quantity ratios, and these 18S-normalized quantity ratios were used for estradiol 
treatment effect on GS and ALT mRNA expression. The 18S-normalized ratio from the 
control animals (i.e., sham-implanted) was designated as a calibrator. Then the 18S-
normalized ratios for the estradiol-implanted cows, as well as the control animals, were 
divided by the ratio of the calibrator, respectively. The CT values for 18S rRNA 
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quantities and the calibrated values for SH infusion treatment effect were all subjected to 
statistical analysis. 
Statistical Analysis 
Individual cows were the experimental units. Data are presented as least square 
means (± SEM). The effect of treatment on all measured parameters (non-implanted vs 
implanted) was evaluated by ANOVA, using the MIXED procedure of SAS with 
REPEATED MEASUREMENT (version 8.01, SAS Inst. Inc., Cary, NC). The main 
effects of estradiol treatment (TRT), time after implant (DAY), age of cow (AGE), and 
their interaction (TRT x DAY, TRT x AGE, AGE x DAY, TRT x AGE x DAY) were 
assessed. DAY was included in the REPEATED statement and cow was included random 
statement.  Kenward-Roger adjustment was used to calculate the denominator df 
(Kenward and Roger, 1997). 
RESULTS 
Plasma Hormones 
The potential effect of estradiol treatment on plasma estradiol and progesterone 
was determined (Table 4.3). Age did not affect (P = .336) plasma estradiol 
concentrations, whereas plasma estradiol concentrations of estradiol implanted cows were 
47.3% higher (P = 0.025) than non-supplemented cows. Also, there was a day effect (P = 
0.001) reflecting a 48% higher plasma estradiol concentration for both estradiol treatment 
groups on d 28 vs d 16. For progesterone, neither estradiol implantation, age, or day of 
experiment affected (P ≥ 0.285) plasma levels. 
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Body Weight and Average Daily Gain 
By design, initial BW within each age group did not differ (P = 0.628) between 
the young control (645 kg) and implant (663 kg) cows. Similarly, the initial BW did not 
differ (P = 0.765) between control (770 kg) and estradiol (760 kg) treatment groups of old 
cows. Over the experiment (Table 4.4), BW increased (P = 0.001) for both age groups, 
but BW was not affected by estradiol implantation (P = 0.689). In contrast, the average 
daily gain was higher (P = 0.061) in estradiol-supplemented cows, reflecting a 50% 
higher ADG by old, and 20% higher ADG by young, estradiol-supplemented vs non-
supplemented old and young cows. Feed intake of control and implant animals range 
from 8 to 12 kg with orts ranging from 0 to 6 kg. 
ALT and GS hepatic protein content 
To determine if the ALT and GS expression was affected by estradiol 
supplementation, their relative protein content was measured in the liver homogenates 
(Table 4.5). For GS, the livers of old cows expressed 45% less (P = 0.015) GS protein 
than young cows.  A treatment x day interaction (P = 0.024) was observed, apparently 
reflecting the relatively high day 16 expression of GS by young and old cows treated with 
estradiol vs lower day 28 GS expression by young and old cows treated with estradiol 
and day 16 and 28 by young and old cows not treated with estradiol. Moreover, the ratio 
of old:young cow GS expression within each of these estradiol x age treatment groups 
was 90, 41, 27 and 37%, respectively, suggesting that the relatively high old:young GS 
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expression ratio (90%) for estradiol treated old cows on day 16 had diminished to 41% by 
day 28.  
In contrast to GS, hepatic ALT content was not affected by cow age (P ≥ 0.623), 
estradiol treatment (P ≥ 0.324), day of experiment (P ≥ 0.658), or their interactions (P ≥ 
0.224).  
ALT and GS hepatic mRNA content 
To determine potential transcription regulatory effects of estradiol on ALT and 
GS, the relative content of ALT and GS mRNA in liver tissue was determined by real-
time RT-PCR (Table 4.6).  Old cows had more (P = 0.012) ALT mRNA than young adult 
cows.  In both treatment groups of old cows, ALT mRNA content was 43% higher when 
compared to hepatic ALT expression of the young control and young implant groups.  
Although ALT mRNA expression was not affected by estradiol treatment (P = 0.331), a 
treatment x age interaction was found (P = 0.035), with ALT mRNA expression by old 
estradiol-treated cows being higher (P ≤ 0.029) than both the control age groups and the 
young implant group.  Also, there was no difference among the two control groups and 
the young implant group (P ≥ 0.387).  
For GS mRNA, although there was no age (P = 0.851) or day (P = 0.921) effect, 
there was an age x day interaction (P = 0.008), seemingly reflecting the lower expression 
of GS mRNA on d 28 than d 16 of young cows. Estradiol treatment stimulated (P = 
0.072) GS mRNA expression by 38%, but there were no (P ≤ 0.286) treatment x other 
main effect interactions.   
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Regulatory Protein Expression 
To detect a potential relationship between GS expression and known regulatory 
proteins affected by estradiol receptor stimulation, and to establish if the hepatic 
expression was affected by estradiol implantation, the relative protein content of total β-
catenin or GPR30 was determined by immunoblot analysis of liver homogenates (Table 
4.7).  Neither age, treatment, nor their interaction affected (P ≥ 0.492) β-catenin 
expression. However, there was a day effect with β-catenin protein content increasing (P 
= 0.054) 17% from 16 d to 28 d. There were no (P ≥ 0.476) main or interaction effects on 
GPR30 expression.   
Serum and Plasma Analytes 
Common blood metabolytes were determined (Table 4.8) to elaborate protein 
expression results. Although plasma ammonia levels were not affected by estradiol 
treatment, age, or day (P ≥ 0.660), urea N levels were 12 to 25% higher (P = 0.021) in old 
vs young cows and consistently increased (P = 0.001) on day 28 vs day 16. Similarly, γ-
glutamyltransferase activities tended (P = 0.086) to be about 15% higher in old vs young 
cows, whereas ALT and AST activities were not affected (P ≥ 0.222) by age. Whereas γ-
glutamyltransferase activities were lower (P = 0.01) on day 28 than 16, ALT and AST 
activities were 29 and 18% higher (P ≤ 0.012) on 28 d than on 16 d. Estradiol treatment 
did not affect (P ≥ 0.392) γ-glutamyltransferase, ALT, or AST activity.  
Old cows had lower (~8%) total protein levels, which were not affected (P = 
0.582 by estradiol treatment). Albumin, globulin, and total bilirubin contents were not 
affected (P ≥ 0.151) by age, day, or estradiol treatment. Estradiol treatment did not affect 
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total protein, albumin, nor globulin levels (P ≥ 0.208). A treatment × age × day 
interaction (P = 0.064) was observed for total bilirubin content, but its meaning is not 
apparent. ALP and creatinine levels were not affected (P ≥ 0.182) by estradiol treatment 
or trial day, but ALP levels were 45 to 60% lower (P = 0.001) in old cows, whereas 
creatinine levels were 7 to 19% lower in old vs young cows. In contrast, creatine kinase 
was not affected by any main effect or interaction (P ≥ 0.264). 
In terms of energy status markers, neither glucose, LDH, triglycerides, nor 
cholesterol levels were affected (P ≥ 0.302) by estradiol treatment or age of cows. 
Triglyceride levels also were not affected by day of experiment or any interactions 
among main effects. However, a day (P = 0.003) and day x estradiol treatment interaction 
(P = 0.015) was found for glucose, the later apparently reflecting the higher level of 
glucose at day 28 for estradiol-treated cows.  Similarly, a day (P = 0.067) and day x 
estradiol treatment interaction (P = 0.023) was found for plasma LDH activity, the later 
apparently reflecting the higher level of activity at day 28 in young cows.  For 
cholesterol, a day (P = 0.024) and estradiol treatment x day interaction (P = 0.009) was 
found, with the later apparently reflecting the lower level of cholesterol for non-estradiol 
supplemented young cows.   
Serum Minerals 
The effect of cow age, estradiol supplementation, and day of experiment on serum 
minerals was determined (Table 4.9). Old cows had less (P ≤ 0.044) chloride (1%) and 
phosphorus (20%) than young cows. Estradiol treatment alone did not affect (P ≥ 0.323) 
mineral levels but an estradiol treatment x age interaction was found (P = 0.038) for 
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chloride, apparently reflecting a higher chloride level for old control cows. In addition, a 
treatment × age × day interaction was observed for sodium levels (P = 0.033), whereas 
there was only a tendency for potassium (P = 0.105) and magnesium (P = 0.117) levels to 
be affected by this interaction. On day 28, cows had 1.4% less (P = 0.002) chloride than 
on day 28.   
Blood Cell Types and Parameters 
The effect of cow age, estradiol supplementation, and day of experiment on blood 
cell types was determined (Table 4.10). Old cows had 6.21% less (P = 0.058) RBC than 
did young cows. Estradiol supplementation did not affect (P ≥ 0.419) the abundance of 
any blood cell types, nor were any estradiol supplementation interactions found (P ≥ 
0.123). The experimental day affected RBC (P = 0.001), hemogloblin (P = 0.001), packed 
cell volume % (P = 0.001), monocytes (P = 0.001), and resulting in 4.6, 4.0, 4.6%, and 
64.8%, respectively, lower values on day 28 than day 16. An observed age x day 
interaction (P = 0.063) appears to reflect more lymphocytes on day 28 than day 16 in old 
cows.  
DISCUSSION 
Aging is associated with decreased metabolic functions and decreased gene 
expression of proteins responsible for intermediary metabolism in the liver (Serstè and 
Bourgeois, 2006). In fact, many enzymes become less active or functionally inactive due 
to aging, ostensibly resulting from the accumulation of reactive oxygen species-directed 
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oxidative damage associated with aging (Kregel and Zhang, 2007). Importantly, the 
activity of GS is highly susceptible to oxidative inactivation (Stadtman, 1990) and GS 
activity is decreased (21%) in the liver of old rats (Danh et al., 1985). Regarding the 
effect of aging on GS expression, GS mRNA content in the liver of old mice is decreased 
(Dhahbi et al., 1999; Spindler, 2001).  
In cattle, little information is known about the relationship between hepatic 
function and aging. However, previous research in our lab has shown that the content of 
GS protein in the liver of old (≥ 10 years old), mature cows is decreased by 46 to 71% 
compared with that of young (3-5 years old) adult cows, whereas ALT content was 61 to 
73% less in old cows (Matthews and Sipe, 2006). In the previous trial (Chapter 3), it was 
determined that 17β-estradiol (estradiol) supplementation (COMPUDOSE implants; 
Vetlife, Des Moines, IA) for 28 days increased the basal content of GS mRNA and 
protein, but not ALT, in the liver tissue of old beef cows with unknown genetic (breed) 
backgrounds, and having had ad libitum access to an alfalfa hay-based diet. 
These findings were exciting because they demonstrated the potential 
applicability of estradiol supplementation in a typical, commercial beef cattle production 
regimen. However, not knowing the actual age, feed intake, and breed type, may have 
confounded or masked treatment effects. Therefore, to test the effect of estradiol 
supplementation using more defined cattle phenotypes, the first goal of the present trial 
was to determine if the same estradiol supplementation regimen equally affected GS 
expression in old and young adult Angus cows with known ages and pedigrees, receiving 
a known amount of a corn silage-based diet.  In the previous trial, the exact ages of the 
old cows were not known. However, they were determined to be greater than 10 years of 
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age (Johnson, 1959).  In this trial, the exact ages of cows were known.  Also, another 
difference between this trial and the previous trial was the breed differences. In the earlier 
trial, the experimental animals represented a composite of many breeds including Angus, 
Brangus, and other crosses, whereas, in this trial the cows were predominantly Angus.  
In the present trial, estradiol supplementation with COMPUDOSE implants 
equally increased plasma estradiol levels in both the young and old cows. For the old 
cows, this result is consistent with the 221% more plasma estradiol of old cows of an 
unknown exact age and breed type implanted with COMPUDOSE (Chapter 3). For 
young adult cows, our current findings are thought to be novel. Also consistent with our 
previous trial (Chapter 3), the increase in plasma estradiol was not accompanied by a 
change in progesterone concentrations, suggesting that a normal reproductive cycle was 
occurring in the presence of continuously elevated estradiol.  
The ability of estradiol, either alone or in combination with progesterone, to 
stimulate the efficiency of BW gain in heifers and cows has been well documented and 
reviewed (Reinhardt, 2007). Consistent with previous observations, the ADG was higher 
for both young and old cows receiving the estradiol supplement. Interestingly, these 
differences were delineated even though only full body weights (not shrunk) were 
measured.  
Estradiol Supplementation Transiently Increases Hepatic GS mRNA and Protein 
Content in both Young and Old Adult Cows  
As noted above, the whole-animal effect of steroidal implants on growth and 
carcass parameters have been well elucidated. However, little is known regarding how 
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estradiol administration affects specific mechanisms in the liver, the tissue responsible for 
coordinating alteration of whole-body nutrient fluxes. However, findings from 
exploratory research conducted in our laboratory suggested that liver GS is up-regulated 
by SYNOVEX-S (20 mg 17β-estradiol benzoate + 200 mg progesterone) in finishing 
steers (Sipe et al., 2004). Also, GS protein and activity are increased in rat C6-glioma 
cells by supplemental estrogen (Haghighat, 2005), whereas estradiol up-regulates GS 
mRNA and protein content of the hypothalamus and hippocampus of humans (Blutstein 
et al., 2006).  
The activities of GS, ALT, and other anionic amino acid-metabolizing enzymes 
are essential to facilitate metabolism of glutamine and aspartate (Heidger and Welbourne, 
1999; Welbourne and Nissim, 2001). In the liver, glutamine arriving from the portal vein 
is absorbed by the periportal hepatocytes by the hepatic system N activity (Kilberg et al., 
1980) and converted to L-glutamate and ammonia by mitochondrial glutaminase. 
Mitochondrial ALT also can produce glutamate by converting skeletal muscle-derived 
alanine to glutamate and pyruvate in the periportal hepatocytes. Glutaminase- and ALT-
derived glutamate can be metabolized by periportal hepatoycte-localized glutamate 
dehydrogenase to ammonia and α-ketoglutarate, or glutamate can be exported into the 
sinusoid and then absorbed by pericentral hepatocyte-localized EAAC1 or GLT-1 
glutamate transporter. Once absorbed by the periportal hepatocytes, sinusoidal glutamate 
and ammonia can be conjugated by GS to glutamine. In cultured rat glial cells 
(Hagheighat, 2005) and mouse brain tissue (Blutstein et al., 2006), estradiol is known to 
upregulate GS content and function. In contrast, estrogen did not affect GS activity in 
cultured primary rat hepatocytes (Sirma et al., 1996).  
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In cattle, little information is known about the relationship between hepatic 
function and aging. The first hypothesis tested in this experiment was that COMPUDOSE 
supplementation of estradiol to young and old adult cows would increase hepatic content 
of GS. The livers of old control cows expressed less GS protein than did livers of young, 
mature control cows (Table 4.5). Interestingly, exogenous estradiol supplementation 
increased hepatic content of GS mRNA and protein in both young and old adult cows by 
d 16. However, by d 28, this stimulation was diminished, suggesting that the estradiol 
stimulatory effect may become refractory with time.  In contrast, previous research from 
our laboratory (Chapter 3) found that hepatic GS mRNA expression was increased 34 and 
99% at d 14 and 28, respectively, by estradiol-supplemented vs non-supplemented old 
cows of uncertain age, feed intake, and breed history. Concomitantly, GS content was 
increased 350% by d 14 and 200% by d 28.  Collectively, these studies demonstrate that 
estradiol supplementation by ear implants can stimulate GS expression in old and young 
beef cows. Because of the lower GS expression in old cows, these findings indicate that 
estradiol supplementation may be most effective in old cows, as suggested by the greater 
increase in ADG for old than young estradiol-supplemented cows (Table 4.4). However, 
because GS activity was not measured, confirmation that estradiol supplementation-
mediated increase in GS protein actually results in increased GS function, awaits 
validation by future trials. 
Previous research in our laboratory with adult Angus cows indicated that hepatic 
ALT protein also was reduced in the liver of old cows (Matthews and Sipe, 2006). In the 
present trial, however, a difference in hepatic ALT protein content was not observed 
between young and old cows. At the transcriptional level, old cows actually possessed 
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more hepatic ALT mRNA content than young mature cows.  However, this greater ALT 
mRNA content did not result in the increase of ALT protein expression and suggests that 
ALT protein content may be post-transcriptionally regulated.  
Elevated Plasma Estradiol Is Not Associated with Altered Hepatic GPR30 or β-
catenin Content 
The second goal of this experiment was to gain insight into potential mechanisms 
by which estradiol may upregulate GS mRNA and protein content, as has been reported  
in the hypothalamus and hippocampus of humans (Blutstein et al., 2006).  As presented 
in the Introduction, estrogen-activated events can be mediated through estradiol binding 
of -α and ER-β receptors in the “classical” pathway (Figure 4.1), or by binding non-ER 
receptors, including GPR30- and β-catenin, as part of the “non-classical” pathway 
(Figure 4.2).  In cattle, the mRNA for ERα and ERβ mRNA are expressed by the liver 
(Pfaffl et al., 2001). However, we attempted to validate the commercial anti-ERα 
antibodies in cow liver homogenates but failed. In contrast, we successfully validated the 
use of anti-β-catenin (Chapter 3) and anti-GPR30 (Figure 4.3). Moreover, evidence exists 
that β-catenin may be a modulator of estradiol stimulation of GS expression in pericentral 
hepatocytes (Burke and Tosh, 2006).   
Accordingly, we tested the hypothesis that estradiol supplementation would 
increase hepatic expression of GRP30, β-catenin, or both, in estradiol-supplemented 
young and old adult cow.  However, the relative content of neither GPR30 nor β-catenin 
was affected. These results indicate that stimulation of hepatic GS expression by 
exogenous estadiol was not associated with altered liver content of GPR30 and β-catenin.  
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Effect of Age and Estradiol Supplementation on Blood Biochemical and Clinical 
Parameters 
The third hypothesis tested was that estradiol supplementation would alter blood 
biochemical and clinical indicators of whole-body physiological status. In terms of the 
blood metabolites, however, no differences were observed in response to estradiol 
treatment.  However, age differences were observed for some of the metabolites. The old 
cows experienced higher serum blood urea nitrogen levels, but lower total protein levels 
in the blood, thus possibly indicating an increase in protein catabolism in these animals. 
Serum ALP levels were higher in the old animals. In contrast, it has been reported that 
serum ALP activity is lowly expressed in aged rats (Sakamoto et al., 2005; Hashimoto et 
al., 2008). As for γ-glutamyltransferase activity, the old cows exhibited higher levels than 
the young cows. Also, γ-glutamyltransferase activity has been shown to be higher in aged 
rats, but these rats were male and produced lower levels of estradiol compared to the 
young rat group (Hamden et al., 2007). In addition, chloride and phosphorus levels were 
decreased in our old cows. In aged rats, Hashimoto et al. (2008) reported higher levels of 
serum aspartate aminotransferase, alanine aminotransferase, total bilirubin, total 
cholesterol, globulin, and creatinine, but observed lower levels of triglyceride, and 
albumin/globulin. Furthermore, it has been reported that sodium and chloride levels are 
higher in aged rats, but the phosphorus levels were low (Hashimoto et al., 2008). 
In terms of the blood cell types, estradiol implants did not affect any blood cell 
parameter. Similarly, RBC was the only blood cell type to be affected by age, with RBC 
abundance tending to be lower in old cows. In aged humans, red blood cell count and 
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hemoglobin are reported to be lower (Coppola et al., 2000). Also, packed cell volume is 
lower in aged humans (Gelmini et al., 1989). This result may indicate a reduced oxygen 
carrying capacity in aged cows.  
Conclusions 
The first primary hypothesis tested in this experiment was that exogenous 
estradiol supplementation by implant (estradiol) to young and old adult cows would 
increase hepatic content of GS is accepted, whereas the second primary hypothesis that 
estradiol supplementation would increase hepatic expression of β-catenin or, GRP30, and 
the third hypothesis that estradiol supplementation would alter blood biochemical and 
clinical indicators of whole-body physiological status are rejected.   
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Table 4.1: Proximate and mineral analysis of corn silage-based diet fed to young and old 
cows throughout the trial (dry matter basis)1  
Item 
Proximate analysis 
  DM, % 41.6 
  CP, % 9.6 
  Soluble Protein % CP 61 
  ADF, % 22.6 
  NDF, % 38.7 
  Lignin, % 3.2 
  NFC, % 43.6 
  Starch, % 35.3 
  Crude Fat, % 2.7 
  TDN, % 71 
  NEL, Mcal/lb 0.74 
  NEM, Mcal/lb 0.74 
  NEG, Mcal/lb 0.46 
Mineral analysis 
  Ash, % 5.42 
  Calcium, % 0.30 
  Phosphorus, % 0.32 
  Magnesium, % 0.13 
  Potassium, % 1.22 
  Sodium, % 0.458 
  Iron, ppm  473 
  Zinc, ppm 94 
  Copper, ppm 26 
  Manganese, ppm 79 
  Molybdenum, ppm 0.4 
1 Proximate and mineral values are an average of 3-4 samples collected throughout the 
trial and presented on a DM basis.  
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      Table 4.2:  Primer and probe sets used for the real-time quantitative PCR analyses of metabolic enzyme mRNA and 18S rRNA 
Primer and Probea Location on template (bp) Sequence
b Amplicon size (bp) 
GS (TIGR  TC274284) 
  Forward 702-720 5'-CACGAATGCCGAGGTCATG-3' 
  Probe (fwd.) 726-739 5'-FAM-ACAGTGGGAATTCC-3' 62 
  Reverse 740-763 5'-CGATTCCTTCACAGGGTCCTATCT-3'
ALT (TIGR  TC310617) 
  Forward 975-996 5'-CCTCCTTCCACTCGATCTCCAA-3' 
  Probe (rev.) 1002-1017 5'-FAM-CCGCACTCGCCCATGT-3' 79 
  Reverse 1031-1053 5'-TCCATATTCACCACCTCCACGTA-3'
18S (GenBank  DQ222453) 
  Forward 548-572 5'-CCCTGTAATTGGAATGAGTCCACTT-3' 
  Probe (rev.) 593-611 5'-FAM-CCAGACTTGCCCTCCAATG-3' 100 
  Reverse 625-647 5'-ACGCTATTGGAGCTGGAATTACC-3'
aGS = glutamine synthetase; ALT = alanine transaminase; 18S = 18S ribosomal RNA.  The contents in the parentheses associated with each         
protein are the accession numbers for the reported sequences retrieved from the public databases (TIGR or GenBank) and used as templates for  
designing primers and probes. The custom TaqMan probes were supplied in either the forward (fwd.) or the reverse (rev.) orientation as 
indicated in the parentheses for each probe. 
b“FAM” labeled at the 5’ end of the TaqMan probe is six-carboxy-fluorescein which is used as a reporter dye in the real-time PCR procedure. 
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   Table 4.3: Plasma estradiol and progesterone concentrations of young and old adult cows receiving Control or Estradiol treatment1
Treatment
Control Estradiol
16 d 28 d 16 d 28 d 
Item Young  Old  Young Old  Young  Old  Young  Old SEM2 
Estradiol, 
pg/mL 2.26  2.44  4.03  4.16 3.27  4.90  5.15  5.67 0.75 
Progesterone, 
ng/mL 3.53  2.63  1.96  1.77 2.34  1.66  1.63  2.18 0.84 
Overall P-value











Estradiol  0.025  0.001  0.336 0.542 0.473  0.412 0.446 
Progesterone 0.285  0.308  0.525 0.384 0.619  0.448 0.844 
1Data are presented as least square means (n = 4-6) ± SEM for hormone concentrations of Control and Implant (25.7 mg 
estradiol) young vs. old treatment cows collected at 16 and 28 d after implantation. Data were analyzed as a repeated measure 
as described in Materials and Methods.  
2Most conservative error of the mean. 
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Table 4.4: Bodyweight changes of young and old adult cows receiving Control or Estradiol  treatment1 
 Treatment 
 Control Estradiol 
0 d 16 d 28 d 0 d 16 d 28 d 
Item Young Old Young Old Young Old Young Old Young Old Young Old SEM 
BW, 
kg 
645 770 667 780 673 785 663 760 680 779 694 793 26 
 Overall 
 Control Implant 
 Young Old Young Old SEM 
ADG, 
kg 
1.00 0.55 1.20 1.11 0.43 
 Overall P-Value 












BW 0.689 0.001 0.001 0.160 0.714 0.549 0.267  
ADG 0.061 N/A2 0.316 N/A2 0.137 N/A2 N/A2  
1Values are least square means (n = 5-6) ± SEM for weight of Control and Implant (25.7 mg estradiol) treatment cows collected at 0, 
16, and 28 d after implantation.  
2 For ADG, day effect and its interactions are not applicable for the statistical analysis. 
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Table 4.5: Normalized densitometric analysis of relative liver content of ALT and GS in young and old adult cows receiving Control 
or Estradiol  treatment1,2   
Treatment
Control Estradiol
16 d 28 d 16 d 28 d 
Item Young  Old  Young  Old  Young  Old  Young  Old SEM3
ALT 1.00  1.02  1.07  1.05 1.00  1.00  0.98  0.79 0.12 
GS 1.00  0.27  0.84  0.31 1.14  1.03  0.75  0.44 0.19 
Overall P-value











ALT 0.324  0.658  0.623  0.224 0.619  0.378  0.594  
GS 0.151  0.005  0.015  0.024 0.197  1.000  0.254  
1Values (normalized arbitrary units) are least square means (n = 5-6) ± SEM from liver biopsy samples of Control and Implant (25.7 
mg estradiol) treatment cows collected at 16 and 28 d after implanting. Densitometric evaluation of all immunoreactive species was 
performed. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Values were normalized to the average young control value at 16 d for each protein by dividing the actual value for the animal by the 
average young control value. Average control values (in arbitrary units) ± SE used for normalization: ALT, 1785 ± 296;GS, 3073 ± 
457. 
3Most conservative error of the mean. 
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16 d 28 d 16 d 28 d 
Item Young  Old Young Old  Young  Old Young  Old SEM3
ALT 1.00  0.68 0.83 1.25 0.68  1.26 0.80  1.52 0.21 
GS 1.00  0.48 0.68 0.81 1.07  1.00 0.83  1.17 0.18 
Overall P-value










ALT 0.331  0.230 0.012 0.965 0.035  0.187 0.379 
GS 0.072  0.921 0.851 0.782 0.286  0.008 0.522 
1Data are the least square means (n = 5-6) ± SEM of the relative mRNA quantities from liver biopsy samples of Control and 
Implant (25.7 mg estradiol) treatment cows collected at 16 and 28 d after implanting.  
2The normalized quantities of the control and estradiol treatment groups from both ages on 16 and 28 d calibrated to the young 
control group on 16 d. 
3Most conservative error of the mean. 
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Table 4.7: Normalized densitometric analysis of relative liver content of β-catenin and GPR30 in young and old adult cows receiving 
Control or Estradiol  treatment1,2   
Treatment
Control Estradiol
16 d 28 d 16 d 28 d 
Item Young  Old  Young  Old  Young  Old Young Old SEM 
β-Catenin 1.00  0.86  1.03 1.07 0.91  0.78  1.11  0.95 0.19 
GPR30 1.00  0.66  1.07 0.96 0.81  0.76  0.89  0.77 0.29 
Overall P-value










β-Catenin 0.755  0.054  0.572 0.670  0.784  0.599  0.492 
GPR30 0.607  0.476  0.495 0.676  0.745  0.795  0.637 
1Values (normalized arbitrary units) are least square means (n = 5-6) ± SEM from liver biopsy samples of Control and Implant (25.7 
mg estradiol) treatment cows collected at 16 and 28 d after implanting. Densitometric evaluation of all immunoreactive species was 
performed.  
2Values were normalized to the average young control value at 16 d for each protein by dividing the actual value for the animal by the 
average young control value. The following is a list of those average control values (in arbitrary units) ± SE used for normalization: 
Total β-catenin, 3540 ± 453; GPR30, 2822 ± 670. 
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Table 4.8: Serum and plasma analytes of young and old adult cows receiving Control or Estradiol  treatment1
Treatment
Control  Estradiol
16 d 28 d 16 d 28 d 
Item2 Young Old  Young  Old  Young Old  Young Old SEM3
Ammonia, mM4 0.0708 0.0792  0.0800  0.0819  0.0975 0.0772  0.0782  0.0784 0.0128 
Urea nitrogen, 
mg/100 mL 
5 6  6 7 4 5  6  7 1 
ALT, U/L 27 26  33 32  27 22  33  32 2 
AST, U/L 83 72  113  71  68 74  83  84 11 
γ-glutamyl-
transferase, U/L 
19 22  17 16  19 23  15  18 2 
Total protein, 
g/100 mL 
7.9 8.3  7.9 8.3  7.7 8.2  8.0  8.2 0.2 
Albumin, g/100 
mL 
3.3 3.3  3.4 3.4  3.3 3.6  3.5  3.5 0.1 
Globulin, g/100 
mL 
4.6 5.0  4.5 4.9  4.4 4.7  4.5  4.6 0.2 
Albumin/Globulin 
ratio 
0.7 0.7  0.8 0.7  0.8 0.8  0.8  0.8 0.0 
Total bilirubin, 
mg/100 mL 
0.2 0.2  0.2 0.2  0.2 0.2  0.2  0.2 0.0 
ALP, U/L 58 30  62 34  66 31  63  25 5 
Creatinine, 
mg/100 mL 
1.6 1.3  1.6 1.3  1.5 1.4  1.5  1.4 0.1 
Creatine kinase, 
U/L 
119 101  125  119  142 107  141  112 23 
Glucose, g/100 
mL 
67 81  67  
77 
 83 90  73  76 9 
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Table 4.8 (con’t): Serum and plasma analytes of young and old adult cows receiving Control or Estradiol  treatment1 
Treatment
Control  Estradiol
16 d 28 d 16 d 28 d 
Item2 Young Old  Young  Old  Young Old  Young Old SEM3
LDH, U/L 1017 1122  1173  1108  1084 1053  1170  1039 66 
Triglycerides, 
g/100 mL 
22 24  18 25  21 21  21  20 3 
Cholesterol, 
mg/100 mL 
65 83  50 89  87 73  76  60 9 
100
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Table 4.8 (con’t): Serum and plasma analytes of young and old adult cows receiving Control or Estradiol  treatment1 
Overall P-value 











Ammonia, mM4 0.660  0.765  0.824 0.150 0.493  0.498 0.197 
Urea nitrogen, mg/100 mL 0.545  0.001  0.021 0.094 0.922  0.857 0.657 
ALT, U/L 0.592  0.001  0.325 0.290 0.638  0.312 0.435 
AST, U/L 0.392  0.012  0.220 0.839 0.101  0.083 0.190 
γ-glutamyltransferase, U/L 0.842  0.001  0.086 0.890 0.329  0.071 0.521 
Total protein, g/100 mL 0.582 0.582 0.032 0.383 0.898 0.204 0.243 
Albumin, g/100 mL 0.208  0.186  0.379 0.727 0.196  0.103 0.401 
Globulin, g/100 mL 0.367  0.756  0.151 0.321 0.634  0.755 0.504 
Albumin/Globulin ratio 0.125  0.336  0.285 0.162 0.427  0.292 0.706 
Total bilirubin, mg/100 mL 0.929 0.233 0.482 0.557 0.236 0.895 0.064 
ALP, U/L 0.942  0.838  0.001 0.067 0.268  0.681 0.692 
Creatinine, mg/100 mL 0.530  0.182  0.018 0.793 0.197  0.513 0.336 
Creatine kinase, U/L 0.621 0.545 0.264 0.647 0.597 0.685 0.863 
Glucose, g/100 mL 0.395  0.003  0.302 0.015 0.678  0.306 0.919 
LDH, U/L 0.745  0.067  0.584 0.529 0.379  0.023 0.538 
Triglycerides, g/100 mL 0.590 0.427 0.350 0.900 0.241 0.645 0.442 
Cholesterol, mg/100 mL 0.731  0.024  0.389 0.276 0.009  0.177 0.102 
1Data are presented as least square means (n = 5-6) ± SEM for serum enzymes of Control and Implant (25.7 mg estradiol) treatment 
cows collected at 16 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase. 




Table  4.9: Serum minerals of young and old adult cows receiving Control or Estradiol  treatment1 
Treatment
Control Estradiol
16 d 28 d 16 d 28 d 
Item Young  Old  Young Old  Young  Old  Young  Old SEM2
Calcium, mg/100 
mL 
8.9  8.9  8.9 9.0 8.9  8.8 9.0  8.9 0.2 
Chloride, mmol/L 108  110  106 108 108  108 107  107 1 
Magnesium, 
mg/100 mL 
2.1  1.9  2.1 2.0 2.0  2.1 2.1  2.1 0.1 
Phosphorus, 
mg/100 mL 
6.0  4.6  5.7 5.1 5.5  4.2 6.3  4.8 0.5 
Potassium, mmol/L 3.9  3.9  4.0 3.9 3.8  3.5 4.0  4.0 0.1 
Sodium, mmol/L 142  142  141 142 141  142 142  139 1 
Overall P-value











Calcium 0.944  0.536  0.763 0.595 0.624  0.881 0.520 
Chloride 0.346  0.002  0.044 0.375 0.038  0.197 0.716 
Magnesium 0.578  0.325  0.146 0.942 0.083  0.740 0.117 
Phosphorus 0.744  0.122  0.005 0.176 0.609  0.526 0.308 
Potassium 0.323  0.018  0.358 0.065 0.686  0.593 0.105 
Sodium 0.432  0.039  0.967 0.969 0.465  0.197 0.033 
1Data are presented as least square means(n = 5-6) ± SEM for serum minerals of Control and Implant (25.7 mg estradiol) treatment 
cows collected at 16 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Most conservative error of the mean. 
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Table 4.10: Blood cell types and parameters of young and old adult cows receiving Control or Estradiol  treatment1 
Treatment
Control Estradiol
16 d 28 d 16 d 28 d 
Item Young  Old  Young  Old  Young  Old  Young  Old SEM2
RBC, 
1×106/µL 
7.54  6.86  7.24  6.66  7.30  6.91  6.77  6.62 0.25 
Hemoglobin, 
g/dL 
13.9  14.0  13.3  13.6  13.5  14.4  13.0  13.7 0.4 
Packed cell 
volume, % 
42.0  42.3  40.5  40.8  41.5  43.7  38.7  42.1 1.3 
WBC, 1 × 
103/µL 
7.310  7.017  6.227  5.777  6.763  7.892  7.220  6.932 0.918 
Neutrophils, 1 
× 103/µL 
1.885  2.493  1.694  2.496  2.317  2.075  2.660  2.516 0.416 
Lymphocytes, 
1 × 103/µL 
4.050  3.449  3.847  2.737  3.462  4.874  3.741  4.008 0.682 
Monocytes, 1 
× 103/µL 
0.854  0.771  0.213  0.208  0.648  0.570  0.372  0.250 0.150 
Eosinophils, 1 
× 103/µL 
0.512  0.333  0.419  0.305  0.336  0.372  0.412  0.246 0.852 
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Table 4.10 (con’t): Blood cell types and parameters of young and old adult cows receiving Control or Estradiol  treatment1 
Overall P-value











RBC 0.441  0.001  0.058  0.289  0.438  0.267  0.641 
Hemoglobin 0.910  0.001  0.120  0.659  0.333  0.814  0.523 
Packed Cell 
Volume 
0.940  0.001  0.192  0.431  0.288  0.516  0.554 
WBC 0.429  0.097  0.975  0.274  0.611  0.342  0.445 
Neutrophils 0.452  0.511  0.441  0.287  0.184  0.746  0.917 
Lymphocytes 0.419  0.088  0.989  0.698  0.178  0.063  0.455 
Monocytes 0.628  0.001  0.502  0.123  0.794  0.929  0.748
Eosinophils 0.470  0.346  0.139  0.699  0.558  0.451  0.151 
1Data are presented as least square means (n = 5-6) ± SEM for serum minerals of Control and Implant (25.7 mg estradiol) treatment 
cows collected at 16 and 28 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
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Figure 4.3: Immunoblot validation of mouse monoclonal anti-chicken β-catenin /goat 
anti-mouse Ig-horseradish peroxidase antibody for the detection of β-catenin in cow liver 
tissue  
Companion immunoblots containing 15, 30, 60, or 90 µg of cow liver homogenate 
protein in lanes 1,5; 2,6; 3,7; and 4,8, respectively, were hybridized with either the 
primary/secondary pair (lanes 1-4) or only the secondary antibody (lanes 5-8). The Mr 
markers (kDa) are located to the left of the immunoblots. 




Glutamine synthetase and alanine transaminase were not affected by 17β-estradiol 
in developing heifers 
INTRODUCTION 
Past research in our lab has focused on studying the effect of exogenous estradiol 
on liver metabolism of aging cows. Specifically, we have observed how estradiol affects 
glutamine synthetase, an enzyme involved with nitrogen metabolism, in young and old 
cows. Also, we studied possible estradiol-mediated effects on blood metabolism in the 
old vs. young adult cow.   
On the other side of the aging spectrum, we are also interested in studying the 
effect of estradiol and its combination with other sex steroids to promote cattle growth. 
Much research has been performed regarding the effects of anabolic implants on growth 
rate and carcass traits of growing steers and heifers (Heitzman, 1976). For instance, 
increased weight gain has been reported in steer and heifer calves treated with either 
estradiol 17 beta or zeranol, a non-steroidal estradiol agonist (Sawyer, 1987). However, 
on the cellular level, in the growing animal model, little is known about the effect of 
estradiol supplementation on blood metabolites and other parameters. For instance, even 
though blood estradiol levels of feedlot steers given Synovex-S (a combination of 
estradiol and progesterone) were reported to increase after 60 days after implantation  
(Rumsey and Beaudry, 1979), there is little research indicating the levels of blood 
estradiol in growing heifers  given estradiol-only implants.  
Currently, there is a need in the animal science industry to learn more about the 
underlying cellular and/or molecular mechanisms involved with growth and development 
109
of food animals when given estradiol and other anabolic steroids (Chung and Johnson, 
2008). Surprisingly, given the length of time that estradiol supplements have been used in 
cattle, little is known regarding the relationship between time of estradiol implantation 
and blood estradiol levels, and their correlation to biochemical and clinical blood 
parameters. To gain an understanding of these relationships, we conducted a trial to 
determine the effects of exogenous estradiol (Compudose® ear implants) on plasma 
estradiol levels and biochemical and clinical blood metabolites of growing beef heifers. 
(Trial 3).  
MATERIALS AND METHODS 
Animals 
All experimental procedures were approved by the University of Kentucky 
Institutional Animal Care and Use Committee. Nineteen young (8 to 10 months of age) 
non-pregnant beef heifers were weighed and using full BW were randomly allotted (0 d) 
to either a sham (Control; 0.5 mg oxytetracycline; BW = 293 kg) or Compudose® 
(Implant; 25.7 mg estradiol; Vetlife, Des Moines, IA; BW = 292 kg)) implant. Heifers 
were housed in dry lot conditions as four groups of 4-5 animals/pen, at the University of 
Kentucky Research and Education Center at Princeton, KY.  Although housed in groups, 
heifers were individually fed through the use of a Calan gate system. Heifers had ad 
libitum access to water during the trial. Each animal was fed 105% of their previous 
week’s average intake of a common late vegetative Bermudagrass hay/soybean hull/corn-
based diet (Table 5.1) to achieve 1.1 kg BW gain/d for the duration of the trial (56 d). 
Full BW were taken on days 21 and 63 and shrunk BW determined on days 43 and 85. 
110
Full BW were recorded on d 0, 28, and 56. Proximate analysis of the diet was determined 
by a commercial laboratory (Dairy One Forage Lab, Ithaca, NY; Table 1).  
Compudose and Sham Implant Treatments  
On day 1, Compudose® implants were inserted into the animal’s left ear according 
to manufacturer’s instructions. Briefly, the back of the ear was clipped, cleansed with 
70% ethyl alcohol solution, and dried. The implant was placed subcutaneously in the 
dorsal-medial area of the ear using an implant device (Compudose® Implanter; Vetlife, 
Des Moines, IA). Sham implants were administered by injecting 5 mL of sterilized corn 
oil containing oxytetracycline in the same site of the ear as indicated above for the other 
treatments. Oxytetracycline was administered as part of the Control treatment to replicate 
the content of oxytetracycline supplied with each dose of Compudose.  
Blood Collection and Analysis 
Jugular venous blood samples were collected by venipuncture on d 14, 28, 43, 
and56. For preparation of plasma, 16 mL of blood was collected in EDTA-containing 
(0.9375 mg/mL) blood collection tubes (Becton Dickinson, Franklin Lakes, NJ). For 
serum, 16 mL of blood was collected in serum blood collection tubes without an 
anticoagulant. For whole blood, 2 mL of blood was collected in EDTA containing (2.7 
mg/mL) blood collection tubes, Becton Dickinson). Plasma and sera were recovered by 
refrigerated centrifugation at 3,000 × g for 10 min at 4°C and stored at −80°C. 
Plasma estradiol levels (d 14, 28, 43, 56) were evaluated using the 3rd Generation 
Estradiol Radioimmunoassay kit (Diagnostic Systems Labs, Webster, TX) by Dr. Brian 
McBride (University of Guelph in Ontario, Canada). Briefly, plasma samples were 
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prepared for analysis by placing 800 µL of plasma in diethyl ether pre-rinsed glass 
16×125 mm tubes. Diethyl ether (5 mL) was added to each tube and vortexed for 5 
minutes. To freeze the aqueous layer, tubes were frozen in liquid nitrogen for 
approximately 60 seconds. The unfrozen ether top layer was immediately poured into 
respective glass 12×75 mm tubes. Tubes were allow to sit at room temperature in the 
fume hood for a minimum of 30 minutes to warm up and to allow the ether to evaporate 
about a half inch volume to avoid spillage and placed in the Savant vacuum for 
approximately 1 hour to allow tubes to be 95% dry. A second ether extraction was 
performed on the samples, using the same protocol as described previously, except that 
samples were completely dried by the Savant (1-2 hours) in the second extraction. 
For RIA analysis, all samples were performed in duplicate. The ether-extracted 
samples were reconstituted using estradiol antiserum (primary antibody; 100 µL), 
vortexed for 1 minute, and then placed at 4°C for 19 hours. The standards used were 1.5, 
3.25, 5, 7.5, 10, 15, 25, 50, 100, and 150 pg/mL. The standards were not  prepared by 
ether extraction and were aliquoted (200 µL) to tubes appropriately labeled for each 
standard. Also, tubes were prepared to determine non-specific binding (NSB) and 
maximum binding (MB) of estradiol . In the MB and NSB tubes, 200 and 300 µL of the 0 
pg/mL standard were aliquoted, respectively. Primary antibody was added to the MB and 
standards, vortexed for 60 seconds, and incubated for 19 hours at 4°C. Next, the tracer 
(125iodine-labeled estradiol; 100 µL) was added to all tubes, vortexed for 60 seconds, and 
incubated for 19 hours at 4°C. Also, to determine total counts (TC), only the tracer was 
added to an empty tube. Next, the secondary antibody (1 mL) was added to all tubes 
except for the TC and was incubated for 1 hour at 4°C. After the secondary antibody 
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incubation, all tubes except for the TC were centrifuge at 2,400 rpm at 30 min at 4°C. All 
tubes were decanted, drained, and counted in a gamma counter for 1 minute. The 
intraassay and interassay CV of the RIA kit was 7.2 and 7.4%, respectively. The assay 
sensitivity is reported to be 0.54 pg/mL. 
Plasma progesterone levels were measured using the Coat-A-Count Progesterone 
125I Radioimmunoassay kit per manufacturer’s instructions (Siemens Medical Solutions 
Diagnostics, Los Angeles, CA). The sensitivity of this assay was determined to be 0.018 
ng/mL. The interassay and intrassay CV was 5% and 5.86%, respectively.  The methods 
of other serum analytes, minerals, and blood cell type evaluation by the University of 
Kentucky Livestock Disease Diagnostic Center has been described (Brown et al., 2009). 
For serum enzymes, the following specific activities were assayed: ALP, E.C. 3.1.3.1; 
ALT, E.C. 2.6.1.2; AST, E.C. 2.6.1.1; γ-glutamyltransferase, E.C. 2.3.22; creatine kinase, 
E.C. 2.7.3.2; LDH, E.C. 1.1.1.27. 
STATISTICAL ANALYSES 
Data are presented as least square means (± SEM). All experimental parameters 
between non-implanted and implanted animals were evaluated by ANOVA, using the 
MIXED procedure of SAS (version 8.01, SAS Inst. Inc., Cary, NC). Heifers were the 
individual experimental units. The effects of estradiol treatment(s), time after implant 
(DAY), and their interaction (TRT X DAY) were assessed. The statistical model used 
estradiol treatment as the fixed effect. Class variables were estradiol treatment (TRT) and 
animal, with animal included in the random statement. If a main treatment effect was 
observed, the protected Fisher’s LSD procedure of SAS was used to separate treatment 
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means. Kenward-Roger adjustment was used to calculate the denominator df (Kenward 
and Roger, 1997). The GLM procedure of SAS with the MANOVA option was used to 
determine the strength of the relationship between plasma estradiol concentration and 
each blood parameter of all treatment groups and within each treatment group.  
RESULTS 
Animal Model. Before the start of the trial, all heifers were observed to exhibit 
behaviors of estrus, thus indicating these animals were cycling before the trial began. To 
validate and characterize the effect of a single dose of exogenous estradiol treatment 
(Implant) on circulating estradiol (pg/mL) and progesterone (ng/mL) over the 56 d 
experimental period, the concentrations of estradiol (d 14, 28, 43, 56) and progesterone (d 
28, 56) in plasma were determined (Table 5.2). Plasma estradiol was 123, 60, 40, and 
75% greater (P = 0.001) for Implant  vs Control heifers at d 14, 28, 43, and 56, 
respectively. Despite the effect of Implant on plasma estradiol levels, plasma 
progesterone was not affected (P = 0.210). However, quantitatively, plasma progesterone 
levels were 38 and 47% less than Control at d 28 and 56, respectively. 
The effect of Implant treatment (and its resulting elevated estradiol levels) on 
growth parameters was assessed (Table 5.3). By design, d 0 BW did not differ (P = 
0.934) between heifers assigned to Control (293 kg) and Implant (292 kg) groups. Both 
groups of heifers gained BW at d 28 and 56 d (day effect, P = 0.001) but Implant did not 
affect (P = 0.704) BW gain. Overall average daily gain was 1.17 ±0.10 and 1.33 ± 0.09 
kg for Control and Implant groups, respectively, and did not differ (P = 0.271). To 
determine if the efficiency of gain differed, the overall feed intake and feed:gain ratios 
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for each group was calculated and compared.  Feed intake of the treated heifer group was 
not affected by exogenous estradiol (P = 0.453), whereas Implant heifers tended (P = 
0.107) to have a greater efficiency of gain (3.57 vs 4.05). Feed intake of control and 
implant animals range from 19.5 to 27.7 kg/d. 
Biochemical and Clinical Blood Profiles. To gain insight into the effects of 
implant-mediated elevated estradiol on metabolic capacities, profiles of serum enzymes 
and other blood constituents of Implant and Control heifers were compared after 28 and 
56 d of treatment (5.4). Implant  treatment did not affect (P > 0.06) any parameter. 
However, Implant heifers tended to have decreased (P = 0.077) creatinine levels on d 28 
(11%) and 56 (7.8%), yet increased (P = 0.071) creatine kinase levels of 13 and 19% on d 
28 and 56, respectively. Although the levels of certain metabolites (blood urea nitrogen, 
albumin, creatinine, and cholesterol) and enzymes (ALP, ALT, λ-glutamyltransferase,) 
differed (P ≤ 0.008) between d 28 and 56, the levels changed in the same manner for both 
Control and Implant heifers. In contrast, a treatment x d interaction was found for total 
protein (P ≤ 0.015) reflecting a 4.5% increase, but 3% decrease, from d 28 to 56 in 
Control vs Implant heifers. Likewise, triglyceride concentration decreased 19% in 
Control heifers but increased 13 % from d 28 to 56 in Implant heifers (P ≤ 0.005). Also, 
there was a tendency (P = 0.06) for globulin levels to increase 2.9% in Control heifers 
with time, whereas they decreased 8% from d 28 to 56 in Implant heifers.  
The potential effect of exogenous estradiol on serum mineral levels also was 
examined (Table 5.5). Potassium levels were 9.9 and 2.4% lower (p = 0.029) on d 28 and 
56, respectively, for Implant vs Control heifers.  No other exogenous estradiol treatment 
effects were found. Although calcium and magnesium levels were decreased (P ≤ 0.042) 
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from 1.1 to 9.1% on d 28 to 56, both treatments responded in the same manner. No 
treatment x d interactions were found (P ≥ 0.164).  
The potential effect of exogenous estradiol on abundance of blood cell types was 
compared (Table 5.6). Although the amount of red blood cells, hemoglobin, and packed 
cell volume all consistently increased (P ≤ 0.041) 3.3 to 5.9% from d 28 to d 56, estradiol 
treatment had no effect (P ≥ 0.194). Similarly, estradiol treatment did not affect (P ≥ 
0.137) total white blood cell numbers, nor lymphocytes, monocytes, or neutrophils. 
However, estradiol-implant heifers had 118 and 235% more (P = 0.057) eosinophils at d 
28 and 56, respectively, than did the control animals. No implant treatment x d 
interactions were found (P ≥ 0.126). 
Correlations between Plasma Estradiol and Biochemical and Clinical Blood 
Profiles. The strength of relationships between plasma estradiol levels and metabolic 
capacities, profiles of serum enzymes, and other blood constituents was determined 
through correlation analysis (Tables 5.7, 5.8, 5.9). Plasma estradiol-dependent 
relationships for combined (overall) and individual treatment (Control or Implant) were 
assessed. For blood, serum, and plasma analytes, no overall (P ≥ 0.175), Control (P ≥ 
0.096), or Implant (P ≥ 0.412) correlations were found, except for glucose (Table 5.7). 
For glucose, a moderate positive relationship (r = 0.560; P = 0.047) was observed 
between plasma estradiol concentrations and serum glucose levels in Control heifers, 
whereas no Implant or overall relationship was found (P ≥ 0.240).  
Potential relationships between plasma estradiol and blood minerals also were 
evaluated (Table 5.8). Neither an overall nor treatment-specific relationship was found (P 
≥ 0.128) for calcium, chloride, magnesium, phosphorus, or sodium. In contrast, a 
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moderate (r = 0.464) positive, overall relationship between estradiol levels and potassium 
levels was found (P = 0.020). Delineation of this effect into treatment-specific groups 
revealed that plasma estradiol and serum potassium levels of Implant heifers were 
strongly correlated (r = 0.697; P = 0.008), whereas no correlation (P = 0.274) was found 
for Control heifers.  
For blood cell types and parameters (Table 5.9), no correlation (P ≥ 0.623) was 
found between plasma estradiol and red blood cells, hemoglobin, or packed cell volume. 
Similarly, no correlation was found (P ≥ 0.172) for total white blood cells or specific 
white blood cell type, except for monocytes. For monocytes, a moderate negative (r = -
0.4135) relationship between monocyte abundance and estradiol level was observed 
overall (P = 0.045) and more strongly negative relationship (r = -0.605) for Implant 
heifers (P = 0.037). In contrast, there was no correlation (P = 0.673) between plasma 
estradiol levels and blood monocyte abundance in Control heifers.  
Discussion 
In general, mammals produce estradiol and, in females, the predominant 
source of estradiol is the ovaries. Specifically, the developing follicles of the ovaries 
produce estradiol (Hadley and Levine, 2007). Also, in the pregnant females, estradiol can 
be supplied by the placenta. The previous trials (Trial 1 and 2) involved using the old and 
young mature cow models. The main goal of Trial 3 was to establish a growing heifer 
cattle model to complete the young-to-old life spectrum for female cattle. Similar to Trial 
1 (old cow model) and Trial 2 (old vs. young, mature cows), the plasma estradiol levels 
of the Compudose-implanted heifers increased. These results support our understanding 
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that plasma estradiol levels are affected by the presence of exogenous estradiol in the 
female cattle model despite the age of their body.  In contrast to estradiol levels, 
progesterone levels were not affected by estradiol in the growing heifer model.  
Previous research with growing cattle evaluated the plasma levels of estradiol, 
estrone, and estriol in response to Synovex-S (estradiol and progesterone) implanted 
feedlot steers (Rumsey and Beaudry, 1979). Plasma estradiol concentration was increased 
by implantation, whereas plasma estriol and estrone levels were not. Moreover, even 
though growth rate was determined to be higher in implanted steers, the rate of gain was 
not significantly correlated to estimated plasma estradiol levels. Interestingly, the study 
did not determine if the regulation of growth rate by Synovex-S is due to the synergistic 
effect of estradiol and progesterone or to the effects of estradiol or progesterone.  
However, in the present trial, in which exogenous estradiol increased defined plasma 
estradiol concentrations to levels consistent with in-estrus cattle, heifer growth rate was 
not affected.   
In terms of nitrogen metabolism, blood urea nitrogen of growing heifers was not 
affected by estradiol, indicating other possible checkpoints in the nitrogen retention cycle 
to be affected by estradiol, similar to the estradiol-mediated effects observed during the 
previous trials. It was interesting to note that elevated plasma estradiol did not affect 
blood ALT or AST levels in this growing heifer model because it has been reported that 
zearalenone, a naturally-occurring estradiolic compound, can increase ALT and AST in 
the blood of rats (Stadnik and Borzecki, 2009).  
Total bilirubin was decreased in response to the elevated estradiol levels in 
Implant heifers.  This finding also differed from rat models in that ethynlestradiol, a 
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derivative of estradiol, was found to increase bilirubin and λ-glutamyltransferase levels in 
the blood of rats (Janssen et al., 2008).  Also, creatinine levels of implant heifers were 
lower, thus indicating a possible increase in the removal of creatinine from the blood by 
the kidneys. The 16% increase in creatine kinase levels, is consistent with past research 
showing the increased activity of creatine kinase in the presence of increased estradiol-17 
beta (Somjen et al., 2009). 
In Trials 1 and 2, estradiol had an effect on potassium levels in the blood. 
However, potassium levels were increased in old cows given estradiol whereas increased 
estradiol in growing heifers resulted in decreased potassium levels and a strong positive 
relationship between estradiol and potassium. In ovariectomized female rats, 17beta-
estradiol decreased plasma potassium levels in ovariectomized female rats (Zheng et al., 
2006). The loss of potassium in the renin-angiotensin-aldosterone system in the kidney 
has been shown to be affected by estrogen and progesterone (Zheng et al., 2006). Also, 
the increased eosinophil levels of Implant heifers is consistent previous research with 
pigs, in which administration of 17beta estradiol increased eosinophil levels in 
ovariectomized pigs (Jayachandran et al., 2005). 
Concluding Remarks 
In cattle production, it is important to increase our understanding of the 
mechanism(s) involved in the economical production traits obtained by the implantation 
of sex steroids. With increasing environmental concerns (Kolok and Sellin, 2008), it is 
becoming more important to determine the exact mechanism(s) in which estradiol, 
progesterone, and other growth-promoting compounds work to improve production traits 
in cattle, thus leading to the creation of a non-steroidal implant. 
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The growing female heifer model helps to set the stage for future trials in which 
we can further delineate the mechanistic effects of estradiol and progesterone on hepatic 
and skeletal enzymes and transporters that support nitrogen metabolism and muscle 
growth at the molecular level. 
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Table 5.1: Formulation (as-fed basis) and selected nutrient composition (dry matter basis) 
of the basal diet fed to growing heifers 
Item Composition
Ingredients, % 
Bermudagrass hay, 25.0 
ground
Cracked corn 25.0 
Soybean hulls 25.0 
Soybean meal 8.00 
Mineral mix 1.00 
Nutrient composition1,2 
DM, % 89.2 
CP, % 14.2 
ADF, % 27.2 
NDF, % 42.3 





Ash, % 6.90 
1The values were determined from 7 pooled samples collected throughout the  
trial. 
2Calculated values.  
121
Table 5.2: Plasma estradiol and progesterone concentrations of growing heifers receiving Control or Estradiol  treatment1 
Treatment
Control Estradiol
Item 14 d 28 d 43 d 56 d 14 d  28 d 43 d 56 d SEM2
Estradiol, pg/mL 1.85  2.37  2.80  1.91 4.14  3.79  3.90  3.34 0.493 
Progesterone, ng/mL N/A  2.56  N/A 4.07 N/A  1.86  N/A  2.22 0.918 
Overall P-value




Estradiol pg/mL 0.001  0.408  0.591 
Progesterone, ng/mL 0.210  0.293  0.513 
1Data are presented as least square means(n = 7-9) ± SEM for hormone concentrations of Control (sham) and Estradiol  (25.7 mg 
estradiol) treatment heifers collected at 14, 28, 43, and 56 d after implantation. Data were analyzed as a repeated measure as described 
in Materials and Methods. 
2Most conservative error of the mean. 
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              Table 5.3: Growth performance of growing heifers receiving Control or Estradiol  treatment1 
Treatment
Control  Estradiol
Item 0 d 28 d 56 d 0 d 28 d 56 d SEM2
BW, kg 293 328 359 292 332 366 10 
Overall
Control Estradiol SEM 
ADG3 1.17 1.33 0.10
Feed Efficiency3 4.05 3.57 0.20
Overall P-value
TRT DAY TRT × DAY
BW, kg 0.704 0.001 0.532 
ADG, kg 0.271 N/A N/A 
Feed Efficiency 0.107 N/A N/A 
1Values are least square means (n = 9-10) ± SEM for weight of Control and Estradiol  (25.7 mg estradiol) treatment heifers 
collected at 0, 28, and 56 d after implantation.  
2Most conservative error of the mean. 
3Values are least square means (n = 9-10) ± SEM for ADG and feed efficiency of Control and Estradiol  treatment heifers. 
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  Table 5.4: Blood, serum, and plasma analytes of growing heifers receiving Control or Estradiol  treatment1 
Treatment
Control  Estradiol Overall P-value
Item2 28 d 56 d 28 d 56 d SEM3 TRT  DAY  TRT × DAY 
ALP, U/L 127 202 115 219 27 0.943 0.001 0.433 
ALT, U/L 32 42 31 43 1 0.791 0.001 0.452 
AST, U/L 75 72 67 74 4 0.528 0.593 0.181 
Blood urea nitrogen, 
mg/100 mL 
9  11  9 11 1 0.691  0.006  0.920 
Total protein, g/100 mL 6.6 6.9 7.0 6.8 0.1 0.278 0.416 0.015 
Albumin, g/100 mL 3.2 3.3 3.1 3.3 0.0 0.564 0.004 0.240 
Globulin, g/100 mL 3.5 3.6 3.8 3.5 0.1 0.199 0.265 0.060 
Albumin/Globulin ratio 0.9 0.9 0.9 0.9 0.0 0.580 0.364 0.231 
γ-glutamyltransferase, U/L 10 6 10 9 1 0.493 0.008 0.124 
Total bilirubin, mg/100 mL 0.2 0.2 0.2 0.2 0.0 0.061 0.340 0.340 
Creatinine, mg/100 mL 1.1  1.3  1.0 1.2 0.1 0.077  0.004 0.746 
Creatine kinase, U/L 145 145 164 172 10 0.071 0.638 0.671 
Glucose, g/100 mL 76 86 77 81 6 0.740 0.117 0.475 
LDH, U/L 963 1015 991 995 37 0.912 0.439 0.507 
Triglycerides, g/100 mL 27 22 23 26 2 0.904 0.333 0.005 
Cholesterol, mg/100 mL 82 99 87 111 6 0.201 0.001 0.441 
1Data are presented as least square means (n = 8-9) ± SEM for serum enzymes of Control and Estradiol  (25.7 mg estradiol) treatment 
heifers collected at 28 and 56 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase. 
3Most conservative error of the mean. 
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Table 5.5: Serum minerals of growing heifers receiving Control or Estradiol  treatment1 
Treatment
Control  Estradiol Overall P-value
28 d 56 d 28 d 56 d SEM2 TRT  DAY  TRT × DAY 
Calcium, mg/dL 9.6 9.3 9.6 9.5 0.1 0.251 0.042 0.164 
Chloride, mmol/L 107 107 107 107 1 0.743 1.000 0.612 
Magnesium, mEq/L 2.1 2.0 2.2 2.0 0.1 0.764 0.013 0.527 
Phosphorus, mg/dL 7.1 7.1 6.5 7.1 0.3 0.248 0.208 0.290 
Potassium, mmol/L 4.3 4.3 3.9 4.2 0.1 0.029 0.094 0.233 
Sodium, mmol/L 139 138 138 138 1 0.383 0.397 0.669 
1Data are presented as least square means(n = 8-9) ± SEM for serum minerals of Control and Estradiol  (25.7 mg estradiol) treatment 
heifers collected at 28 d and 56 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Most conservative error of the mean. 
3Taken from the University of Kentucky Livestock Disease Diagnostic Lab. 124
125
Table 5.6: Blood cell types and parameters of growing heifers receiving Control or Estradiol  treatment1 
Treatment
Control  Estradiol Overall P-value
Item 28 d 56 d 28 d 56 d SEM2 TRT DAY 
TRT × 
DAY 
Red blood cells, 1 × 
106/µL 
8.20 8.60  8.00 8.26 0.31 0.525 0.038 0.649 
Hemoglobin, g/dL 12.5 13.0  11.9 12.3 0.4 0.194 0.041 0.863 
Packed cell volume, % 35.6 37.7  34.5 36.3 1.1 0.355 0.007 0.819 
White blood cells, 1 × 
103/µL 
10.56 12.73  10.70 12.33 0.847 0.903 0.002 0.611 
Neutrophils, 1 × 103/µL 2.670 3.287  4.001 3.633 0.447 0.137 0.688 0.126 
Eosinophils, 1 × 103/µL 0.167 0.173  0.360 0.573 0.167 0.057 0.466 0.490 
Lymphocytes, 1 × 103/µL 6.917 8.206  6.109 7.535 0.594 0.338 0.003 0.860 
Monocytes, 1 × 103/µL 0.408 0.537  0.327 0.661 0.130 0.862 0.053 0.370 
1Data are presented as least square means (n = 4-9) ± SEM for serum minerals of Control and Estradiol  (25.7 mg estradiol) treatment 
heifers collected at 28 d and 56 d after implantation. Data were analyzed as a repeated measure as described in Materials and Methods. 
2Most conservative error of the mean. 
3Taken from the University of Kentucky Livestock Disease Diagnostic Lab unless noted otherwise. 
4Taken from Duncan et al., 1994. 
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          Table 5.7: Correlation of estradiol with blood, serum, and plasma analytes of growing heifers receiving Control or  
          Estradiol  treatment    
Correlation
Overall  Control  Estradiol
Item2 Coefficient p-value  Coefficient  p-value  Coefficient p-value 
Urea nitrogen, mg/100 mL -0.003 0.989 0.178 0.561 -0.104 0.723 
ALP, U/L 0.113 0.582 0.103 0.739 0.120 0.683 
ALT, U/L 0.274 0.175 0.482 0.096 0.175 0.549 
AST, U/L 0.116 0.591 0.161 0.618 0.084 0.784 
Total protein, g/100 mL 0.253 0.232 0.284 0.371 0.250 0.412 
Albumin, g/100 mL 0.010 0.963 -0.284 0.347 0.164 0.575 
Globulin, g/100 mL 0.201 0.335 0.269 0.373 0.161 0.599 
Albumin/Globulin ratio -0.132 0.520 -0.157 0.609 -0.119 0.685 
γ-glutamyltransferase, U/L -0.083 0.688 -0.410 0.164 0.117 0.689 
Total bilirubin, mg/100 mL -0.089 0.664 -0.158 0.606 -2 - 
Creatinine, mg/100 mL 0.097 0.643 -0.131 0.684 0.235 0.419 
Creatine kinase, U/L 0.032 0.884 0.327 0.299 -0.127 0.693 
Glucose, g/100 mL 0.239 0.240 0.560 0.047 -0.224 0.440 
LDH, U/L -0.058 0.789 -0.296 0.351 0.030 0.924 
Triglycerides, g/100 mL 0.053 0.795 -0.155 0.612 0.156 0.594 
Cholesterol, mg/100 mL -0.009 0.967  0.065  0.833  -0.071 0.810 
1Data are presented as partial correlation coefficients between d 28 and d 58 plasma estradiol concentration (Table 5.2) and 
blood analytes of Control and Compudose (25.7 mg estradiol, Estradiol ) treatment heifers (Table 5.4). Partial correlation 
coefficients were calculated as described in Materials and Methods. 
2No value is present because the bilirubin values did not varied. 
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Table 5.8: Correlation of plasma estradiol with serum minerals of growing heifers receiving Control or Estradiol  treatment 
Correlation
Overall  Control  Estradiol
Item2 Coefficient p-value  Coefficient  p-value  Coefficient p-value 
Calcium, mg/dL 0.094 0.647 0.045 0.885 0.117 0.691 
Chloride, mmol/L 0.063 0.761 0.404 0.171 -0.194 0.507 
Magnesium, mEq/L 0.034 0.869 0.097 0.751 -0.003 0.992 
Phosphorus, mg/dL 0.306 0.128 0.444 0.129 0.215 0.459 
Potassium, mmol/L 0.464 0.020 0.328 0.274 0.697 0.008 
Sodium, mmol/L 0.137 0.505 0.430 0.142 -0.138 0.639 
1Data are presented as partial correlation coefficients between d 28 and d 58 plasma estradiol concentration (Table 5.2) and 
blood mineral content of Control and Compudose (25.7 mg estradiol, Estradiol ) treatment heifers (Table 5.5). Partial 
correlation coefficients were calculated as described in Materials and Methods. 
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Table 5.9: Correlation of plasma estradiol with blood cell types and parameters of growing heifers receiving Control or 
Estradiol  treatment 
Correlation
Overall  Control  Estradiol
Item2 Coefficient p-value  Coefficient  p-value  Coefficient p-value 
Red blood cells, 1 × 106/µL 0.101 0.623  0.095  0.758  0.109 0.712 
Hemoglobin, g/dL -0.027 0.896 -0.000 0.999 -0.050 0.866 
Packed cell volume, % -0.031 0.883 -0.045 0.889 -0.022 0.940 
White blood cells 1 × 
103/µL 
-0.064 0.754  -0.403  0.172  0.347 0.224 
Neutrophils, 1 × 103/µL 0.093 0.653  -0.276  0.362  0.311 0.280
Eosinophils, 1 × 103/µL 0.114 0.687  -0.193  0.618  0.143 0.760
Lymphocytes, 1 × 103/µL -0.084 0.684  -0.335  0.264  0.183 0.532 
Monocytes, 1 × 103/µL -0.413 0.045  -0.130  0.673  -0.605 0.037
1Data are presented as partial correlation coefficients between d 28 and d 58 plasma estradiol concentration (Table 5.2) and 
blood cell types of Control and Compudose (25.7 mg estradiol, Estradiol ) treatment heifers (Table 5.6). Partial correlation 











In this dissertation, three trials were conducted to study estrogen regulation of GS 
and ALT in young and old, mature cows. In Chapter 3, there are three salient 
observations from this study in which we were determining the effects of supplemental 
exogenous estradiol to old beef cows on (1) plasma estradiol concentration and (2) 
hepatic expression of GS, ALT and other proteins involved in hepatic 
glutamate/glutamine/alanine metabolism. First, the levels of plasma estradiol resulting 
from Compudose implantation in mature, cycling old beef cows, was characterized. 
Second, the defined increase in plasma estradiol of estrogen-implanted old cows is 
concomitant with increased expression of GS protein. Third, the identification that cattle 
liver expresses GRP30 protein is novel and enables subsequent research to identify how 
estradiol affects cellular metabolism. 
In Chapter 4, our research tested the hypotheses that (1) glutamine synthetase 
expression will be up-regulated by estrogen in old and young mature cows and (2) that 
this regulation is affected by the β-catenin/Wnt pathway but not GPR30. Increased 
plasma estrogen levels were observed in both implanted young and old cows. In this trial, 
old cows expressed less GS expression by the liver compared to the young, mature cows. 
The relative hepatic protein content of glutamine synthetase was increased by estrogen in 
the old, mature cows, with more GS at day 14 than 28. In contrast, hepatic GS protein 
expression by young, mature cows was not affected by estrogen treatment. At the 
transcriptional level, GS mRNA was increased by estrogen. The protein expression of 
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both GPR30 and beta-catenin was not affected by estrogen implantation or age of the 
mature beef cows. In conclusion of Chapter 4 results, our hypothesis that GS will be up-
regulated by estrogen for both age groups was partly confirmed because we observed a 
tendency of hepatic GS protein content in old cows to increase in the presence of 
estradiol and a treatment by day interaction, but not have hepatic GS protein content of 
young mature cows to be affected by exogenous estradiol. Also, the hypothesis that β-
catenin/Wnt pathway is involved with estrogen-directed GS regulation was rejected. 
 In Chapter 5, the research goal was to evaluate the effects of estrogen on the 
clinical blood metabolites of growing heifers. The plasma estradiol levels increased in 
Compudose-implanted heifers. Blood urea nitrogen of growing heifers was not affected 
by estradiol. Estrogen did not affect blood ALT or AST levels of the growing heifers. We 
also observed that total bilirubin was decreased in heifers given Compudose implants.  
Furthermore, we noted that creatinine levels of growing heifers given Compudose were 
lower. A 16% increase in creatine kinase levels was observed. In growing heifers given 
estradiol, potassium levels decreased even though we noticed a strong positive 
relationship between estrogen and potassium. Also, eosinophil levels of Compudose-
treated heifers were higher. The hypothesis was accepted in which certain blood 
metabolites of growing heifers are affected by exogenous estradiol, indicating that 
estradiol has many functional roles in the growing female model, other than the 
traditional reproductive capabilities. 
 
 







 The results of these trials indicate that glutamine synthetase is negatively affected 
in the liver of old cows due to age, but not in young cows. Glutamine synthetase is an 
important nitrogen-metabolizing enzyme in the liver. In old cows, this low expression of 
glutamine synthetase can contribute to an impaired liver metabolism.  
In Trial 1, estradiol levels in the blood was increased which supports our 
hypothesis that reduced GS expression can be “fixed” in old cows by estradiol implants. 
Also, in old cows, an elevated immune capacity is possible since we observed slight 
increased levels of total protein and globulin concentrations. As mentioned before, GS, 
ALT, and other anionic amino acid-metabolizing enzymes are essential to facilitate 
metabolism of glutamine and aspartate in peripheral tissues of old and young cows.  
Estradiol supplementation seems to increase glutamine synthetase expression in 
the liver but not alanine transaminase in the liver of old cows but not young cows. Our 
lab has not analyzed other tissues including muscle to determine if glutamine synthetase 
protein expression is affected in a similar manner. It is an opportunity to evaluate the 
expression of GS and ALT in muscle since estradiol implantation is given to cattle to 
improve carcass quality, which is dependent on protein N biosynthesis. Glutamine 
synthetase mRNA and protein expression was increased in the old cows given 
supplemental estradiol, whereas other evaluated hepatic metabolic nitrogen-dependent 
enzymes were not affected. In terms of blood metabolites in old cows, estradiol 




and potassium, indicating certain metabolites are sensitive to estrogen regulation. For 
total protein, estradiol affected the nitrogen content present in the blood. The increased 
content of globulin indicates the ability of estradiol to illicit a strong immune response in 
old cows, possiblyenhancing an old cow’s ability to fight infections. Gamma-
glutamyltransferase was increased in old cows in a estradiol treatment x day interaction, 
indicating that estrogen over time may have a negative impact on liver cell damage and 
cholestasis (the slowdown of bile moving from the liver). This idea can only be 
confirmed with future trials analyzing hepatocytes responsible for bile production and the 
gallbladder itself for its storage/release of bile produced in the liver. As indicative of 
reduced bile production, triglyceride concentration was high in old cows given estradiol 
supplementation, proving a reduced intestinal capacity to digest/absorb fats in the cows’ 
diet. It would be interesting to see if the increased triglyceride concentration can 
contribute to muscle marbling in cows in future trials, in which possibly radiolabeled 
triglycerides can be tracked from entry via the diet to observe its establishment in the 
muscles of these old cows, thus increasing the profitability of old cows sent to market for 
their beef by producers. Another blood metabolite affected by estradiol was potassium. 
Cows given estradiol experienced an increased potassium level, thus indicating a possible 
connection between the absorption and excretion of potassium by the small intestine and 
kidney, respectively; and their regulation by estrogen because these tissues are 
responsible for maintaining potassium levels in the blood (Berne et al., 1998).   
On the molecular level, our lab was interested in determining the potential 
regulation of glutamine synthetase in old cows by the GPR30 pathway. We were able to 




affected by estradiol-directed regulation. It would be intriguing to determine if GPR30 
activity and/or mRNA was affected to further delineate if GPR30 is part of the pathway 
that allows estradiol to positively affect glutamine synthetase, especially in our glutamine 
synthetase-containing cell lines (e.g. MDBK) were research can be performed to test 
GPR30 inbitiors. 
 In Trial 2, it was observed that increased plasma estradiol levels were present in 
both implanted young and old cows, as seen in the previous trial. In this trial, young vs. 
old, mature beef cows were used to determine if GS of young, cycling females function 
in a similar manner when exposed to estradiol. The novelty of this trial was that we 
observed a tendency for GS protein content to be increased in the liver of old cows 
indicating that estradiol seems to regulate GS expression by hepatocytes of old cows. 
Exogenous estradiol supplementation increased hepatic content of GS protein in both 
young and old cows on d16, but not on d 28, indicating that estradiol’s stimulatory action 
may be refractory over time.  Further trials will need to be conducted to determine if GS 
activity is also affected by estradiol regulation, since GS protein content is not completely 
indicative of GS activity in hepatocytes. It is interesting that hepatic GS of young cows 
were not affected by GS due to probably GS expression “running” at its optimal level due 
to the young cows being at their “peak” in terms of health.  At the transcriptional level, 
GS mRNA was increased by estrogen, that resulted in a time-dependent increased GS 
protein expression, indicating that estrogen regulation may have occurred at the 
transcriptional level, but post-translational modifications occurred to negate the estradiol-
directed GS mRNA synthesis. In concurrence with the tendency of GS to decrease in old 




pathways used by estradiol to regulate GS, thus indicating that another trial will need to 
be completed comparing old and young, mature cows to validate the findings that GS of 
young cows are not affected by estradiol and both estrogen-directed cell signaling 
pathways are not involved with estradiol-directed GS regulation.   
 In Trial 3, we used a growing heifer cattle model to understand if young females 
are affected by estradiol in a similar fashion as old cows. Estradiol levels in blood was 
increased in heifers, similar to mature young and old cows, thus indicating that increased 
plasma estradiol levels can be connected to estrogen supplementation throughout the life 
spectrum of a female bovine in the beef industry. The hepatic GS and ALT expression 
were not measured at the time of this trial. However, samples of hepatic and skeletal 
tissues were collected for future analyses of GS and nitrogen-metabolizing enzymes of 
growing heifers. We did observed significant changes in blood metabolites. The levels of 
bilirubin were decreased in growing heifers. In humans and other species, aging red 
blood cells are destroyed by the reticuloendothelial cells, in which case, the porphryin 
moiety of hemoglobin is converted to bilirubin (Berne et al., 1998). Normally, bilirubin is 
released into the plasma, where it is bound to albumin for transport (Berne et al., 1998). 
In growing heifers, hepatocytes may be able to be more efficient in removing bilirubin 
from the blood to produce bilirubin glucuronides, a main component of bile in the 
presence of estradiol. Further research analyzing the hepatocytes responsible for 
synthesizing bile and storage of the bile by the gall bladder will need to be done to test 
this notion of efficient bilirubin removal. Also, creatinine levels were decreased in the 
growing heifer model. As a by-product of skeletal muscle creatine metabolism, the 




estradiol implantation may have a potential effect with loss muscle mass in heifers.  
Creatine kinase levels were increased, thus indicating the “regenerative” properties of 
estradiol-directed creatine kinase to possibly re-establish the ATP pools during the 
contraction of skeletal muscles, in concurrent with humans and other species as indicated 
by Berne et al. (1998). Because blood potassium levels were decreased in the growing 
heifer model, estradiol has a negative impact on the retention of plasma potassium 
homeostasis in the blood and indicating a potential “dumping” of potassium by the small 
intestine and kidney into feces and urine, respectively. In this chapter and other chapters, 
we have observed an estradiol-directed immune response in our growing heifer model. 
Specifically, eosinophil levels were higher in estradiol-supplemented heifers, thus 
indicating estrogen’s immunological “fighting” response has been examined in which 
these heifers have a potential efficient way to respond to the invasion of parasites and 
infections as they grow (Berne et al., 1998). 
 In conclusion, estrogen regulation increases glutamine synthetase expression in 
the liver but not for alanine transaminase in the liver of old cows. Our lab has not 
analyzed other tissues including muscle to determine if glutamine synthetase protein 
expression is affected in a similar manner. Extending the findings of this dissertation to 
that of determining the effect of estrogen supplementation on the expression of GS and 
ALT by muscle is the logical next step for this project, as estrogen implants typically are 
given to cattle to improve carcass mass, which is dependent on protein N biosynthesis.  
  




Appendix: Examples of SAS Analyses and Outputs 
A.1. Analysis of estradiol supplementation on the levels of plasma estradiol levels in the 
blood of old cows (Chapter 3) 
 
A.1.1. Representative of SAS editor programming language using Proc Mixed (Plasma 
Estrogen Level of old cows) (Chapter 3) 
filename new dde 'Excel|H:\[Estrogen Data.xls]SAS!R8C3:R35C6'; 
TITLE '601L Estrogen Data SAS- Repeated Measurements w/o Day 0 
(Vanzant)'; 
data estrogen; 
infile new missover; 




PROC MIXED  data=estrogen; 
CLASSES TREATMENT COW TIME; 
MODEL Estrogen =  TREATMENT TIME TREATMENT*TIME / DDFM=KR; 
REPEATED TIME/type = ar(1) subject = COW(TREATMENT); 









A.1.2. SAS output 
601L Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                        1 
                                                                           14:58 Saturday, July 31, 2004 
 
                             Obs    COW      TIME    TREATMENT    Estrogen 
 
                               1    169       14      Control       1.500 
                               2    169       28      Control       1.500 
                               3    174       14      Control       2.572 
                               4    174       28      Control       1.500 
                               5    175       14      Control       1.482 
                               6    175       28      Control       1.500 
                               7    3/510     14      Control       1.511 
                               8    3/510     28      Control       1.500 
                               9    3/611     14      Control       1.500 
                              10    3/611     28      Control       1.500 
                              11    4/517     14      Control       1.500 
                              12    4/517     28      Control       1.500 
                              13    F068      14      Control       1.500 
                              14    F068      28      Control       1.500 
                              15    166       14      Implant       6.400 
                              16    166       28      Implant       2.950 
                              17    167       14      Implant       2.543 
                              18    167       28      Implant       2.710 
                              19    168       14      Implant       3.960 
                              20    168       28      Implant      15.130 
                              21    170       14      Implant       3.099 




                              23    171       14      Implant       1.500 
                              24    171       28      Implant       3.102 
                              25    172       14      Implant       3.417 
                              26    172       28      Implant       1.500 
                              27    E8        14      Implant       8.081 
                              28    E8        28      Implant       6.645 
 
                        601L Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                        2 
                                                                           14:58 Saturday, July 31, 2004 
 
                                          The Mixed Procedure 
 
                                           Model Information 
 
                         Data Set                     WORK.ESTROGEN 
                         Dependent Variable           Estrogen 
                         Covariance Structure         Autoregressive 
                         Subject Effect               COW(TREATMENT) 
                         Estimation Method            REML 
                         Residual Variance Method     Profile 
                         Fixed Effects SE Method      Prasad-Rao-Jeske- 
                                                      Kackar-Harville 
                         Degrees of Freedom Method    Kenward-Roger 
 
 
                                        Class Level Information 
 





                         TREATMENT         2    Control Implant 
                         COW              14    166 167 168 169 170 171 172 
                                                174 175 3/510 3/611 4/517 E8 
                                                F068 
                         TIME              2    14 28 
 
 
                                              Dimensions 
 
                                  Covariance Parameters             2 
                                  Columns in X                      9 
                                  Columns in Z                      0 
                                  Subjects                         14 
                                  Max Obs Per Subject               2 
                                  Observations Used                28 
                                  Observations Not Used             0 
                                  Total Observations               28 
 
 
                                           Iteration History 
 
                      Iteration    Evaluations    -2 Res Log Like       Criterion 
 
                              0              1       124.33302914 






                                       Convergence criteria met. 
 
                        601L Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                        3 
                                                                           14:58 Saturday, July 31, 2004 
 
                                          The Mixed Procedure 
 
                                    Covariance Parameter Estimates 
 
                                Cov Parm     Subject           Estimate 
 
                                AR(1)        COW(TREATMENT)     0.06748 
                                Residual                         7.5259 
 
 
                                            Fit Statistics 
 
                                 -2 Res Log Likelihood           124.3 
                                 AIC (smaller is better)         128.3 
                                 AICC (smaller is better)        128.8 
                                 BIC (smaller is better)         129.6 
 
 
                                    Null Model Likelihood Ratio Test 
 
                                      DF    Chi-Square      Pr > ChiSq 
 






                                     Type 3 Tests of Fixed Effects 
 
                                             Num     Den 
                          Effect              DF      DF    F Value    Pr > F 
 
                          TREATMENT            1      12      10.68    0.0067 
                          TIME                 1      12       0.71    0.4146 
                          TREATMENT*TIME       1      12       0.99    0.3386 
 
 
                                          Least Squares Means 
 
                                                          Standard 
       Effect            TREATMENT    TIME    Estimate       Error      DF    t Value    Pr > |t| 
 
       TREATMENT         Control                1.5761      0.7555      12       2.09      0.0590 
       TREATMENT         Implant                5.0676      0.7555      12       6.71      <.0001 
       TIME                           14        2.8975      0.7332    23.9       3.95      0.0006 
       TIME                           28        3.7462      0.7332    23.9       5.11      <.0001 
       TREATMENT*TIME    Control      14        1.6521      1.0369    23.9       1.59      0.1242 
       TREATMENT*TIME    Control      28        1.5000      1.0369    23.9       1.45      0.1610 
       TREATMENT*TIME    Implant      14        4.1429      1.0369    23.9       4.00      0.0005 
       TREATMENT*TIME    Implant      28        5.9924      1.0369    23.9       5.78      <.0001 
 
                        601L Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                        4 





                                          The Mixed Procedure 
 
                                   Differences of Least Squares Means 
 
                                                                    Standard 
Effect           TREATMENT   TIME   _TREATMENT   _TIME   Estimate      Error     DF   t Value   Pr > |t| 
 
TREATMENT        Control            Implant               -3.4916     1.0685     12     -3.27     0.0067 
TIME                         14                  28       -0.8487     1.0043     12     -0.85     0.4146 
TREATMENT*TIME   Control     14     Control      28        0.1521     1.4203     12      0.11     0.9165 
TREATMENT*TIME   Control     14     Implant      14       -2.4907     1.4664   23.9     -1.70     0.1024 
TREATMENT*TIME   Control     14     Implant      28       -4.3403     1.4664   23.9     -2.96     0.0068 
TREATMENT*TIME   Control     28     Implant      14       -2.6429     1.4664   23.9     -1.80     0.0841 
TREATMENT*TIME   Control     28     Implant      28       -4.4924     1.4664   23.9     -3.06     0.0053 














A.2. Analysis of estradiol supplementation on the expression of protein and for glutamate 
transporters and metabolizing enzymes of old cows (Chapter 3) 
 
A.2.1. Representative of SAS editor programming language using Proc Mixed (GS 
protein content of old cows) (Chapter 3) 
filename new dde 'Excel|H:\stuff 2\[601L GS Redo Densitometry 
Calculations Normalized to d14 Ctrl.xls]SAS!R5C1:R32C4'; 
TITLE '601L GS Densitometry SAS without 173 without d0- Repeated 
Measurements Normalized to d14 Ctrl (Vanzant)'; 
data protein; 
infile new missover; 




PROC MIXED  data=protein; 
CLASSES TREATMENT COW TIME; 
MODEL SAS =  TREATMENT TIME TREATMENT*TIME / DDFM=KR; 
REPEATED TIME/type = ar(1) subject = COW(TREATMENT); 









A.2.2. SAS output 
601L GS Densitometry SAS without 173 without d0- Repeated Measurements Normalized to d14 
Ctrl (Vanzan 13 
                                                                             11:40 Friday, July 30, 2004 
 
                               Obs    COW      TIME    TREATMENT     SAS 
 
                                 1    F068      14      Control     0.97 
                                 2    175       14      Control     0.58 
                                 3    172       14      Implant     2.97 
                                 4    169       14      Control     0.26 
                                 5    171       14      Implant     3.62 
                                 6    3/611     14      Control     3.31 
                                 7    170       14      Implant     6.55 
                                 8    3/510     14      Control     0.13 
                                 9    168       14      Implant     0.40 
                                10    4/517     14      Control     1.56 
                                11    167       14      Implant     7.01 
                                12    174       14      Control     0.19 
                                13    E8        14      Implant     4.24 
                                14    166       14      Implant     6.74 
                                15    F068      28      Control     0.06 
                                16    175       28      Control     2.13 
                                17    172       28      Implant     3.25 
                                18    169       28      Control     0.31 




                                20    3/611     28      Control     2.99 
                                21    170       28      Implant     4.64 
                                22    3/510     28      Control     0.08 
                                23    168       28      Implant     0.22 
                                24    4/517     28      Control     1.22 
                                25    167       28      Implant     5.25 
                                26    174       28      Control     0.00 
                                27    E8        28      Implant     2.86 
                                28    166       28      Implant     2.90 
 
601L GS Densitometry SAS without 173 without d0- Repeated Measurements Normalized to d14 
Ctrl (Vanzan 14 
                                                                             11:40 Friday, July 30, 2004 
 
                                          The Mixed Procedure 
 
                                           Model Information 
 
                         Data Set                     WORK.PROTEIN 
                         Dependent Variable           SAS 
                         Covariance Structure         Autoregressive 
                         Subject Effect               COW(TREATMENT) 
                         Estimation Method            REML 
                         Residual Variance Method     Profile 
                         Fixed Effects SE Method      Prasad-Rao-Jeske- 




                         Degrees of Freedom Method    Kenward-Roger 
 
 
                                        Class Level Information 
 
                         Class        Levels    Values 
 
                         TREATMENT         2    Control Implant 
                         COW              14    166 167 168 169 170 171 172 
                                                174 175 3/510 3/611 4/517 E8 
                                                F068 
                         TIME              2    14 28 
 
 
                                              Dimensions 
 
                                  Covariance Parameters             2 
                                  Columns in X                      9 
                                  Columns in Z                      0 
                                  Subjects                         14 
                                  Max Obs Per Subject               2 
                                  Observations Used                28 
                                  Observations Not Used             0 






                                           Iteration History 
 
                      Iteration    Evaluations    -2 Res Log Like       Criterion 
 
                              0              1       101.75353916 
                              1              1        90.06468257      0.00000000 
 
 
                                       Convergence criteria met. 
 
601L GS Densitometry SAS without 173 without d0- Repeated Measurements Normalized to d14 
Ctrl (Vanzan 15 
                                                                             11:40 Friday, July 30, 2004 
 
                                          The Mixed Procedure 
 
                                    Covariance Parameter Estimates 
 
                                Cov Parm     Subject           Estimate 
 
                                AR(1)        COW(TREATMENT)      0.7890 
                                Residual                         2.9374 
 
 





                                 -2 Res Log Likelihood            90.1 
                                 AIC (smaller is better)          94.1 
                                 AICC (smaller is better)         94.6 
                                 BIC (smaller is better)          95.3 
 
 
                                    Null Model Likelihood Ratio Test 
 
                                      DF    Chi-Square      Pr > ChiSq 
 
                                       1         11.69          0.0006 
 
 
                                     Type 3 Tests of Fixed Effects 
 
                                             Num     Den 
                          Effect              DF      DF    F Value    Pr > F 
 
                          TREATMENT            1      12       9.99    0.0082 
                          TIME                 1      12       6.71    0.0236 
                          TREATMENT*TIME       1      12       6.23    0.0282 
 
 
                                          Least Squares Means 
                                                          Standard 





       TREATMENT         Control                0.9850      0.6084      12       1.62      0.1314 
       TREATMENT         Implant                3.7043      0.6084      12       6.09      <.0001 
       TIME                           14        2.7521      0.4581    14.8       6.01      <.0001 
       TIME                           28        1.9371      0.4581    14.8       4.23      0.0008 
       TREATMENT*TIME    Control      14        1.0000      0.6478    14.8       1.54      0.1438 
       TREATMENT*TIME    Control      28        0.9700      0.6478    14.8       1.50      0.1553 
       TREATMENT*TIME    Implant      14        4.5043      0.6478    14.8       6.95      <.0001 
       TREATMENT*TIME    Implant      28        2.9043      0.6478    14.8       4.48      0.0005 
  
 
601L GS Densitometry SAS without 173 without d0- Repeated Measurements Normalized to d14 
Ctrl (Vanzan 16 
                                                                             11:40 Friday, July 30, 2004 
 
                                          The Mixed Procedure 
 
                                   Differences of Least Squares Means 
 
                                                                    Standard 
Effect           TREATMENT   TIME   _TREATMENT   _TIME   Estimate      Error     DF   t 
Value   Pr > |t| 
 
TREATMENT        Control            Implant               -2.7193     0.8604     12     -3.16     0.0082 
TIME                         14                  28        0.8150     0.3146     12      2.59     0.0236 





TREATMENT*TIME   Control     14     Implant      14       -3.5043     0.9161   14.8     -3.83     
0.0017 
TREATMENT*TIME   Control     14     Implant      28       -1.9043     0.9161   14.8     -2.08     
0.0555 
TREATMENT*TIME   Control     28     Implant      14       -3.5343     0.9161   14.8     -3.86     
0.0016 
TREATMENT*TIME   Control     28     Implant      28       -1.9343     0.9161   14.8     -2.11     
0.0522 
TREATMENT*TIME   Implant     14     Implant      28        1.6000     0.4449     12      3.60     
0.0037 
 
A.3. Analysis of estradiol supplementation on the levels of plasma estradiol levels in the 
blood of old and young, mature cows (Chapter 4) 
 
A.3.1. Representative of SAS editor programming language using Proc Mixed (Plasma 
Estrogen Level of old and young, mature cows) (Chapter 4) 
filename new dde 'Excel|F:\602L only\Data\Blood Data\Estrogen\[602L 
Estrogen Data-Matthews and Boling.xls]SAS!R4C2:R49C7'; 
TITLE '602L Estrogen Data SAS- Repeated Measurements w/o D0 (Dr. 
Vanzant)'; 
data Estrogen; 
infile new missover; 







PROC MIXED  data=Estrogen; 
CLASSES TREATMENT COW AGE TIME; 
MODEL ESTROGEN = TREATMENT TIME AGE TREATMENT*TIME TREATMENT*AGE 
TIME*AGE TREATMENT*TIME*AGE/ DDFM=KR; 
REPEATED TIME/type = ar(1) subject = COW(TREATMENT*AGE); 




A.3.2. SAS output 
602L Estrogen Data SAS- Repeated Measurements w/o D0 (Dr. Vanzant)              456 
                                                                       19:01 Friday, March 27, 2009 
 
                          Lab 
                   Obs     ID    COW      AGE     TIME    TREATMENT    ESTROGEN 
 
                     1      1    M119    Young     16      Control       1.779 
                     2      4    M060    Young     16      Control       1.540 
                     3      5    M068    Young     16      Control       3.490 
                     4      6    N076    Young     16      Control       1.677 
                     5      7    N088    Young     16      Control       1.196 
                     6     10    N096    Young     16      Control       3.857 
                     7      2    M002    Young     16      Implant       2.560 
                     8      3    M034    Young     16      Implant       5.312 
                     9      8    N087    Young     16      Implant       3.078 
                    10      9    N082    Young     16      Implant       1.997 




                    12     12    N069    Young     16      Implant       3.504 
                    13     13    C221    Old       16      Control       1.211 
                    14     15    D151    Old       16      Control       1.403 
                    15     16    D229    Old       16      Control       1.886 
                    16     19    C188    Old       16      Control        . 
                    17     21    D255    Old       16      Control       1.663 
                    18     23    G104    Old       16      Control       3.603 
                    19     14    D029    Old       16      Implant       4.360 
                    20     17    G025    Old       16      Implant       8.239 
                    21     18    G027    Old       16      Implant       4.622 
                    22     20    D222    Old       16      Implant       3.287 
                    23     22    G094    Old       16      Implant       3.980 
                    24      1    M119    Young     28      Control       3.303 
                    25      4    M060    Young     28      Control       5.760 
                    26      5    M068    Young     28      Control       6.599 
                    27      6    N076    Young     28      Control       2.561 
                    28      7    N088    Young     28      Control       2.818 
                    29     10    N096    Young     28      Control       3.117 
                    30      2    M002    Young     28      Implant       4.425 
                    31      3    M034    Young     28      Implant       5.795 
                    32      8    N087    Young     28      Implant       7.012 
                    33      9    N082    Young     28      Implant       5.232 
                    34     11    N106    Young     28      Implant       4.224 
                    35     12    N069    Young     28      Implant       4.219 
                    36     13    C221    Old       28      Control       2.871 
                    37     15    D151    Old       28      Control       5.681 
                    38     16    D229    Old       28      Control       2.698 




                    40     21    D255    Old       28      Control       1.933 
                    41     23    G104    Old       28      Control       3.412 
                    42     14    D029    Old       28      Implant       5.616 
                    43     17    G025    Old       28      Implant       8.883 
                    44     18    G027    Old       28      Implant       4.512 
                    45     20    D222    Old       28      Implant       3.520 





                602L Estrogen Data SAS- Repeated Measurements w/o D0 (Dr. Vanzant)              457 
                                                                       19:01 Friday, March 27, 2009 
 
                                        The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.ESTROGEN 
                      Dependent Variable           ESTROGEN 
                      Covariance Structure         Autoregressive 
                      Subject Effect               COW(TREATMENT*AGE) 
                      Estimation Method            REML 
                      Residual Variance Method     Profile 
                      Fixed Effects SE Method      Prasad-Rao-Jeske- 
                                                   Kackar-Harville 
                      Degrees of Freedom Method    Kenward-Roger 
 
 
                                      Class Level Information 
 
                       Class        Levels    Values 
 
                       TREATMENT         2    Control Implant 
                       COW              23    C188 C221 D029 D151 D222 D229 
                                              D255 G025 G027 G094 G104 M002 
                                              M034 M060 M068 M119 N069 N076 




                       AGE               2    Old Young 
                       TIME              2    16 28 
 
 
                                            Dimensions 
 
                                Covariance Parameters             2 
                                Columns in X                     27 
                                Columns in Z                      0 
                                Subjects                         23 
                                Max Obs Per Subject               2 
 
 
                                      Number of Observations 
 
                            Number of Observations Read              46 
                            Number of Observations Used              45 
                            Number of Observations Not Used           1 
 
 
                                         Iteration History 
 
                    Iteration    Evaluations    -2 Res Log Like       Criterion 
 
                            0              1       154.77542012 
                            1              2       150.33876997      0.00852430 





                602L Estrogen Data SAS- Repeated Measurements w/o D0 (Dr. Vanzant)              458 
                                                                       19:01 Friday, March 27, 2009 
 
                                        The Mixed Procedure 
 
                                         Iteration History 
 
                    Iteration    Evaluations    -2 Res Log Like       Criterion 
 
                            3              1       149.89760526      0.00000704 
                            4              1       149.89731500      0.00000000 
 
 
                                    Convergence criteria met. 
 
 
                                  Covariance Parameter Estimates 
 
                            Cov Parm     Subject               Estimate 
 
                            AR(1)        COW(TREATMENT*AGE)      0.5711 
                            Residual                             2.8091 
 
 
                                          Fit Statistics 
 




                               AIC (smaller is better)         153.9 
                               AICC (smaller is better)        154.3 
                               BIC (smaller is better)         156.2 
 
 
                                 Null Model Likelihood Ratio Test 
 
                                   DF    Chi-Square      Pr > ChiSq 
 
                                    1          4.88          0.0272 
 
 
                                   Type 3 Tests of Fixed Effects 
 
                                             Num     Den 
                      Effect                  DF      DF    F Value    Pr > F 
 
                      TREATMENT                1    16.3       6.07    0.0253 
                      TIME                     1    15.7      20.23    0.0004 
                      AGE                      1    16.3       0.98    0.3361 
                      TREATMENT*TIME           1    15.7       0.39    0.5421 
                      TREATMENT*AGE            1    16.3       0.54    0.4726 
                      AGE*TIME                 1    15.7       0.71    0.4118 





                602L Estrogen Data SAS- Repeated Measurements w/o D0 (Dr. Vanzant)              459 
                                                                       19:01 Friday, March 27, 2009 
 
                                        The Mixed Procedure 
 
                                        Least Squares Means 
 
                                                             Standard 
  Effect               TREATMENT   AGE     TIME   Estimate      Error     DF   t Value   Pr > |t| 
 
  TREATMENT            Control                      3.2207     0.4304   16.6      7.48     <.0001 
  TREATMENT            Implant                      4.7468     0.4458     16     10.65     <.0001 
  TIME                                     16       3.2157     0.3569   27.1      9.01     <.0001 
  TIME                                     28       4.7519     0.3506   26.1     13.55     <.0001 
  AGE                              Old              4.2909     0.4509   16.6      9.52     <.0001 
  AGE                              Young            3.6767     0.4251     16      8.65     <.0001 
  TREATMENT*TIME       Control             16       2.3462     0.5021   28.1      4.67     <.0001 
  TREATMENT*TIME       Control             28       4.0953     0.4838   26.1      8.46     <.0001 
  TREATMENT*TIME       Implant             16       4.0851     0.5074   26.1      8.05     <.0001 
  TREATMENT*TIME       Implant             28       5.4085     0.5074   26.1     10.66     <.0001 
  TREATMENT*AGE        Control     Old              3.3000     0.6160   17.3      5.36     <.0001 
  TREATMENT*AGE        Control     Young            3.1414     0.6012     16      5.23     <.0001 
  TREATMENT*AGE        Implant     Old              5.2817     0.6585     16      8.02     <.0001 
  TREATMENT*AGE        Implant     Young            4.2119     0.6012     16      7.01     <.0001 
  AGE*TIME                         Old     16       3.6668     0.5249   27.9      6.99     <.0001 
  AGE*TIME                         Old     28       4.9150     0.5074   26.1      9.69     <.0001 




  AGE*TIME                         Young   28       4.5887     0.4838   26.1      9.48     <.0001 
  TREATMENT*AGE*TIME   Control     Old     16       2.4359     0.7351   29.9      3.31     0.0024 
  TREATMENT*AGE*TIME   Control     Old     28       4.1642     0.6842   26.1      6.09     <.0001 
  TREATMENT*AGE*TIME   Control     Young   16       2.2565     0.6842   26.1      3.30     0.0028 
  TREATMENT*AGE*TIME   Control     Young   28       4.0263     0.6842   26.1      5.88     <.0001 
  TREATMENT*AGE*TIME   Implant     Old     16       4.8976     0.7495   26.1      6.53     <.0001 
  TREATMENT*AGE*TIME   Implant     Old     28       5.6658     0.7495   26.1      7.56     <.0001 
  TREATMENT*AGE*TIME   Implant     Young   16       3.2727     0.6842   26.1      4.78     <.0001 
  TREATMENT*AGE*TIME   Implant     Young   28       5.1512     0.6842   26.1      7.53     <.0001 
 
 
                                Differences of Least Squares Means 
 
                                                                                  Standard 
  Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  Estimate     Error    DF 
 
  TREATMENT           Control                 Implant                    -1.5261    0.6197  16.3 
  TIME                                  16                       28      -1.5362    0.3415  15.7 
 
 
                                Differences of Least Squares Means 
 
     Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  t Value   Pr > |t| 
 
     TREATMENT           Control                 Implant                     -2.46     0.0253 
     TIME                                  16                       28       -4.50     0.0004 
 




                                                                       19:01 Friday, March 27, 2009 
 
                                        The Mixed Procedure 
 
                                Differences of Least Squares Means 
 
                                                                                  Standard 
  Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  Estimate     Error    DF 
 
  AGE                            Old                      Young           0.6142    0.6197  16.3 
  TREATMENT*TIME      Control           16    Control            28      -1.7490    0.4813    16 
  TREATMENT*TIME      Control           16    Implant            16      -1.7389    0.7139  27.1 
  TREATMENT*TIME      Control           16    Implant            28      -3.0623    0.7139  27.1 
  TREATMENT*TIME      Control           28    Implant            16      0.01012    0.7011  26.1 
  TREATMENT*TIME      Control           28    Implant            28      -1.3132    0.7011  26.1 
  TREATMENT*TIME      Implant           16    Implant            28      -1.3234    0.4847  15.5 
  TREATMENT*AGE       Control    Old          Control     Young           0.1586    0.8607  16.6 
  TREATMENT*AGE       Control    Old          Implant     Old            -1.9817    0.9017  16.6 
  TREATMENT*AGE       Control    Old          Implant     Young          -0.9119    0.8607  16.6 
  TREATMENT*AGE       Control    Young        Implant     Old            -2.1403    0.8917    16 
  TREATMENT*AGE       Control    Young        Implant     Young          -1.0705    0.8502    16 
  TREATMENT*AGE       Implant    Old          Implant     Young           1.0698    0.8917    16 
  AGE*TIME                       Old    16                Old    28      -1.2482    0.5030    16 
  AGE*TIME                       Old    16                Young  16       0.9022    0.7139  27.1 
  AGE*TIME                       Old    16                Young  28      -0.9220    0.7139  27.1 
  AGE*TIME                       Old    28                Young  16       2.1504    0.7011  26.1 
  AGE*TIME                       Old    28                Young  28       0.3262    0.7011  26.1 




  TREATMENT*AGE*TIME  Control    Old    16    Control     Old    28      -1.7283    0.7067  16.5 
  TREATMENT*AGE*TIME  Control    Old    16    Control     Young  16       0.1794    1.0043  28.1 
  TREATMENT*AGE*TIME  Control    Old    16    Control     Young  28      -1.5904    1.0043  28.1 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    16      -2.4617    1.0499  27.9 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    28      -3.2299    1.0499  27.9 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  16      -0.8368    1.0043  28.1 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  28      -2.7153    1.0043  28.1 
  TREATMENT*AGE*TIME  Control    Old    28    Control     Young  16       1.9077    0.9677  26.1 
  TREATMENT*AGE*TIME  Control    Old    28    Control     Young  28       0.1378    0.9677  26.1 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    16      -0.7334    1.0149  26.1 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    28      -1.5016    1.0149  26.1 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  16       0.8915    0.9677  26.1 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  28      -0.9870    0.9677  26.1 
  TREATMENT*AGE*TIME  Control    Young  16    Control     Young  28      -1.7698    0.6536  15.5 
  TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    16      -2.6411    1.0149  26.1 
  TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    28      -3.4093    1.0149  26.1 
  TREATMENT*AGE*TIME  Control    Young  16    Implant     Young  16      -1.0162    0.9677  26.1 
  TREATMENT*AGE*TIME  Control    Young  16    Implant     Young  28      -2.8947    0.9677  26.1 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    16      -0.8713    1.0149  26.1 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    28      -1.6395    1.0149  26.1 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  16       0.7537    0.9677  26.1 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  28      -1.1248    0.9677  26.1 
  TREATMENT*AGE*TIME  Implant    Old    16    Implant     Old    28      -0.7682    0.7160  15.5 
  TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  16       1.6249    1.0149  26.1 
  TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  28      -0.2536    1.0149  26.1 
  TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  16       2.3931    1.0149  26.1 
 




                                                                       19:01 Friday, March 27, 2009 
 
                                        The Mixed Procedure 
 
 
                                Differences of Least Squares Means 
 
     Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  t Value   Pr > |t| 
 
     AGE                            Old                      Young            0.99     0.3361 
     TREATMENT*TIME      Control           16    Control            28       -3.63     0.0022 
     TREATMENT*TIME      Control           16    Implant            16       -2.44     0.0217 
     TREATMENT*TIME      Control           16    Implant            28       -4.29     0.0002 
     TREATMENT*TIME      Control           28    Implant            16        0.01     0.9886 
     TREATMENT*TIME      Control           28    Implant            28       -1.87     0.0723 
     TREATMENT*TIME      Implant           16    Implant            28       -2.73     0.0152 
     TREATMENT*AGE       Control    Old          Control     Young            0.18     0.8560 
     TREATMENT*AGE       Control    Old          Implant     Old             -2.20     0.0425 
     TREATMENT*AGE       Control    Old          Implant     Young           -1.06     0.3045 
     TREATMENT*AGE       Control    Young        Implant     Old             -2.40     0.0289 
     TREATMENT*AGE       Control    Young        Implant     Young           -1.26     0.2260 
     TREATMENT*AGE       Implant    Old          Implant     Young            1.20     0.2477 
     AGE*TIME                       Old    16                Old    28       -2.48     0.0246 
     AGE*TIME                       Old    16                Young  16        1.26     0.2171 
     AGE*TIME                       Old    16                Young  28       -1.29     0.2074 
     AGE*TIME                       Old    28                Young  16        3.07     0.0050 
     AGE*TIME                       Old    28                Young  28        0.47     0.6456 




     TREATMENT*AGE*TIME  Control    Old    16    Control     Old    28       -2.45     0.0260 
     TREATMENT*AGE*TIME  Control    Old    16    Control     Young  16        0.18     0.8595 
     TREATMENT*AGE*TIME  Control    Old    16    Control     Young  28       -1.58     0.1245 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    16       -2.34     0.0264 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    28       -3.08     0.0047 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  16       -0.83     0.4118 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  28       -2.70     0.0115 
     TREATMENT*AGE*TIME  Control    Old    28    Control     Young  16        1.97     0.0594 
     TREATMENT*AGE*TIME  Control    Old    28    Control     Young  28        0.14     0.8878 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    16       -0.72     0.4763 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    28       -1.48     0.1509 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  16        0.92     0.3653 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  28       -1.02     0.3171 
     TREATMENT*AGE*TIME  Control    Young  16    Control     Young  28       -2.71     0.0159 
     TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    16       -2.60     0.0151 
     TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    28       -3.36     0.0024 
     TREATMENT*AGE*TIME  Control    Young  16    Implant     Young  16       -1.05     0.3033 
     TREATMENT*AGE*TIME  Control    Young  16    Implant     Young  28       -2.99     0.0060 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    16       -0.86     0.3984 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    28       -1.62     0.1182 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  16        0.78     0.4431 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  28       -1.16     0.2556 
     TREATMENT*AGE*TIME  Implant    Old    16    Implant     Old    28       -1.07     0.2998 
     TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  16        1.60     0.1214 
     TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  28       -0.25     0.8047 
     TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  16        2.36     0.0261 
 




                                                                       19:01 Friday, March 27, 2009 
 
                                        The Mixed Procedure 
 
                                Differences of Least Squares Means 
 
                                                                                  Standard 
  Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  Estimate     Error    DF 
 
  TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  28       0.5146    1.0149  26.1 
  TREATMENT*AGE*TIME  Implant    Young  16    Implant     Young  28      -1.8785    0.6536  15.5 
 
 
                                Differences of Least Squares Means 
 
     Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  t Value   Pr > |t| 
 
     TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  28        0.51     0.6164 
     TREATMENT*AGE*TIME  Implant    Young  16    Implant     Young  28       -2.87     0.0113 
 
 
A.4. Analysis of estradiol supplementation on the expression of protein and for glutamate 
transporters and metabolizing enzymes of old and young, mature cows (Chapter 4) 
 
A.4.1. Representative of SAS editor programming language using Proc Mixed (GS 




filename new dde 'Excel|F:\602L 
only\Data\Protein\Liver\Densitometry\GS\Data\Need to PRint\[602L Old 
and Young Liver GS Protein Data Normalized to d16 
YC.xls]SAS!R7C2:R52C6'; 
TITLE '602L GS Densitometry SAS- Repeated Measurements Normalized to 
d16 YC (Dr. Vanzant)'; 
data protein; 
infile new missover; 




PROC MIXED  data=protein; 
CLASSES TREATMENT COW AGE TIME; 
MODEL SAS = TREATMENT TIME AGE TREATMENT*TIME TREATMENT*AGE TIME*AGE 
TREATMENT*TIME*AGE/ DDFM=KR; 
REPEATED TIME/type = ar(1) subject = COW(TREATMENT*AGE); 




A.4.2. SAS output 
        602L GS Densitometry SAS- Repeated Measurements Normalized to d16 YC (Dr. Vanzant)       50 
                                                                       09:52 Sunday, March 29, 2009 
 
                         Obs    COW     AGE     TIME    TREATMENT     SAS 
 




                           2    13     Old       16      Control     0.09 
                           3    9      Young     16      Implant     0.75 
                           4    17     Old       16      Implant     0.11 
                           5    6      Young     16      Control     0.59 
                           6    19     Old       16      Control     0.10 
                           7    3      Young     16      Implant     0.88 
                           8    18     Old       16      Implant     1.35 
                           9    1      Young     16      Control     0.70 
                          10    16     Old       16      Control     0.13 
                          11    2      Young     16      Implant     0.62 
                          12    14     Old       16      Implant     1.63 
                          13    7      Young     16      Control     1.22 
                          14    15     Old       16      Control     0.48 
                          15    12     Young     16      Implant     1.67 
                          16    5      Young     16      Control     1.22 
                          17    23     Old       16      Control     0.81 
                          18    11     Young     16      Implant     2.10 
                          19    20     Old       16      Implant     1.18 
                          20    4      Young     16      Control     1.51 
                          21    21     Old       16      Control     0.00 
                          22    8      Young     16      Implant     0.81 
                          23    22     Old       16      Implant     0.88 
                          24    10     Young     28      Control     0.73 
                          25    13     Old       28      Control     0.33 
                          26    9      Young     28      Implant     1.27 
                          27    17     Old       28      Implant     0.01 
                          28    6      Young     28      Control      . 




                          30    3      Young     28      Implant     0.42 
                          31    18     Old       28      Implant     0.78 
                          32    1      Young     28      Control     0.83 
                          33    16     Old       28      Control     0.10 
                          34    2      Young     28      Implant     0.44 
                          35    14     Old       28      Implant     1.12 
                          36    7      Young     28      Control     0.95 
                          37    15     Old       28      Control     1.02 
                          38    12     Young     28      Implant     0.68 
                          39    5      Young     28      Control     0.82 
                          40    23     Old       28      Control     0.35 
                          41    11     Young     28      Implant     1.12 
                          42    20     Old       28      Implant     0.14 
                          43    4      Young     28      Control     1.09 
                          44    21     Old       28      Control     0.00 
                          45    8      Young     28      Implant     0.58 
                          46    22     Old       28      Implant     0.14 
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                                        The Mixed Procedure 
 
                                        Model Information 
 
                      Data Set                     WORK.PROTEIN 
                      Dependent Variable           SAS 




                      Subject Effect               COW(TREATMENT*AGE) 
                      Estimation Method            REML 
                      Residual Variance Method     Profile 
                      Fixed Effects SE Method      Prasad-Rao-Jeske- 
                                                   Kackar-Harville 
                      Degrees of Freedom Method    Kenward-Roger 
 
 
                                      Class Level Information 
 
                       Class        Levels    Values 
 
                       TREATMENT         2    Control Implant 
                       COW              23    1 10 11 12 13 14 15 16 17 18 
                                              19 2 20 21 22 23 3 4 5 6 7 8 9 
                       AGE               2    Old Young 
                       TIME              2    16 28 
 
 
                                            Dimensions 
 
                                Covariance Parameters             2 
                                Columns in X                     27 
                                Columns in Z                      0 
                                Subjects                         23 






                                      Number of Observations 
 
                            Number of Observations Read              46 
                            Number of Observations Used              45 
                            Number of Observations Not Used           1 
 
 
                                         Iteration History 
 
                    Iteration    Evaluations    -2 Res Log Like       Criterion 
 
                            0              1        55.49588136 
                            1              2        48.76806958      0.00000000 
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                                        The Mixed Procedure 
 
                                    Convergence criteria met. 
 
 
                                  Covariance Parameter Estimates 
 
                            Cov Parm     Subject               Estimate 
 
                            AR(1)        COW(TREATMENT*AGE)      0.5598 






                                          Fit Statistics 
 
                               -2 Res Log Likelihood            48.8 
                               AIC (smaller is better)          52.8 
                               AICC (smaller is better)         53.1 
                               BIC (smaller is better)          55.0 
 
 
                                 Null Model Likelihood Ratio Test 
 
                                   DF    Chi-Square      Pr > ChiSq 
 
                                    1          6.73          0.0095 
 
 
                                   Type 3 Tests of Fixed Effects 
 
                                             Num     Den 
                      Effect                  DF      DF    F Value    Pr > F 
 
                      TREATMENT                1    18.9       2.24    0.1510 
                      TIME                     1    18.3       9.98    0.0053 
                      AGE                      1    18.9       7.18    0.0149 
                      TREATMENT*TIME           1    18.3       6.05    0.0241 
                      TREATMENT*AGE            1    18.9       1.79    0.1974 




                      TREATMENT*AGE*TIME       1    18.3       1.39    0.2535 
 
 
                                        Least Squares Means 
 
                                                             Standard 
  Effect               TREATMENT   AGE     TIME   Estimate      Error     DF   t Value   Pr > |t| 
 
  TREATMENT            Control                      0.6045     0.1090   19.2      5.54     <.0001 
  TREATMENT            Implant                      0.8395     0.1130   18.6      7.43     <.0001 
  TIME                                     16       0.8596    0.08897   28.4      9.66     <.0001 
  TIME                                     28       0.5844    0.09057   29.2      6.45     <.0001 
  AGE                              Old              0.5116     0.1130   18.6      4.53     0.0002 
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                                        The Mixed Procedure 
 
                                        Least Squares Means 
 
                                                             Standard 
  Effect               TREATMENT   AGE     TIME   Estimate      Error     DF   t Value   Pr > |t| 
 
  AGE                              Young            0.9324     0.1090   19.2      8.55     <.0001 
  TREATMENT*TIME       Control             16       0.6350     0.1228   28.4      5.17     <.0001 
  TREATMENT*TIME       Control             28       0.5740     0.1274   30.1      4.51     <.0001 




  TREATMENT*TIME       Implant             28       0.5948     0.1288   28.4      4.62     <.0001 
  TREATMENT*AGE        Control     Old              0.2892     0.1523   18.6      1.90     0.0733 
  TREATMENT*AGE        Control     Young            0.9198     0.1561   19.8      5.89     <.0001 
  TREATMENT*AGE        Implant     Old              0.7340     0.1669   18.6      4.40     0.0003 
  TREATMENT*AGE        Implant     Young            0.9450     0.1523   18.6      6.20     <.0001 
  AGE*TIME                         Old     16       0.6492     0.1288   28.4      5.04     <.0001 
  AGE*TIME                         Old     28       0.3740     0.1288   28.4      2.90     0.0071 
  AGE*TIME                         Young   16       1.0700     0.1228   28.4      8.71     <.0001 
  AGE*TIME                         Young   28       0.7948     0.1274   30.1      6.24     <.0001 
  TREATMENT*AGE*TIME   Control     Old     16       0.2683     0.1737   28.4      1.55     0.1334 
  TREATMENT*AGE*TIME   Control     Old     28       0.3100     0.1737   28.4      1.79     0.0849 
  TREATMENT*AGE*TIME   Control     Young   16       1.0017     0.1737   28.4      5.77     <.0001 
  TREATMENT*AGE*TIME   Control     Young   28       0.8379     0.1864   31.6      4.49     <.0001 
  TREATMENT*AGE*TIME   Implant     Old     16       1.0300     0.1902   28.4      5.41     <.0001 
  TREATMENT*AGE*TIME   Implant     Old     28       0.4380     0.1902   28.4      2.30     0.0289 
  TREATMENT*AGE*TIME   Implant     Young   16       1.1383     0.1737   28.4      6.55     <.0001 
  TREATMENT*AGE*TIME   Implant     Young   28       0.7517     0.1737   28.4      4.33     0.0002 
 
 
                                Differences of Least Squares Means 
 
                                                                                  Standard 
  Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  Estimate     Error    DF 
 
  TREATMENT           Control                 Implant                    -0.2350    0.1570  18.9 
  TIME                                  16                       28       0.2752   0.08709  18.3 
  AGE                            Old                      Young          -0.4208    0.1570  18.9 




  TREATMENT*TIME      Control           16    Implant            16      -0.4492    0.1779  28.4 
 
 
                                Differences of Least Squares Means 
 
     Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  t Value   Pr > |t| 
 
     TREATMENT           Control                 Implant                     -1.50     0.1510 
     TIME                                  16                       28        3.16     0.0053 
     AGE                            Old                      Young           -2.68     0.0149 
     TREATMENT*TIME      Control           16    Control            28        0.50     0.6246 
     TREATMENT*TIME      Control           16    Implant            16       -2.52     0.0175 
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                                        The Mixed Procedure 
 
                                Differences of Least Squares Means 
 
                                                                                  Standard 
  Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  Estimate     Error    DF 
 
  TREATMENT*TIME      Control           16    Implant            28      0.04017    0.1779  28.4 
  TREATMENT*TIME      Control           28    Implant            16      -0.5102    0.1811  29.2 
  TREATMENT*TIME      Control           28    Implant            28     -0.02088    0.1811  29.2 
  TREATMENT*TIME      Implant           16    Implant            28       0.4893    0.1237    18 




  TREATMENT*AGE       Control    Old          Implant     Old            -0.4448    0.2260  18.6 
  TREATMENT*AGE       Control    Old          Implant     Young          -0.6558    0.2154  18.6 
  TREATMENT*AGE       Control    Young        Implant     Old             0.1858    0.2285  19.1 
  TREATMENT*AGE       Control    Young        Implant     Young         -0.02521    0.2181  19.2 
  TREATMENT*AGE       Implant    Old          Implant     Young          -0.2110    0.2260  18.6 
  AGE*TIME                       Old    16                Old    28       0.2752    0.1237    18 
  AGE*TIME                       Old    16                Young  16      -0.4208    0.1779  28.4 
  AGE*TIME                       Old    16                Young  28      -0.1456    0.1811  29.2 
  AGE*TIME                       Old    28                Young  16      -0.6960    0.1779  28.4 
  AGE*TIME                       Old    28                Young  28      -0.4208    0.1811  29.2 
  AGE*TIME                       Young  16                Young  28       0.2752    0.1227  18.6 
  TREATMENT*AGE*TIME  Control    Old    16    Control     Old    28     -0.04167    0.1667    18 
  TREATMENT*AGE*TIME  Control    Old    16    Control     Young  16      -0.7333    0.2456  28.4 
  TREATMENT*AGE*TIME  Control    Old    16    Control     Young  28      -0.5696    0.2548  30.1 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    16      -0.7617    0.2576  28.4 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    28      -0.1697    0.2576  28.4 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  16      -0.8700    0.2456  28.4 
  TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  28      -0.4833    0.2456  28.4 
  TREATMENT*AGE*TIME  Control    Old    28    Control     Young  16      -0.6917    0.2456  28.4 
  TREATMENT*AGE*TIME  Control    Old    28    Control     Young  28      -0.5279    0.2548  30.1 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    16      -0.7200    0.2576  28.4 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    28      -0.1280    0.2576  28.4 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  16      -0.8283    0.2456  28.4 
  TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  28      -0.4417    0.2456  28.4 
  TREATMENT*AGE*TIME  Control    Young  16    Control     Young  28       0.1638    0.1800  19.1 
  TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    16     -0.02833    0.2576  28.4 
  TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    28       0.5637    0.2576  28.4 




  TREATMENT*AGE*TIME  Control    Young  16    Implant     Young  28       0.2500    0.2456  28.4 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    16      -0.1921    0.2664    30 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    28       0.3999    0.2664    30 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  16      -0.3004    0.2548  30.1 
  TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  28      0.08624    0.2548  30.1 
  TREATMENT*AGE*TIME  Implant    Old    16    Implant     Old    28       0.5920    0.1826    18 
  TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  16      -0.1083    0.2576  28.4 
  TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  28       0.2783    0.2576  28.4 
  TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  16      -0.7003    0.2576  28.4 
  TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  28      -0.3137    0.2576  28.4 
  TREATMENT*AGE*TIME  Implant    Young  16    Implant     Young  28       0.3867    0.1667    18 
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                                Differences of Least Squares Means 
 
     Effect              TREATMENT  AGE    TIME  _TREATMENT  _AGE   _TIME  t Value   Pr > |t| 
 
     TREATMENT*TIME      Control           16    Implant            28        0.23     0.8230 
     TREATMENT*TIME      Control           28    Implant            16       -2.82     0.0086 
     TREATMENT*TIME      Control           28    Implant            28       -0.12     0.9090 
     TREATMENT*TIME      Implant           16    Implant            28        3.96     0.0009 




     TREATMENT*AGE       Control    Old          Implant     Old             -1.97     0.0641 
     TREATMENT*AGE       Control    Old          Implant     Young           -3.04     0.0068 
     TREATMENT*AGE       Control    Young        Implant     Old              0.81     0.4261 
     TREATMENT*AGE       Control    Young        Implant     Young           -0.12     0.9092 
     TREATMENT*AGE       Implant    Old          Implant     Young           -0.93     0.3624 
     AGE*TIME                       Old    16                Old    28        2.23     0.0391 
     AGE*TIME                       Old    16                Young  16       -2.36     0.0251 
     AGE*TIME                       Old    16                Young  28       -0.80     0.4280 
     AGE*TIME                       Old    28                Young  16       -3.91     0.0005 
     AGE*TIME                       Old    28                Young  28       -2.32     0.0273 
     AGE*TIME                       Young  16                Young  28        2.24     0.0373 
     TREATMENT*AGE*TIME  Control    Old    16    Control     Old    28       -0.25     0.8055 
     TREATMENT*AGE*TIME  Control    Old    16    Control     Young  16       -2.99     0.0058 
     TREATMENT*AGE*TIME  Control    Old    16    Control     Young  28       -2.24     0.0329 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    16       -2.96     0.0062 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Old    28       -0.66     0.5154 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  16       -3.54     0.0014 
     TREATMENT*AGE*TIME  Control    Old    16    Implant     Young  28       -1.97     0.0589 
     TREATMENT*AGE*TIME  Control    Old    28    Control     Young  16       -2.82     0.0087 
     TREATMENT*AGE*TIME  Control    Old    28    Control     Young  28       -2.07     0.0469 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    16       -2.80     0.0092 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Old    28       -0.50     0.6231 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  16       -3.37     0.0022 
     TREATMENT*AGE*TIME  Control    Old    28    Implant     Young  28       -1.80     0.0828 
     TREATMENT*AGE*TIME  Control    Young  16    Control     Young  28        0.91     0.3742 
     TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    16       -0.11     0.9132 
     TREATMENT*AGE*TIME  Control    Young  16    Implant     Old    28        2.19     0.0370 




     TREATMENT*AGE*TIME  Control    Young  16    Implant     Young  28        1.02     0.3173 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    16       -0.72     0.4764 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Old    28        1.50     0.1437 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  16       -1.18     0.2476 
     TREATMENT*AGE*TIME  Control    Young  28    Implant     Young  28        0.34     0.7373 
     TREATMENT*AGE*TIME  Implant    Old    16    Implant     Old    28        3.24     0.0045 
     TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  16       -0.42     0.6772 
     TREATMENT*AGE*TIME  Implant    Old    16    Implant     Young  28        1.08     0.2890 
     TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  16       -2.72     0.0111 
     TREATMENT*AGE*TIME  Implant    Old    28    Implant     Young  28       -1.22     0.2334 


















A.5. Analysis of estradiol supplementation on the levels of plasma estradiol levels in the 
blood of heifers (Chapter 5) 
 
A.5.1. Representative of SAS editor programming language using Proc Mixed (plasma 
estradiol levels of heifers) (Chapter 5) 
filename new dde 'Excel|D:\604P\Data\Blood data\Estrogen\[604P Plasma 
Estrogen Data.xls]SAS!R4C2:R75C7'; 
TITLE '604 Estrogen Data SAS- Repeated Measurements w/o Day 0 
(Vanzant)'; 
data estrogen; 
infile new missover; 




PROC MIXED  data=estrogen; 
CLASSES TREATMENT HEIFER TIME; 
MODEL Estrogen =  TREATMENT TIME TREATMENT*TIME / DDFM=KR; 
REPEATED TIME/type = ar(1) subject = HEIFER(TREATMENT); 











A.5.2. SAS output 
       604 Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                  1 
                                                                        14:53 Saturday, August 1, 2009 
 
                           Lab 
                    Obs     ID    HEIFER       AGE     TIME    TREATMENT    Estrogen 
 
                      1      2    251      Young     14      Control       1.409 
                      2      4    694      Young     14      Control       1.864 
                      3      5    268      Young     14      Control       2.056 
                      4      7    274      Young     14      Control       1.028 
                      5     10    271      Young     14      Control       3.519 
                      6     11    50       Young     14      Control       1.628 
                      7     14    247      Young     14      Control       1.338 
                      8     15    2634     Young     14      Control        . 
                      9     20    256      Young     14      Control       1.930 
                     10      1    2624     Young     14      Implant       5.290 
                     11      3    249      Young     14      Implant       4.433 
                     12      6    2608     Young     14      Implant       3.676 
                     13      8    301R1    Young     14      Implant       3.393 
                     14      9    264      Young     14      Implant       2.397 
                     15     12    252      Young     14      Implant       2.886 
                     16     13    301R2    Young     14      Implant       1.260 
                     17     18    311R     Young     14      Implant       6.025 
                     18     19    705R2    Young     14      Implant       7.871 
                     19      2    251      Young     28      Control       1.179 




                     21      5    268      Young     28      Control       1.776 
                     22      7    274      Young     28      Control       4.621 
                     23     10    271      Young     28      Control        . 
                     24     11    50       Young     28      Control       3.022 
                     25     14    247      Young     28      Control       1.956 
                     26     15    2634     Young     28      Control       2.512 
                     27     20    256      Young     28      Control        . 
                     28      1    2624     Young     28      Implant       3.174 
                     29      3    249      Young     28      Implant       7.097 
                     30      6    2608     Young     28      Implant       4.037 
                     31      8    301R1    Young     28      Implant       2.787 
                     32      9    264      Young     28      Implant        . 
                     33     12    252      Young     28      Implant        . 
                     34     13    301R2    Young     28      Implant       3.075 
                     35     18    311R     Young     28      Implant       3.848 
                     36     19    705R2    Young     28      Implant       2.916 
                     37      2    251      Young     43      Control       2.950 
                     38      4    694      Young     43      Control       2.760 
                     39      5    268      Young     43      Control       4.739 
                     40      7    274      Young     43      Control       2.339 
                     41     10    271      Young     43      Control       3.105 
                     42     11    50       Young     43      Control       3.709 
                     43     14    247      Young     43      Control       1.667 
                     44     15    2634     Young     43      Control       1.866 
                     45     20    256      Young     43      Control       2.039 
                     46      1    2624     Young     43      Implant       3.925 
                     47      3    249      Young     43      Implant       6.610 




                     49      8    301R1    Young     43      Implant       2.969 
                     50      9    264      Young     43      Implant       6.406 
  
 
                   604 Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                  2 
                                                                        14:53 Saturday, August 1, 2009 
 
                           Lab 
                    Obs     ID    HEIFER       AGE     TIME    TREATMENT    Estrogen 
 
                     51     12    252      Young     43      Implant       2.177 
                     52     13    301R2    Young     43      Implant       3.558 
                     53     18    311R     Young     43      Implant       3.047 
                     54     19    705R2    Young     43      Implant       2.597 
                     55      2    251      Young     56      Control       2.353 
                     56      4    694      Young     56      Control       1.877 
                     57      5    268      Young     56      Control       1.987 
                     58      7    274      Young     56      Control       1.786 
                     59     10    271      Young     56      Control       1.880 
                     60     11    50       Young     56      Control       2.569 
                     61     14    247      Young     56      Control        . 
                     62     15    2634     Young     56      Control       1.283 
                     63     20    256      Young     56      Control        . 
                     64      1    2624     Young     56      Implant       4.723 
                     65      3    249      Young     56      Implant       3.480 
                     66      6    2608     Young     56      Implant       3.074 
                     67      8    301R1    Young     56      Implant       3.853 




                     69     12    252      Young     56      Implant       2.304 
                     70     13    301R2    Young     56      Implant       1.655 
                     71     18    311R     Young     56      Implant       3.026 
                     72     19    705R2    Young     56      Implant       4.176 
  
 
                   604 Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                  3 
                                                                        14:53 Saturday, August 1, 2009 
 
                                         The Mixed Procedure 
 
                                          Model Information 
 
                        Data Set                     WORK.ESTROGEN 
                        Dependent Variable           Estrogen 
                        Covariance Structure         Autoregressive 
                        Subject Effect               HEIFER(TREATMENT) 
                        Estimation Method            REML 
                        Residual Variance Method     Profile 
                        Fixed Effects SE Method      Prasad-Rao-Jeske- 
                                                     Kackar-Harville 
                        Degrees of Freedom Method    Kenward-Roger 
 
 
                                       Class Level Information 
 





                        TREATMENT         2    Control Implant 
                        HEIFER              18    247 249 251 252 256 2608 2624 
                                               2634 264 268 271 274 301R1 
                                               301R2 311R 50 694 705R2 
                        TIME              4    14 28 43 56 
 
 
                                             Dimensions 
 
                                 Covariance Parameters             2 
                                 Columns in X                     15 
                                 Columns in Z                      0 
                                 Subjects                         18 
                                 Max Obs Per Subject               4 
 
 
                                       Number of Observations 
 
                             Number of Observations Read              72 
                             Number of Observations Used              64 
                             Number of Observations Not Used           8 
 
 
                                          Iteration History 
 
                     Iteration    Evaluations    -2 Res Log Like       Criterion 
 




                             1              2       203.61988307      0.00000000 
 
 
                                      Convergence criteria met. 
  
 
                   604 Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                  4 
                                                                        14:53 Saturday, August 1, 2009 
 
                                         The Mixed Procedure 
 
                                   Covariance Parameter Estimates 
 
                               Cov Parm     Subject           Estimate 
 
                               AR(1)        HEIFER(TREATMENT)      0.1795 
                               Residual                         1.6873 
 
 
                                           Fit Statistics 
 
                                -2 Res Log Likelihood           203.6 
                                AIC (smaller is better)         207.6 
                                AICC (smaller is better)        207.8 
                                BIC (smaller is better)         209.4 
 
 





                                     DF    Chi-Square      Pr > ChiSq 
 
                                      1          1.17          0.2799 
 
 
                                    Type 3 Tests of Fixed Effects 
 
                                            Num     Den 
                         Effect              DF      DF    F Value    Pr > F 
 
                         TREATMENT            1    20.9      18.56    0.0003 
                         TIME                 3    40.4       0.99    0.4083 
                         TREATMENT*TIME       3    40.4       0.64    0.5914 
 
 
                                         Least Squares Means 
 
                                                         Standard 
      Effect            TREATMENT    TIME    Estimate       Error      DF    t Value    Pr > |t| 
 
      TREATMENT         Control                2.2325      0.2593    21.6       8.61      <.0001 
      TREATMENT         Implant                3.7933      0.2530    20.1      14.99      <.0001 
      TIME                           14        2.9932      0.3158    54.1       9.48      <.0001 
      TIME                           28        3.0811      0.3483    55.7       8.85      <.0001 
      TIME                           43        3.3492      0.3062    53.7      10.94      <.0001 
      TIME                           56        2.6281      0.3368    54.7       7.80      <.0001 




      TREATMENT*TIME    Control      28        2.3694      0.4926    55.7       4.81      <.0001 
      TREATMENT*TIME    Control      43        2.7971      0.4330    53.7       6.46      <.0001 
      TREATMENT*TIME    Control      56        1.9137      0.4922      55       3.89      0.0003 
      TREATMENT*TIME    Implant      14        4.1368      0.4330    53.7       9.55      <.0001 
      TREATMENT*TIME    Implant      28        3.7928      0.4926    55.7       7.70      <.0001 
      TREATMENT*TIME    Implant      43        3.9012      0.4330    53.7       9.01      <.0001 
  
 
                   604 Estrogen Data SAS- Repeated Measurements w/o Day 0 (Vanzant)                  5 
                                                                        14:53 Saturday, August 1, 2009 
 
                                         The Mixed Procedure 
 
                                         Least Squares Means 
 
                                                         Standard 
      Effect            TREATMENT    TIME    Estimate       Error      DF    t Value    Pr > |t| 
 
      TREATMENT*TIME    Implant      56        3.3426      0.4598    54.4       7.27      <.0001 
 
 
                                 Differences of Least Squares Means 
 
                                                                 Standard 
   Effect          TREATMENT  TIME  _TREATMENT  _TIME  Estimate     Error    DF  t Value  Pr > |t| 
 
   TREATMENT       Control          Implant             -1.5609    0.3623  20.9    -4.31    0.0003 




   TIME                       14                43      -0.3559    0.4391  55.3    -0.81    0.4210 
   TIME                       14                56       0.3651    0.4635  55.5     0.79    0.4343 
   TIME                       28                43      -0.2680    0.4273  34.9    -0.63    0.5345 
   TIME                       28                56       0.4530    0.4832  54.9     0.94    0.3527 
   TIME                       43                56       0.7210    0.4180  35.5     1.73    0.0932 
   TREATMENT*TIME  Control    14    Control     28      -0.5197    0.6260  37.4    -0.83    0.4117 
   TREATMENT*TIME  Control    14    Control     43      -0.9474    0.6305  55.3    -1.50    0.1386 
   TREATMENT*TIME  Control    14    Control     56     -0.06402    0.6761  55.6    -0.09    0.9249 
   TREATMENT*TIME  Control    14    Implant     14      -2.2871    0.6316  54.1    -3.62    0.0006 
   TREATMENT*TIME  Control    14    Implant     28      -1.9431    0.6738  55.2    -2.88    0.0056 
   TREATMENT*TIME  Control    14    Implant     43      -2.0515    0.6316  54.1    -3.25    0.0020 
   TREATMENT*TIME  Control    14    Implant     56      -1.4929    0.6503  54.4    -2.30    0.0256 
   TREATMENT*TIME  Control    28    Control     43      -0.4277    0.6043  34.9    -0.71    0.4838 
   TREATMENT*TIME  Control    28    Control     56       0.4557    0.6946  54.9     0.66    0.5145 
   TREATMENT*TIME  Control    28    Implant     14      -1.7674    0.6558    55    -2.69    0.0093 
   TREATMENT*TIME  Control    28    Implant     28      -1.4234    0.6966  55.7    -2.04    0.0458 
   TREATMENT*TIME  Control    28    Implant     43      -1.5318    0.6558    55    -2.34    0.0232 
   TREATMENT*TIME  Control    28    Implant     56      -0.9732    0.6738  55.2    -1.44    0.1543 
   TREATMENT*TIME  Control    43    Control     56       0.8834    0.6040  36.4     1.46    0.1521 
   TREATMENT*TIME  Control    43    Implant     14      -1.3397    0.6123  53.7    -2.19    0.0331 
   TREATMENT*TIME  Control    43    Implant     28      -0.9957    0.6558    55    -1.52    0.1347 
   TREATMENT*TIME  Control    43    Implant     43      -1.1041    0.6123  53.7    -1.80    0.0770 
   TREATMENT*TIME  Control    43    Implant     56      -0.5455    0.6316  54.1    -0.86    0.3916 
   TREATMENT*TIME  Control    56    Implant     14      -2.2231    0.6555  54.5    -3.39    0.0013 
   TREATMENT*TIME  Control    56    Implant     28      -1.8791    0.6963  55.4    -2.70    0.0092 
   TREATMENT*TIME  Control    56    Implant     43      -1.9875    0.6555  54.5    -3.03    0.0037 
   TREATMENT*TIME  Control    56    Implant     56      -1.4289    0.6736  54.7    -2.12    0.0384 




   TREATMENT*TIME  Implant    14    Implant     43       0.2356    0.6112  55.3     0.39    0.7014 
   TREATMENT*TIME  Implant    14    Implant     56       0.7942    0.6342  55.3     1.25    0.2158 
   TREATMENT*TIME  Implant    28    Implant     43      -0.1084    0.6043  34.9    -0.18    0.8587 
   TREATMENT*TIME  Implant    28    Implant     56       0.4502    0.6719  54.8     0.67    0.5056 
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